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ABSTRACT 
 
Malaria still remains one of the most dangerous widespread 
parasitic diseases in developing nations. Reported alarming 
figures of malaria infections annually highlight the ‘gap’ 
that remains to be filled to rid endemic of malaria. As 
cases of increasing spread of malaria and the emergence of 
resistance continue to exert pressure on health systems in 
most affected areas, novel antimalarial compounds are 
endlessly needed to overcome the problem of malaria 
infections. 
 
This thesis presents research investigating a series of 
thiosemicarbazones (TSCs) and their novel gold complexes 
and dendrimers as potential antimalarial agents. 
 
A series of TSCs were synthesised in one step using Schiff 
base chemistry. On the other hand pyrazoline analogues were 
obtained in two steps using both Mannich and Schiff base 
chemistries. A range of gold(I) TSC complexes were achieved 





(THT)Cl] (4.3), [AuI(Ph3P)Cl] 
(4.5), [AuI(PTA)Cl] (4.24), and C6F5Au
I
(THT) (4.34). Further 
reaction of TSCs with starting gold(III) complex 2.15 
yielded the corresponding series of gold(III) TSC 
complexes. All the compounds were characterised by 
multinuclear NMR and FT-IR spectroscopies, mass 
spectrometry and elemental analysis. Gold(I) complexes 4.15 
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The synthesised ligands and complexes were tested for their 
antiplasmodial activity against chloroquine-sensitive (D10, 
3D7) and chloroquine-resistant (W2, K1) strains of the 
malaria parasite Plasmodium falciparum. These compounds 
were also evaluated for inhibitory activity against the 
malarial cysteine protease (falcipain-2). In most cases 
gold complexes showed enhanced antiplasmodial activities 
relative to their corresponding ligands. However, no 
correlation was found between antiplasmodial activities and 
the inhibition of falcipain-2 in respect of studied 
compounds. 
 
Reaction of TSC thioesters 6.23 with branched dendritic 
polyamines (PAs) led to two series of polyamine-TSC 
dendrimers 6.24 and 6.25 whose chemical structures were 
elucidated using a range of techniques. Similarly, these 
dendritic TSCs were also tested for their antiplasmodial 
activity against the W2 strain. Generally, this class of 
compounds displayed improved antiplasmodial activities in 
the mid to low micromolar range. The most active compounds 
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CHAPTER 1 
 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 HISTORY OF MALARIA AND ITS DISCOVERY 
 
alaria remains amongst the leading global health 
security threats worldwide.
1
 It is one of the earliest 
diseases,
2
 which has infected humans for many centuries.
3
 It 
could be traced as far back as in 2700 BC, and evidence 
showing early documentations of the disease is found in 
recorded history in China, the Middle East and ancient 
Egypt.
4
 The Romans named the disease “mala aria” – as at 





It was however, not until 1880 that the true cause of 
malaria became clear. Charles Louis Alphonse Laveran 
discovered the parasite in human blood, and was awarded a 
Nobel Prize in 1907.
3
 Several years later the mode of 
transmission of the disease was demonstrated by Ronald 
Ross. He identified mosquitoes as being the vector of the 
protozoan parasite, and established the complete parasite 





1.1.1 Malaria Today and Extent of the Problem 
 
Malaria puts economic affairs of many affected countries in 
jeopardy. Despite years of research,
5,6
 to date, malaria 
remains a major cause of illness. The burden of this 
disease remains a major concern as recent estimates stand 
well above 300 million infections annually.
7,8
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toll due to the disease is on the increase and more 




Table 1.1: Estimates of malaria cases and death by region. 
 
Region Global cases [%] Global death [%] 
Africa 71 85.7 
Asia 26 9.4 
The Americas 1 0.1 
Middle East <3 ~5 
 
Currently, between 1 and 3 million people are being killed 
by the disease each year.
11,12
 More than 75% of the victims 
are African children under the age of five years and women 
during pregnancy.
12,13
 About thirty high-burden countries in 
Africa and five in Asia contribute to 98% of the total 
deaths globally. 
 
1.1.2 Malaria Distribution and Population at Risk 
 
In many countries, malaria is widely accepted as a greater 
health problem. Fig. 1.1 below illustrates the geographical 
distribution of the disease worldwide.
14
 The disease is 
prevalent in areas where environmental conditions are 
conducive for vector multiplication. It is estimated that 
over 40% of the world‟s population resides in malaria 
endemic areas, which are centred not only in tropical, but 
also in many temperate regions.
15
 As malaria is a non-
uniform disease due to many manifestations, its impact 
varies depending on the epidemiological setting. Some of 
the figures released by WHO are that 36% of the global 
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risk of malaria transmission, 7% is in areas where there 
has been non-existence of meaningful malaria control.
16
 
While regions which were once declared malaria free zones, 
29% of the population in those areas is now experiencing 




Figure 1.1: Geographical distribution of malaria.14 
 
Whilst the development of new treatments to combat drug 
resistant strains is critical, it is equally essential to 
understand the biochemistry (i.e. the life cycle of 
Plasmodium species) of the parasite as it forms the basis 
for the discovery of new drugs. 
 
1.2 BIOCHEMISTRY OF PLASMODIUM FALCIPARUM 
 
1.2.1 The Life Cycle of the Parasite 
 
P. falciparum is one of the four species of protozoan 
parasites (the other three are P. vivax, P. malariae and P. 
ovale), which are pathogenic in humans and also the most 
dangerous. The life cycle of the malaria parasite is 
depicted in Fig. 1.2.
17
 It is comprised of the asexual and 
sexual phases. The former takes place in the host and the 
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1.2.1.1 Host: Asexual Phase 
 
Malaria transmission to humans is initiated by the bite of 
an infected female anopheles mosquito during blood feeding. 
In the course of this event, the mosquito injects saliva 





Figure 1.2: The life cycle of the malaria parasite.17 
 
The sporozoites, after at least four hours at the injection 
site, find their way to the liver where they invade 
hepatocyte cells. Inside the cells, sporozoites develop 
into exo-erythrocytic schizonts in a period of 9–16 days.
7
 
Each schizont contains thousands of “daughter” parasites 
called merozoites (2). Upon the release (coinciding with 
sharp increases in body temperature) from hepatocyte cells, 
they invade the red-blood cells (RBC) where each matures 
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rupturing of the RBC results in the release of merozoites 
(3), which are free to invade additional RBC. The rupturing 
of RBC is associated with intermittent fever, which signals 




1.2.1.2 Mosquito: Sexual Phase 
 
The parasite may differentiate into sexual forms called 
gametocytes (4). Ingestion of gametocytes by the mosquito 
vector during its blood meal results in fusion of gametes 
(macro and microgametes) to form a zygote, enabling the 
parasite to escape from the erythrocytic host. The 
resulting zygote elongates and forms ookinetes, which 
develop in the oocysts once it has penetrated the cell wall 
of the mosquito vector. The oocyst is then multiplied 
asexually within the vector resulting in the production of 
sporozoites. Rupture of the mature oocysts releases 
thousands of sporozoites into the body cavity of the 
mosquito, which migrate to and invade the salivary glands, 
thus completing the life cycle. The Plasmodium life-cycle 
is initiated again when an infected mosquito bites a 
susceptible vertebrate host (5). 
 
1.2.2 Ingestion and Haemoglobin (Hb) Degradation 
 
As merozoites intensely multiply within the RBC during the 
life cycle, a constant availability and/or supply of 
nutrients is required for parasite proliferation.
19
 The 
parasite has limited capacity to synthesize its own amino 
acids, therefore, degradation of Hb is a viable option as a 
source of amino acids for protein synthesis.
20
 In addition, 
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osmotic stability within the RBC.
20a,21
 During the life 
cycle, the P. falciparum trophozoite ingests and degrades 
approximately 75% of host cell Hb.
20a,22
 This process occurs 







Figure 1.3: A schematic diagram of RBC showing the transport of 




During this event, Hb is ingested by means of cytosomes via 
endocytosis, an essential process occurring in all 
eukaryotic cells for uptake of external macromolecules 
(e.g. proteins), particles and fluids as nutrient sources 
to sustain their survival.
24
 Vesicles from cytosome 
transport Hb to the acidic FV (pH~5.2-5.8) where the 
degradation occurs mediated by proteolytic enzymes. 
Essentially, degradation of haem-protein complex by the P. 
falciparum parasite during its life cycle results in the 
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1.2.3 Haem Detoxification 
 
During the process of Hb hydrolysis, free haem or Fe(II)-
protoporphyrin-lX is released.
21,22,25
 Haem, which leads to 
cell lysis is oxidized to haematin. Released haematin is 
detoxified to a cyclic dimer called ß-haematin. The 
crystallization of dimers gives rise to micrometer-sized 
crystals, haemozoin (malaria pigment),
26
 which are harmless 
to the parasite. These crystals are considered markers of 




1.2.4 Proteolytic Enzymes 
 
Several enzymes have been demonstrated to be involved in Hb 
proteolysis. These include: i) aspartic proteases namely: 
plasmepsins I, II, IV and a closely related histo-aspartic 
protease (HAP), ii) cysteine proteases namely: falcipain-2, 
-2‟ and -3, iii) Zinc metalloprotease or falcilysin and 
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1.2.4.1 Aspartic Proteases 
 
Plasmepsins I and II have been postulated to initiate Hb 
digestion by cleaving preferentially the peptide bond 
between residues Phe33-Leu34 of Hb protein (Fig. 1.4).
27,28
 
Although plasmepsin IV is presumed to have weak proteolytic 
activity against the native protein, it appears to act 
synergistically with plasmepsins I and II as well as FP-2 
and FP-3. However, the histo-aspartic protease is active 
against globin. In essence, these enzymes are responsible 
for splitting Hb into globin and haem (Fig. 1.4). 
 
1.2.4.2 Cysteine Proteases 
 
During the erythrocytic stage of the life cycle P. 
falciparum is reported to express three cysteine proteases: 
falcipain-1 (FP-1), identical copies of falcipain-2 (FP-2 
and 2‟) and falcipain-3 (FP-3) (Fig. 1.4).
27,29
 FP-1, located 
on chromosome 14, shares approximately 40% sequence 
identity with FP-2 and FP-3. However, the function of FP-1 
remains uncertain due to its low abundance in trophozoites 
and inadequate systems to produce recombinant protease. 
This enzyme has been suggested to play a role in oocyst 





On the other hand, FP-2 and FP-3 with 65% of amino acids 
identity are abundant trophozoidal proteases. The location 
of these enzymes in the FV is consistent with their roles 
in Hb digestion.
27
 Although FP-2 and FP-3 show a high level 
of sequence homology, they differ in terms of substrate 
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1.2.4.3 Metalloproteases and Aminopeptidases 
 
Falcilysin is a zinc metalloprotease, which is active in 
cleaving the smaller peptides into oligomers. These are 
hydrolyzed further into smaller fragments (amino acids) in 




1.3 TREATMENT OF MALARIA: “OLD DRUGS” 
 
The principal means to combat the disease remains 
chemotherapy.
32
 Treatment of the disease with clinically 
established antimalarial drugs has been a success in 
fighting severe clinical cases. However, millions of people 
are still at risk of contracting malaria due to drug 
resistant parasites.
9,33
 It is noteworthy that although the 
discussion is on “OLD DRUGS”, antimalarial drugs which were 
discovered more than 50 years ago, there has been 
significant work done in terms of new chemical entities 
that are effective against the resistant parasite, and 







1.3.1 Classification of Available Antimalarial Drugs 
 
Antimalarial drugs can be classified into three main 
categories,
35,36
 and these include i) the stage of the 
malaria parasite that they affect and the corresponding 
clinical objective. ii) the antimalarial activity, and iii) 
the common structural feature. Herein, the antimalarial 
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1.3.1.1 4-Aminoquinolines 
 
The most common antimalarial drugs in this class include 
chloroquine (CQ, 1.1) and amodiaquine (AQ, 1.2) in Fig. 
1.5. These agents are considered the main antimalarial 
drugs due to their proven success in both treatment and 
prophylaxis. However, the reputable agent has been 1.1. Its 
initial success as the preferred drug to control malaria 
was mainly due to its safety, affordability and efficacy. 
The widespread emergence of chloroquine-resistant parasites 
however, has destabilized the usefulness of this drug.
37
 
This prompted the use of alternative antimalarial drugs 
such as 1.2. This structurally related drug has been used 
as prophylaxis for several years,
38
 but a degree of cross-
resistance and potential hepatic toxicity are limiting the 














Figure 1.5: Chloroquine (1.1) and amodiaquine (1.2). 
 
Whilst the 4-aminoquinolines, in particular 1.1, have been 
effective for many decades, understanding their mechanisms 
of action and resistance remain a major challenge. The 
commonly accepted hypothesis is that quinoline-containing 
drugs act by binding to haematin, thus preventing the 
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Despite the partial understanding and complexity of 
resistance to quinolines, it is reported that resistance 
seems to be related to the appearance of gene mutations in 
two FV membrane proteins, which lower the concentration of 
quinoline drugs in the target.
40
 This gene pfcrt, believed 
to function as a transporter in the parasite FV,
12
 encodes a 
424-amino acid protein commonly known as P. falciparum 
chloroquine resistance transporter (PfCRT).
40,41
 Studies by 
Fidock and co-workers correlated the point mutations in 
pfcrt to CQ resistance in vitro using strains from Africa, 






The 8-aminoquinolines are comprised of drugs such as 
primaquine (PQ, 1.3a) and pamaquine (1.3b), originally 









1.3a: R = H, Primaquine
1.3b: R = Et, Pamaquine
 
 
Figure 1.6: Primaquine (PQ, 1.3a), pamaquine (1.3b) and methylene 
blue (MB, 1.4). 
 
Compound 1.3a was developed after it was noted that the 
first synthetic drug, methylene blue (MB, 1.4),43 exhibited 
antimalarial properties. Although 1.3a exhibited radical 
cure, its high toxicity led to the search for a milder 
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appears to be different from those of 4-aminoquinolines. 
For example, 1.3b is believed to radically cure P. vivax 
infections by acting on the gametocyte and hypnozoite 
(liver reservoirs) stages, and has been regarded as an 
ideal drug for this purpose. Other studies suggest that 





Arylamino alcohols, which also possess the quinoline 
scaffold, are a class of compounds with reputable history 
in the treatment of malaria. The first quinoline-methanols 
to be reported originating from the bark of the Cinchona 

















Figure 1.7: Quinine (1.5), quinidine (1.6). 
 
For many years 1.5 was the only known effective treatment 
of malaria.
12,46
 Although the clinical use of 1.5 and 1.6 
have been in decline due to the low therapeutic index and 
toxicity, the advent of multi-drug resistant strains 
necessitated the use of 1.5 for treatment of severe cases. 
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A second class of quinoline-methanols are synthetic 
analogues mefloquine (MQ, 1.7) and halofantrine (1.8) in 
Fig. 1.8. Whilst 1.7 and 1.8 are effective against 
chloroquine resistant (CQR) strains, they are also 
vulnerable to the emergence of cross-resistance.
47
 
Additional limitations to these drugs include occasional 
neuropsychiatric disturbances for 1.7, and strong contra-





















Figure 1.8: Mefloquine (1.7) and halofantrine (1.8). 
 
Although compounds 1.7 and 1.5 are antagonistic in action 
with CQ, they primarily act on intraerythocytic asexual 
stages of the parasite as CQ. Reported cases of resistance 
to 1.7 and 1.5 are being associated with the P. falciparum 
multidrug resistance protein (PfMDR1). The protein PfMDR1 
is reported to form a vacuolar channel and by means of its 
expression (through copy number) or mutations, modulates 
sensitivity to antimalarial molecules, including, compounds 
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1.3.1.4 Pyrimidines, Amidines and Guanidines 
 
This class of compounds is classified as type-2 
antifolates:
49
 pyrimethamine (1.9), cycloguanil (1.10), 




























Figure 1.9: Pyrimethamine (1.9), cycloguanil (1.10), proguanil 
(1.11) and trimethoprim (1.12). 
 
As the parasite requires folates for protein synthesis, 
pyrimethamine (1.9) and proguanil (1.11) inhibit the 
activity of dihydrofolate reductase (DHFR), an enzyme 
responsible for the synthesis of parasitic DNA. It is 
believed that DHFR inhibitors such as 1.9 inhibit parasitic 
DHFR via the active metabolite cycloguanil (1.10), thus 
resulting in the inhibition of tetrahydrofolic acid 
synthesis. These inhibitors mimic the pteridine ring of 
DHF, and thereby compete with DHF for the active site of 
the enzyme. Single mutations in the gene encoding for DHFR 
are believed to be the cause of resistance by the parasite. 
 
1.3.1.5 Sulfonamides and Sulfones 
 
A second class of antifolates, which are classified as 
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include sulfonamides and sulfones: sulfadoxine (1.13) and 















Figure 1.10: Sulfadoxine (1.13) and dapsone (1.14). 
 
These compounds act by competing with para-aminobenzoic 
acid (PABA) for the active site of dihydropteroate synthase 
(DHPS), thereby, preventing the formation of 
dihydropteroate from hydroxymethyldihydropterin, a reaction 
catalysed by DHPS.
35
 As in type-2, resistance to type-1 
antifolates is conferred by single mutations of the gene 




In this class the common drug is atovaquone (1.15) in Fig. 
1.11. The antimalarial properties of these compounds were 
first noted in the early 1940s when hydrolapachol (1.16) 
was found to be active against avian malaria.
12,50
 Atovaquone 
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Although it is known that 1.15 primarily acts on 
mitochondrial functions, the mechanism by which it acts, 
and its synergistic effect with 1.11 remain not fully 
understood. By and large, the consensus is that 1.15 acts 
on the mitochondria via an electron transfer chain. The 
activity and synergy of 1.15 have been attributed to its 




The tetracyclines (Fig. 1.12) are a class of compounds with 
pronounced history in the treatment of malaria.
18
 The 
interest in tetracyclines (antibiotics) emerged from the 





















Figure 1.12: Tetracycline (1.17) and doxycycline (1.18). 
 
These are well exemplified by 1.17 and 1.18 (Fig. 1.12). 
Tetracyclines are believed to act by inhibiting the 
parasite protein synthesis in the mitochondria and/or 
apicoplast (an organelle that is unique to apicomplexan 
parasites).
47
 Relative slow action of these antimalarials 
warrants concurrent treatment with 1.5 (Fig. 1.7) for rapid 
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1.3.1.8 Sesquiterpene Lactones 
 
Artemisinin (1.19, Fig. 1.13), a natural product derived 
from the Chinese herb „qinghao‟ (Artemisia annua) 
represents this class of compounds. In China, it has been 
utilised to treat high fevers for many years including 
cases of multidrug-resistant P. falciparum.
51
 However, 
artemisinin possesses low solubility in water and lipids. 
Consequently, the derivatives artemether (1.20), arteether 
(1.21) and artesunate (1.22) have been developed to improve 
its bioavailability (Fig. 1.13). Although resistance to 
these drugs has not been observed,
48
 a few cases of 
decreased sensitivity have been reported in some areas, and 
evidence of resistance to artemisinin-based combination 




1.19 1.20: R = CH3
1.21: R = CH2CH3










Figure 1.13: Artemisinin (1.19), artemether (1.20), arteether (1.21) 
and artesunate (1.22). 
 
The mode of action of these drugs is not fully understood, 
but it is believed that the antimalarial action is as a 
consequence of reductive cleavage of intact peroxide by 
haem to form C-centred radicals. The resulting radicals 
alkylate haem to form haem-artemisinin adducts, which lead 
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by C-centred radicals has been put forward as a possible 
mode of action of artemisinins. Instead of heterolytic 
cleavage of the peroxide bridge, it has been hypothesised 
that the bridge undergoes homolytic cleavage to generate 
hydroperoxides, which might be converted into peroxy 
radicals or transfer oxygen to oxidizable substrates.
49,51
 
Other mechanisms of action that have been suggested include 
the inhibition of a Ca
2+
 ATPase (a protein which is not 
localized in the FV) together with inducible nitric oxide 
synthetase and nuclear factor NF-B.53 
 
1.3.2 Antimalarial Effects of Iron Chelators 
 
Several studies have been conducted to evaluate the 
clinical potential of iron chelators.
12,54
 Desferrioxamine 
(DFO, 1.23 in Fig. 1.14) and other iron chelators have been 































Figure 1.14: Iron chelators as antimalarial agents. 
 
This compound inhibited the growth of P. falciparum in 
vitro. More importantly, clinical cases were resolved 
faster when 1.23 was used in combination with traditional 
antimalarial drugs. For example, 1.23 demonstrated fast 
clearance of the parasite and recovery from coma when it 
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The other extensively studied member of this group is a 
spermidine derivative (polyamine) 1.24 (Fig. 1.14), which 
displayed good activity against P. falciparum in culture. 
Although the mode of action of iron chelators remains 
unclear, it has been suggested that they may act by 
depriving iron for rapidly multiplying parasites or form 




1.4 APPROACHES TO ANTIMALARIAL DRUG DEVELOPMENT 
 
Amongst various approaches that have been adopted,
56
 the 
most widely used is the development of chemically related 
analogs of existing drugs and identification of novel drug 
targets including the design of chemical entities acting on 
these targets.
57
 Currently, there exists enough evidence 
suggesting that cysteine proteases are potential drug 
targets.
31
 More importantly, these enzymes are found in 
viruses, bacteria, protozoa, plants, mammals and fungi,
58
 
which justify more research efforts to identify novel 
inhibitors. In this work FP-2, which is a member of 
cysteine proteases family is being pursued as one of 
targets for gold thiosemicarbazone (TSC) complexes (details 
in Chapter 3, 4 and 5). 
 
1.4.1 Parasitic Cysteine Proteases and Their Inhibitors 
 
These enzymes are potential chemotherapeutic targets due to 
their role in the life cycle of protozoan parasites. In the 
malaria parasite, proteases appear to be useful in Hb 
hydrolysis, erythrocyte invasion and erythrocyte rupture.
56a
 
In humans these enzymes are implicated in various diseases 
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respiratory, viral, musculoskeletal, immunological, CNS 
disorders and cancer.
59
 Since our focus in this work is on 
P. falciparum, discussion will be limited to cysteine 




The first cysteine protease to be purified and 
characterised in 1879 originated from papaya fruit Carica 
papaya, and was then named papain.
60
 Proteases exhibiting 
common sequences with papain have been referred to as 
„papain-like‟. The genome sequence of P. falciparum 
revealed that there exist over ninety proteases.
61
 Cysteine 
proteases in P. falciparum are grouped according to their 
catalytic mechanism into five clans. 
 
The active site comprises of two amino acid residues (i.e. 
Cys 25 and His 159), which are important in the hydrolysis 
of peptide bonds. Depending on sequence identities and 
similarities, clans are further divided into three main 
groups known as clan CA, CD and CE. Clan CA family C1 
consists of falcipains, dipeptidyl peptidases, serine-rich 
antigen (proteins) and calpain homologs. Analysis of clan D 
and E have suggested members of these families to be 
corresponding to the P. falciparum genome. 
 
1.4.1.2 Proteases and Binding Sites 
 
For the hydrolysis of a peptide bond to occur, binding 
efficiency of a protease and the substrate is of great 
importance.
60
 This is comprised of a combination of both 
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and the chemical nature of the substrates (P) that interact 





























Figure 1.15: Nomenclature of substrate and protease subsite. 
 
The limitation of substrates to interact with the available 
subsites may include factors such as size, polarity, 
charge, hydrophobicity and accessibility. The standard 
nomenclature to designate substrate residues and the enzyme 
subsites originated from the model described by Schechter 
and Berger, and is still commonly used to date.
62
 The 
catalytic site is located within the substrate with the 
binding pockets (subsites) for amino acids N-terminal to 
the scissile amide bond are designated S (i.e. S1, 
S2...Sn), and S‟ (i.e. S1‟, S2‟…Sn‟) for the C-terminal. 
Substituents of the corresponding substrate (or inhibitor) 
to interact with subsites are designated with P (i.e. P1, 
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1.4.1.3 Proteolytic Mechanism of Cysteine Proteases 
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The catalytic process starts with imidazole moiety of the 
histidine residue whose close proximity to the sulfhydryl 
group polarises the „SH‟ group. Deprotection of the latter 
give rise to a thiolate/imidazolium ion pair (I). The 
resulting nucleophilic thiolate attacks the carbonyl carbon 
of the scissile amide bond to produce a tetrahedral 
intermediate, which is stabilized by H bonding of both the 
backbone NH of Cys 25 and NH2 group of the Gln 19 side chain 
(II). The tetrahedral intermediate transforms into an acyl 
enzyme (enzyme-substrate thiol ester) (III) and 
simultaneously releases the C-terminal portion of the 
substrate (deacylation). Subsequently, the hydrolysis of 
the acyl enzyme with water (IV) results in the formation of 
a second tetrahedral intermediate (V), which finally splits 
(VI) into free enzyme and N-terminal portion of the 
substrate (deacylation). 
 
1.4.2 Falcipain Inhibitors 
 
To date, many chemotypes have been identified as inhibitors 
of malarial cysteine protease FP-2. These include peptides 
(1.25-1.27), peptidomimetics (1.28), isoquinolines (1.29), 
chalcones (1.30) and TSCs (1.31-1.35) in Fig. 1.16.27 These 
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Figure 1.16: Falcipain inhibitors. 
 
As part of ongoing research on novel inhibitors of FP-2, 
Chiyanzu et al.
64
 designed TSCs as potential antimalarial 
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series was found to be compound 1.31. In a subsequent study 
of Greenbaum et al.
65
 compound 1.32 was the only TSC active 
against FP-2, but inactive against the whole parasite 
cultures at highest tested concentration (ED50 = 20 M). 
More recently, TSCs with a phenolic Mannich base component 
were synthesised from our laboratory and screened for their 
activities against FP-2 and CQ-resistant P. falciparum W2 
strain.
66
 From the series, compounds 1.33-1.35 displayed 
good activity against FP-2. The study suggested that the 
activity of this series was not only due to the TSC side 
chain, but the combined effects of both Mannich base and 
TSC components. 
 
A recent report by De Oliveira et al.
67
 demonstrated the 
activity of some TSCs against the P. falciparum W2 strain, 
further lending support to some of observations made by 
others. In contrast, Mallarai et al.
68
 concluded recently 
that TSCs do not represent promising antimalarial leads as 
some of the tested compounds in their library were 
virtually ineffective against the parasite. 
 
1.4.3 Drug-Polyamine Conjugates 
 
Given the role of PAs in key process such as cell growth, 
differentiation and macromolecular synthesis; enzymes 
involved in PA biosynthesis pathways have been suggested as 
targets in treatment of parasitic diseases.
57
 However, an 
attractive approach which has been a success in cancer 
chemotherapy in recent years is the development of drug-
polyamine conjugates, to target the polyamine transporter 
(PAT).
69
 Drug-polyamine conjugation involves covalent 
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utilised by cells to import PAs from external sources. Due 
to their multivalent and cell recognition properties, 
branched PAs have been proposed as ideal scaffolds to 
covalently anchor TSCs (for details see Chapter 6, p 183). 
In this study, it was hypothesized that formation of TSC-PA 
conjugates could lead to enhanced antiplasmodial potency. 
 
1.4.4 Metal-Based Antimalarial Agents 
 
Due to the limited number of effective drugs and the 
emergence of drug resistance, there exists a need for 
increased efforts to search for new compounds with novel 
modes of action. Currently, new chemical entities are 
continuously being discovered and screened for their 
activities against the parasite;
34
 and the category of 
metallodrugs is receiving considerable attention as 
potential antimalarial agents. 
 
In this work, the approach of using metal-based compounds 
against P. falciparum will be exploited further due to the 
observed pharmacological properties of gold (Chapter 2) and 
TSCs (Chapter 3) against various diseases. The real 
question behind this approach is whether gold complexation 
will enhance the antimalarial potency of TSCs against P. 
falciparum strains. Briefly, Chapter 2 reviews the role of 
starting metal complexes and ligands in the design of 
metal-based agents. The role of gold in medicine and its 
relevance in the fight against P. falciparum malaria, and 
other metalloantimalarial compounds which have been 
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CHAPTER 2 
 




he advent of Cisplatin

 (2.1, Fig.2.1) and its 
derivatives as potent anticancer metallodrugs (metal-
based drugs) has prompted interest in using other metal-
based compounds for the treatment of various diseases.
1
 
Although the utility of metallodrugs as antiparasitic 
agents is limited, there are some successes such as the 
clinical use of antimony-based compounds (e.g. Glucantime
®
, 
2.2 in Fig. 2.1) to treat leishmaniasis.2,3 Generally, 
metallodrugs can be described as chemically synthetic 
agents containing a metal or metal ion coordinated to a 
suitable ligand. On the other hand, a ligand is a molecule 
(in some cases biologically active) with sufficient donor 






















 (2.1) and Glucantime® (2.2). 
 
Although some pharmaceutical companies have removed metal-
based compounds from their libraries which are used in 
high-throughput screening programs,
4
 there are some existing 
opportunities to exploit metal complexes in the development 
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especially malaria due to its prevalence in poor countries.
5
 
The potential toxicity of metals is often cited as one of 
the reasons for their exclusion in companies and some 
academic institutions. 
 
2.2 METAL COMPLEXES 
 
Metal complexes have been reported to compliment organic 
molecules as structural scaffolds for bioactive compounds.
5b
 
They can be designed such that instead of the metal 
assuming the structural role, it contains a vacant 
coordination site - in some cases with the loss of a labile 
ligand - to bind with amino acids (e.g. cysteine, histidine 
and tyrosine) in the target active sites. 
 
A key feature in the design of metal complexes with 
desirable effects lies with suitable ligands to support 
metals directed towards a particular target. Different 
ligands are believed to impart various physical and 
chemical characteristics on a metal.
6
 Metal complexes with 
suitable ligands exhibit unique properties that may be 
exploited for the development of probes to unravel the 





2.3 DESIGN AND THE ROLE OF LIGAND SYSTEMS 
 
Apart from their role in traditional coordination 
chemistry, ligands are of greater importance in 
modification of biological effects of metal complexes.
6
 
Depending on the requirements (therapy or diagnosis), 
ligands are capable of: i) modifying the oral or systematic 
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or enzymes, iii) delivering, protecting or sequestering 
metal ions. They can also be involved in protecting tissues 
from toxic metals or enhance uptake of pharmacologically 
beneficial metals. Fine-tuning of ligands by appending 
substituents that bind membrane receptors or mimic 
naturally-occurring hormones, is believed to render metal 
complexes with target specificity to achieve the desired 




In some cases the strategy of using bioactive ligands to 
form metallodrugs has been widely used to form metal 
complexes with enhanced bioactivities.
5a
 For example, 
bioactive ligands (Fig. 2.2) clotrimazole (2.3) and 
ketoconazole (2.4) formed effective anti-malarial and anti-
trypanosomal complexes (compared to their free form) with 





















Figure 2.2: Clotrimazole (2.3) and ketoconazole (2.4). 
 




Medicinal use of gold dates back to antiquity when both 
Arabic and Chinese cultures used it to treat various 
ailments.
8
 However, it was not until the early 1920s when 
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gain wide support. This followed the disclosure by Robert 
Koch (bacteriologist) in 1890 that the gold complex, 
K[Au(CN)2], was lethal against the micro-organism 
mycobacterium, a causative agent of tuberculosis (TB).
9
 The 
introduction of gold thiolate complexes to treat TB came 
after it was observed that K[Au(CN)2] had significant side 
effects when applied in pulmonary TB. Concurrently, in the 
early 1930s Jacque Forenstier, a French physician, 
introduced gold thiolate complexes for the treatment of 





2.4.2 Antirheumatoid Arthritis Activity 
 
RA is a painful and disabling disease characterised by 
inflammatory and progressive joint erosion. Fig. 2.3 shows 
some of anti-RA gold compounds (2.5-2.7) and indomethacin 
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The first injectable gold(I) thiolate complexes to be used 
clinically for treating RA are aurothiomalate (2.5) and 
aurothioglucose (2.6).3 However, the toxic side effects 
observed (e.g. nephrotoxicity) with these compounds 
prompted the search for new and less toxic complexes. The 
primary objective during the search was to ensure that the 
proposed gold compound (drug) should be administered orally 
in low doses. This led to the development of auranofin 
(2.7), which was introduced in the clinic (1985) to treat 
severe cases of RA. Regrettably, its efficacy was found to 
be lower compared to that of polymeric gold(I) thiolate 
complexes; and some of the patients who were treated with 
this drug suffered from serious side effects.
8b
 The use of 
2.7 has been declining due to the popularity of NSAIDS such 
as indomethacin (2.8).10 
 
Recently, Sannella et al.
11
 demonstrated that 2.7 in 
combination with artemisinin (1.19) displays good activity 
against the malaria parasite 3D7 strain. This suggested 
that there is great potential for using 2.7 (since it is a 
clinically established drug) in combination therapy to 
counteract cases of drug resistance, a major limiting 
factor in most standard antimalarial drugs. 
 
2.4.3 Antitumour Activity 
 
Since the first report by Simon et al.
12
 on the antitumour 
activity of 2.7 in 1979, gold(I) complexes have been 
considered in cancer chemotherapy due to the growing 
interest in non-platinum metal complexes with novel modes 
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as antitumour agents mainly involved the modification of 
2.7 to generate various analogous complexes. 
 
Recently, Ott et al.,
13
 de Vos et al.
14
 and Casas et al.
15
 
reported gold(I) complexes 2.9-2.12 (Fig. 2.4) with 
pronounced antitumour activities against HeLa and A2780 
(cisplatin resistant) cell lines. These compounds were 
prepared by replacing the carbohydrate ligand with 
naphthalimide, dithiocarbamate, azacoumarin and vitamin K3 
derived TSC. These examples serve as a clear indication of 
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A second class of gold(I) complexes pursued in the 1980s is 
that of four coordinate gold complexes. The prominent 
complex is 2.13 (Fig. 2.4), reported in the mid 80s to be a 
promising compound against solid tumours.
16
 Unlike complex 
2.7, this compound exhibited antitumour activities against 
a panel of human cell lines including leukaemia cells.
16
 
However, it failed to reach clinical trials due to 





Owing to electronic and geometric similarities of gold(III) 
with platinum(II), gold(III) complexes have been reported 
to be amongst the first non-platinum complexes to be tested 
for antitumour activities.
18
 However, the development of 
these compounds as therapeutic drugs has been questioned 
due to their instability under physiological conditions.
9,19
 
The design of better ligands such as PAs, cyclam, 
terpyridines, porphyrins, phenanthrolines, and N-benzyl-
N,N-dimethylamine (damp) to stabilise gold(III) has renewed 
interest in the search for gold(III) complexes as potential 
anti-tumour agents.
20
 As a result, a number of gold(III) 
compounds have been evaluated in vitro against a panel of 





2.4.4 Antimicrobial Activity 
 
The early work by Robert Koch revealing that gold compounds 
were active against the tubercucle bacillus, prompted 
extensive utility of gold(I) thiolate complexes for the 
treatment of tuberculosis during the period 1925-1935, the 
“gold decade”.
22
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compounds were found to be active against a broad spectrum 
of micro-organisms. Although there has been little novel 
work on the antimicrobial activity of gold compounds,
16
 a 
number of different metal complexes have also been tested 
for antimicrobial activity against a panel of bacterial 
strains and clinical isolates of methicillin-resistant S. 
aureus (MRSA), methicillin-sensitive S. aureus, 
enterrococci, coagulase-negative staphylococci and 
streptococci. This came after it was realised that there is 
growing need for new antimicrobial agents such as 
vancomycin (2.14, Fig. 2.5), the drug of choice for these 
organisms, and other standard drugs are facing various 












































Figure 2.5: Chemical structure of vancomycin (2.14). 
 
A gold(I) compound that has been demonstrated to be active 
against Gram positive bacteria and MRSA is the gold(I) 
thiocyanate complex, which has been found to be selective 
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with MIC50 (minimum concentration inhibiting 50% of 
bacterial growth) of 0.33 and 0.77 against Staphylococcus 
aureus and Enterococcus faecalis. This study revealed that 
toxicity doses of at least ten times higher are required to 
kill CHO cells.
16a
 In addition, Nomiya et al.
23
 demonstrated 
the antimicrobial activity of some gold(I) complexes 
derived from heterocyclic, penicillamine and „mercaptant‟ 
acids. 
 
Further search for antimicrobial gold complexes led to the 
identification of gold(I) phosphonium dithiocarboxylate 
complexes, which exhibited activity against Gram positive 
bacteria and cocci.
16a
 Recently, Jackson-Rosario et al.
24
 
reported the activity of 2.7 against Clostridium difficile, 













Figure 2.6: Gold(III) complexes 2.15 and 2.16. 
 
The antimicrobial activity of gold(III) complexes 2.15 and 
2.16 has also been investigated (Fig. 2.6). These compounds 
exhibited broad spectrum activity against a range of 
organisms with a small degree of specificity against Gram 
positive bacteria S aureus and E. faecalis.
16a
 These 
compounds also exhibited remarkable activities against an 
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2.4.5 Anti-HIV Activity 
 
The observations made from clinical data of HIV+ patients 
not undergoing antiretroviral treatment, but treated with 
2.7 (Fig. 2.3) for psoriesis experienced increasing CD4+ 
cells, have stimulated interest in gold compounds for the 
treatment of AIDS.
25
 Consequently, various gold compounds 
have been evaluated for their ability to inhibit the HIV 
virus. Sodium aurothiomalate (2.5) and aurothioglucose 
(2.6) are amongst those gold(I) compounds, which have been 





, has been shown to inhibit the proliferation of 
HIV in cultured T-9 cells (strain of CD4+ T cells) with an 
IC50 value of 20 nM. This has prompted interest in its 
potential to treat HIV/AIDS in combination therapy. 
Gold(III) compounds containing a porphyrin ligand have also 
been reported to be potent against the reverse 





2.5 ANTIMALARIAL ACTIVITY 
 
As previously mentioned, malaria is a tropical disease 
which causes devastation in the populations residing in 
tropical regions. Although gold compounds have been studied 
extensively against other diseases (previous sections), 
their potential application as antimalarial agents has not 
been explored to a great degree. The first attempt to 
explore gold compounds against malaria was reported by Wasi 
and co-workers in 1987.
28
 A metal-synergic effect approach 
reported as far back as 1976 prompted Wasi et al.
28
 to 
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on gold(III).
29
 These complexes were obtained by employing 
amodiaquine (1.2, Fig. 1.5) and primaquine (1.3a, Fig. 1.6) 
as ligands. The complexes were found to be active against 
P. falciparum to the same extent as the parent drugs. 
 
2.5.1 Gold(I) Complexes 
 
In the early 1990s, the group of Sánchez-Delgado conceived 
an approach of developing alternative agents against 
tropical diseases.
7
 It was hypothesised that modification of 
bioactive compounds by chemically incorporating a 
transition metal into the molecular structure could yield 
antiparasitic agents with improved activity. 
 
As a land mark in gold(I) chemistry, Navarro et al.
30
 
reported the first gold(I) CQ complex (2.17, Fig. 2.7), 
which was active against malaria parasites. Since then 
there has been growing interest in gold(I) complexes as 
potential antimalarial agents.
29
 Complex 2.17 effectively 
inhibited P berghei in vitro, and it was also found to be 
effective against CQ-resistant FcB1 (IC50 = 5.1 nM) and FcB2 
(IC50 = 2.3 nM) strains of P. falciparum. More importantly, 
it was 5-10 fold more active compared to the corresponding 
CQDP, thus lending support to the hypothesis that metal 
coordination results in a significant enhancement of the 
activity of the parent drug against resistant parasites. 
This observation prompted further investigations of gold(I) 
complexes as antimalarial agents. Analogous complexes 2.18 
and 2.19 (Fig. 2.7), which were also several fold more 
active than CQDP against the CQ-resistant strain FcB1, were 
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Sparatore et al.
32
 reported gold(I) complex 2.20 (Fig. 2.7) 
with pronounced activity against the W2 strain. 
 
2.17: R = Ph
2.18: R = Me

























































Figure 2.7: Antimalarial gold(I) complexes. 
 
Motivated by their work on ruthenocene
33
 and that of the 
Biot group on ferroquine (FQ, Fig. 2.7)
34
 against the CQ-
resistant parasite, Blackie et al.
35
 investigated the 
approach of using heterobimetallic complexes obtained by 
reacting rhodium and gold-containing fragments with FQ 
instead of CQ. In the series, complexes 2.21-2.23 (L = 
triphenylphosphine or pentafluorobenzene co-ligands) were 
tested for antimalarial activity against the CQ-resistant 
strain of the parasite.
36
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presence of two metal centers [i.e. gold(III) and iron(II)] 





2.5.2 Gold(III) Complexes 
 
In an effort to develop improved antimalarial agents, 
Navarro et al.
37
 demonstrated the activities of gold(III) 
complexes against several P. falciparum strains. Complex 
2.24 (Fig. 2.8) proved to be more active compared to CQDP 
in both sensitive and resistant strains. Due to a limited 
number of compounds, the structure-activity relationship 











































Figure 2.8: Antimalarial gold(III) complexes. 
 
Recently, Gabbiani et al.
38
 reported gold(III) complexes 
(2.25-2.27) with marked potency (IC50 values of 2.3-12.2 M) 
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compounds were found to be one order of magnitude less 
potent than gold(I) complex 2.7 (IC50 value of 0.142 M). 
 
2.6 GOLD COMPOUNDS: POSSIBLE MODES OF ACTION 
 
Over the last several decades, mechanisms of action of gold 
complexes (antirheumatoid or antiproliferative) remain the 
subject of intense debate.
39
 As a result, several hypotheses 
have been suggested,
40
 but the exact molecular mechanism 
responsible for the pharmacological effects of gold 
compounds is unclear.
41,42
 The available pharmacological data 
for a variety of these compounds has led to the 
identification of a few cellular processes, which are 
likely to be involved in their cytotoxicity.
40
 These include 
direct DNA damage, modification of the cell cycle, 
mitochondrial damage, proteasome inhibition, modulation of 
specific kinases, and other cellular processes. 
 
However, the molecular mechanism of action of gold 
complexes, which may well also account for their anti-
malarial effects (the vast evidence emerged from studies 
mainly involving RA and solid tumour diseases) include DNA 
damage, inhibition of thioredoxin reductase, protein 
kinases (PK) and lysosomal cysteine proteases. These are 
further discussed in the sections hereafter. 
 
2.6.1 DNA as a Target 
 
Mechanistic studies of gold compounds have mostly focused 
on DNA and RNA as these biomolecules are primary targets 
for platinum anticancer drugs.
40
 Several studies based on 
the weak interactions observed in vitro between gold(I) and 
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might be involved in the cytotoxic mechanism of gold(I) 
drugs. 
 
Similarly, extensive studies were conducted on the 
interaction of gold(III) with DNA based on consideration of 
the „harder‟ character of the gold(III) center and its 
propensity to react with nucleobase nitrogens. However, 
these studies revealed that the in vitro interactions of 
several gold(III) compounds are often weak and reversible, 
thus suggesting that interactions are electrostatic in 
nature. The strong gold association with DNA observed in 
some gold(III) compounds is believed to be due to ligand 
dependent interactions, as in the case of porphyrins and 
terpyridines. This indicated that distinct cellular 
processes and targets may be responsible for their 
cytotoxicity.
40
 The overall conclusion from various studies 
is that DNA is neither the primary nor the exclusive target 
for most gold(I) and gold(III) complexes. 
 
2.6.2 Inhibition of Thioredoxin Reductase 
 
Thioredoxin reductase (TrxR) is a homodimeric protein 
belonging to the family of glutathione reductase (GR)-like 
enzymes.
43
 It catalyses the NADPH-dependent reduction of 
thioredoxin (Trx) disulfide and other related oxidised cell 
constituents. This enzyme has been identified in different 
species including the malaria parasite P. falciparum,
44
 
Drosophila melanogaster and humans.
43
 It has broad substrate 
specificities and is involved in numerous metabolic 
pathways (antioxidant network, nucleotide synthesis) and 
pathophysiological conditions.
43
 The active site of TrxR 
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is responsible for the catalytic mode of action of the 
enzyme. 
 
The first study demonstrating the inhibitory effects of 
gold compounds (e.g. 2.6, Fig. 2.3) on crude preparations 
of TrxR was conducted by Hill et al.
45
 A year later, Gromer 
et al.
46
 showed, in more detail, that complex 2.7 (Fig. 2.3) 
inhibited TrxR with high potency and selectivity over the 
other related enzymes (glutathione reductase and 
peroxidase). Consequently, several studies have 
demonstrated that 2.7 is a potent and specific inhibitor of 
both cytosolic and mitochondrial TrxR due to the affinity 
of gold for sulfur and selenium in thiol or selenol 
groups.
47
 In addition, complex 2.7 and other gold(I) 





 mitochondrial permeability and membrane potential 
decrease, possibly due to interaction with the 
mitochondrial isoform of TrxR.
40
 The release of cytochrome c 
triggers apoptosis, which is often accompanied by elevated 
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In the mid 2000s, attention turned to a variety of 
gold(III) complexes for which relevant TrxR inhibitory 
properties were unambiguously established. Rigobello et 
al.
49
 prepared several gold(III) compounds some of which 
inhibited mitochondrial TrxR2. Gold(III) compounds, 
especially Aubipy (2.28) and Aubipyxil (2.29, Fig. 2.9), 
also trigger mitochondrial swelling (but to some degree) 
compared to complex 2.7.49 
 
In a separate study, Urig et al.
50
 demonstrated covalent 
binding of the gold phosphole complex (2.30, Fi.g 2.9) to 
cysteines in the active site of human glutathione reductase 
(hGR), which is structurally related to TrxR but lacks the 
selenol residue in the active site. The experimental 
(crystallography) data, which provided the first concrete 
evidence of gold(I) interacting with hGR, confirmed the 
binding of gold with two cysteine residues to the active 
site of the enzyme. This study suggested that the 
“undressing” – dissociation of surrounding phosphole and 
chloride ligands – of gold complexes might represent the 
general mode of interaction of almost all gold agents with 
cysteine or selenocysteine containing enzymes.
50,51 
 
2.6.3 Inhibition of Cysteine Proteases 
 
Gold(I) salts have been shown to inhibit numerous thiol-
dependent enzymes, including cysteine proteases in vitro.
52
 
The cathepsins, a family of homologous lysosomal cysteine 
proteases, have been extensively studied as biological 





 The enzymes are involved in joint 
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cysteine group in their active site. It is believed that 
coordination of gold(I) with an activated cysteine residue 
in the active site results in inactivation of the enzyme. 
Complexes 2.6, 2.7 and Et3PAuCl are amongst gold(I) 
complexes, which have been shown to moderately inhibit 
cathepsin B activity. Weidauer et al.
54
 showed that complex 
2.5 and 2.7 were moderately potent against cathepsin K and 
S, respectively. 
 
2.6.4 Inhibition of Protein Kinases 
 
Protein kinase C, belonging to a family of structurally 
related protein kinases, is a metalloenzyme containing 
Zn(II) bound to cysteine and histidine residues.
55
 It plays 
an important role in intracellular signal transduction by 
phosphorylating other proteins, especially those with 
serine/threonine residues. The three widely used gold 
complexes, 2.5, 2.6, and 2.7 (Fig. 2.3) have been shown to 
inhibit protein kinase C.
40,55
 This has been suggested as a 
possible mode of action for the therapeutic antirheumatic 
action of gold drugs. 
 
2.7 ANTIMALARIAL ACTIVITY OF OTHER METAL COMPLEXES 
 
2.7.1 Chloroquine-Based Metal Complexes 
 
Metal-based compounds containing CQ have been considered as 
an ideal approach toward novel antimalarial agents over the 
past decade. In the early work of enhancing the 
pharmacological activity of CQ by incorporating metal-
containing fragments, Navarro et al.
56
 demonstrated that 
coordination of rhodium (2.31 in Fig. 2.10) and ruthenium 
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strains of P. falciparum. The same authors reported related 





























Figure 2.10: Antimalarial of platinum group metals with QC. 
 
Recently, Rajapakse et al.
58
 reported Ru--arene-CQ 
complexes, which were active against CQ-resistant strains 
of P. falciparum in vitro. In addition, these compounds 
were consistently more active compared to CQ, and this was 
found to be in agreement (qualitatively) with predictions 
made based on heam aggregation inhibition activity (HAIA) 
measured near water/n-octanol interfaces. Overall, the 
activity of these compounds against the resistant parasite 
has been ascribed to an alteration of the structure, 





On the other hand, Biot and coworkers incorporated a 
ferrocenyl moiety into the side chain of the CQ structure 
through covalent linking to one of the cyclopentadienyl 
units to form an organometallic compound, FQ (Fig. 2.7).
34
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selective against CQ-resistant P. falciparum.
60
 A number of 
FQ analogues have been reported and in most cases they 




2.7.2 Non-Chloroquine-Based Metal Complexes 
 
Metal complexes bearing ligands with a non-chloroquine 
scaffold have also been reported. The overview of some of 
these complexes with antimalarial properties is provided 
below. 
 
2.7.2.1 Bipyradyl and Phenanthroline-Based Complexes 
 
In the late 1990s, Koch et al.
62
 reported self-association 
(i.e. concentration-dependent) of a class of mixed-ligand 
cationic N-acyl-(N’,N’-dialkylthioureato)diimine-derived 
platinum(II) complexes in acetronitrile solution. Intrigued 
by these observations, Egan et al.
63
 hypothesised that these 
complexes may associate with haem. A series of similar 
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Amongst those reported, complexes 2.33-2.35 were found to 
associate strongly with haem and inhibit -haematin 
formation (Fig. 2.11). These complexes – except complex 
2.35 which was moderately active - displayed good in vitro 
antiplasmodial activities (IC50 = 0.28-2.38 M) although it 
was expected that such activities would be weak for two 
reasons. Firstly, since the complexes are cationic, they 
would not efficiently cross biological membranes without 
some specific uptake mechanisms. Secondly, with the 
exception of 2.35 they lack basic groups that are necessary 
for pH trapping in the food vacoule.
63
 Although they 
interacted with haem, there could be no correlation found 
between their acitivity and ability to inhibit -haematin 
formation, which suggested that they may act against other 
targets in the parasite. 
 
2.7.2.2 Naphthoquinone Derived Complexes 
 
In section 1.3.1.6 (p 15), the antimalarial properties of 
naphthoquinones have been discussed. The synthesis and 
investigation into the antimalarial properties of metal 
complexes, e.g. 2.36 (Fig. 2.12), of hydroxynaphthoquinones 
is being stimulated by fact that these compounds are 
capable of chelating biologically relevant ions, and thus 
the metal conjugation influences the redox properties of 
parent quinones.
64
 The research group of Padhye reported 
several transition metal complexes derived from 
hydroxynaphthoquinone ligands. The copper(II) complex 2.36 
(Fig. 2.12) was the most active compound against both P. 
falciparum 3D7 and K1 strains with ED50 values in the range 
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parasitemia at a dose of 15 mg/kg, while the standard drug, 
CQ, needed 10 mg/kg for 100% clearance. More importantly, 
complex 2.36 showed a several hundred-fold enhanced 























Figure 2.12: Antimalarial of copper(II) complexes. 
 
Due to the promising antimalarial activity of copper(II) 
hydroxynaphthoquinone complex 2.36, Gokhale et al.65 
reported the synthesis of copper(II) complex 2.37 (Fig. 
2.12) derived from another class of naphthoquinone ligands, 
viz. 3-arylazo-4-hydroxy-1,2-naphthtoquinones. Within the 
series, complex 2.37 was found to be the most active 
against the 3D7 strain, and displayed approximately 170 
fold enhancement in the antimalarial activity over the 
parent ligand. 
 
2.7.2.3 Schiff-Base Metalloantimalarial Complexes 
 
Schiff-base phenolate coordinated complexes (e.g. 2.38 and 
2.39 in Fig. 2.13) - developed by Sharma and Piwnica-Worms 
– represent an unusual class of antimalarial agents 
targeted against haem aggregation.
66,67
 More importantly, 
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hydrophobicity and delocalized charge for enhanced cell 
membrane permeability. These pseudo-octahedral complexes 
with a N4O2 donor set, which were purposely designed for 
multidrug resistance in cancer cell lines,
68
 have been found 
to possess antimalarial activities (IC50 = 1-3 M) possibly 




















2.40: M = Ga(III), 




M = Al(III), Fe(III), 













Figure 2.13: N4O2 Schiff-based metalloantimalarial complexes. 
 
Several complexes were effective when evaluated against the 
CQ-sensitive and CQ-resistant clones. The efficacy of these 
complexes was found to correlate with their ability to 
inhibit haem dimerization.
68
 This was further supported by 
experimental data showing that neither demetallation 
reactions, counter-ions, nor free ligands were responsible 
for the observed efficacy. This suggested that these 
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Further investigation of the possible mode of action has 
also shown that these complexes displayed no inhibition of 
plasmepsins and falcipains, suggesting that the N4O2-derived 
complexes act by disrupting the formation of haemozoin. 
Additionally others have suggested molecular conformation 





2.7.2.4 Thiosemicarbazone-Derived Complexes 
 
In the early 1980s, Scovill et al.
70
 investigated the 
ability of metal TSC complexes to cure mice infected with 
P. berghei. A small series of complexes of iron(III), 

































Figure 2.14: Antimalarial platinum(II) complexes. 
 
However, it was noted that whereas antimalarial activity is 
retained in the series (i.e. TSCs) upon metal complexation, 
the resulting complexes offered no therapeutic advantage 
over the free ligands. In contrast, platinum(II) and 
ruthenium(III) chelates derived from 2-acetylpyridine 
(2.42) and o-vanillin (2.43) TSC ligands showed significant 
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2.8 AIMS AND OBJECTIVES 
 
Objective: The overall objective of current work is to 
identify novel gold complexes derived from TSC ligands as 
potential antimalarial agents. 
 
Hypothesis: The underlying question and/or hypothesis to 
this research work we seek to address is whether it will be 
possible to enhance the in vitro antimalarial activity of 
TSCs by incorporating gold(I) and gold(III) containing 
fragments. Secondly, whether the incorporation of branched 
PA scaffolds to TSCs to form dendritic structures will 
enhance the in vitro antimalarial activity of TSCs, 
possibly due to increased cellular uptake 
 
2.8.1 Specific Aims: 
 
 to synthesise TSCs (Chapter 3) as bioactive ligands. 
 to synthesise the corresponding gold(I) and gold(III) 
complexes (Chapter 4). 
 to synthesise dendritic TSCs (Chapter 6) for potential 
postulated selective uptake by parasitic RBCs, 
possibly through polyamine transporters (PAT). 
 to pharmacologically evaluate ligands (Chapter 3), 
metal complexes (Chapter 5) and dendritic TSCs 
(Chapter 6) in vitro against P. falciparum strains. 
 to (in part) probe the mechanism of action of potent 
novel compounds with respect to the inhibition of 
malarial cysteine proteases, an important enzyme 
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CHAPTER 3 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 
THIOSEMICARBAZONES AND RELATED PYRAZOLINE ANALOGUES 
 
ABSTRACT: As important scaffolds on which to base the 
development of potential antiparasitic agents, TSCs are 
also vital N,S donor ligands in coordination chemistry. A 
vast array of metal complexes of TSCs has been reported. 
This chapter describes the synthesis, characterization and 
antiplasmodial evaluation of a focused series of TSCs   
3.28a-h and pyrazoline analogues 3.37a-f, respectively. The 
discussion is preceded by a brief introduction and a survey 
of biological activities of TSCs, and subsequently the 
rationale behind their synthesis. 
 
3.1 THIOSEMICARBAZONES: GENERAL OVERVIEW 
 
SCs are a class of compounds belonging to the Schiff 
base family historically discovered as by-products from 
reactions involving organic analysis for identification of 
aldehydes and ketones.
1
 These compounds have played a 
significant role as N,S donor ligands in traditional 
coordination chemistry. Up to now, a number of transition 
and main group metal complexes have been reported.
2
 In 
general, they are broadly classified as mono-TSCs (3.1), 
bis-TSCs (3.2) and di-TSCs (3.3). The general structures of 
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X = -NH-(CH2)n-NH-, n = 1-6, etc
R = H, Me, etc
R = OH, MeO, halogenes, etc
 
 
Figure 3.1: General structures of types of TSCs. 
 
However, for the purpose of this thesis, only mono-TSCs 
will be described although a number of bis-TSCs are of 





3.1.1 Mono-TSCs: Substitution Pattern and Stability 
 
Mono-TSCs are often grouped into two categories. The first 
category involves aldehyde-based derivatives, which have a 
hydrogen atom (R
2
) at the iminic carbon (C1’), while R
1
 may 
be an alkyl, aryl or a heterocyclic moiety. The 
substituents at 
4
N may be similar (e.g. hydrogen atoms, 
alkyl) or a combination of hydrogen atom, alkyl, aryl, or 
cyclic.
2a
 SAR studies revealed that cyclic structures 
possess significant antimalarial activities than their non-
cyclic counterparts.
4
 The second category, however, 
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Due to their ability to delocalise charge as shown in   
Scheme 3.1, TSCs are considerably stable in comparison to 
other imine counterparts. Delocalization decreases the δ
+
 
charge on the carbon atom (C1’) of the imine (C=N) double 
bond, and by so doing C1’ becomes less susceptible to 
nucleophilic attack.
5
 Theoretically, this suggests that TSCs 
are by far more resistant to nucleophilic attack and/or 
















Scheme 3.1: Charge stabilisation in TSCs. 
 
3.1.2 Binding Modes of TSCs with Metal Centers 
 
Several studies have shown that the non-hydrogen atoms in 
TSC template are nearly planar.
6
 In solution, these ligands 
exist as both tautomers [thione(A)-thiol(B)],2,7 hence they 
can bind to a metal center (M) in the neutral (A) and/or 































Scheme 3.2: Thione-thiol tautomers. 
 
A number of intriguing bonding modes have been observed.
2a
 
In neutral form (A), bonding with a metal center occurs 
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coordinating donor atom often gives rise to ONS (e.g.      
2-hydroxybenzaldehyde TSC) or NNS (e.g. 2-acetylpyridine 
TSC) tridentate ligating systems.
2a
 The same argument 
regarding the binding mode can be extended to the anionic 
form (C). However, there have been some reported cases 
where heterocyclic (third atom) and azomethine N donor 
atoms are involved in bidentate coordination with metal 
centers instead of normal tridentate NNS/ONS ligating 
systems exhibited by these ligands. The sulfur atom in 
these cases is considered to be either not coordinated, or 
weakly coordinated to the same metal center or coordinated 




3.2 MEDICINAL APPLICATIONS OF THIOSEMICARBAZONES 
 
It has been reported that a number of known TSCs have poor 
aqueous solubility.
8
 As a result oral administration of TSCs 
in clinical practice is extremely limited. However, the 
biological importance of this class of compounds is well 
established. The available biological data reveal a wide 
spectrum of pharmacological properties,
8,9,10
 and some of 
these properties, including examples of different types of 
TSCs, are described below. 
 
3.2.1 Antitubercular Activity 
 
In the mid 1940s, Domagk et al.
11
 reported for the first 
time the biological properties of TSCs. In the study, they 
demonstrated that TSCs exhibited some antitubercular 
activities in vitro. Amongst the leading clinically 
established agents to treat TB is the relatively 
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However, 3.4 suffers from a range of side effects and the 
development of resistance to the drug by the organism. To 
overcome these problems, compound 3.4 was recommended for 
use in combination with other antitubercular drugs (e.g. 
isoniazid 3.5), and this approach is widely used in 
developing countries.
14
 The clinical success of 3.4 has 
broadened further interest in TSCs as anti-TB agents.
15
 
Analogues of 3.4, compounds 3.6 and 3.7 (Fig. 3.2) have 
been developed and found to be more active compared to 3.4 






























Figure 3.2: Examples of antitubercular TSCs and isoniazid. 
 
3.2.2 Antifungal Activity 
 
In the 1960s, a series of TSCs derived from aldehydes and 
ketones (aliphatic and aromatic), was tested for antifungal 
activity against Chaetomium globosum and Aspergillus 
niger.
17
 Some of these compounds included p-anisaldehyde 
(3.8) and pyridine-2-aldehyde (3.9) TSCs (Fig. 3.3), which 
were screened for antifungal activity against Alternarai 
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However, the corresponding metal complexes were far more 

































Figure 3.3: Antifungal TSCs and fluconazole (3.11). 
 
Recently, acetylpyrazine TSCs were tested against a panel 
of fungal strains.
18
 The most potent compound was 3.10 (Fig. 
3.3), which exhibited comparable efficacy to the clinically 
used agent, fluconazole (3.11), against C. albicans ATCC 
44859, C. tropicalis 156, and T. asahii 1188. This compound 
also showed greater potency than 3.11 when tested for 
antifungal activity against C. krusei E 28, C. glabrata 





3.2.3 Antiviral Activity 
 
Following the first report on the antiviral activity of 
benzaldehyde TSC against neurovaccinal infection in mice,
19
 
a number of TSC derivatives have been evaluated for their 
activities against viral infections.
10
 The classic example 
representing these compounds is N-methyl--isatin TSC 
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against smallpox during clinical trials conducted in India.
9
 
In addition, compound 3.12 has also been used to treat 
individuals infected with the Herpes Simplex Virus (HSV). 
Its derivatives have been shown to inhibit Moloney 












3.13: R = 2-pyridyl
3.14: R = methyl
 
 
Figure 3.4: Chemical structures of antiviral TSCs. 
 
In a separate study, Kolocouris et al
20
 investigated 
adamantane TSC derivatives 3.13 and 3.14 (Fig. 3.4) for 
their ability to inhibit HIV-1 and HIV-2, respectively. 
Regrettably, these compounds displayed no activity against 
these viruses. On the other hand, the purine-6-
carboxaldehyde, 2-acetylpyridine, 2-acetylquinoline and 1-
acetylisoquonile derivatives were found to be highly active 




3.2.4 Antitumour Activity 
 
To date, -N-heterocyclic TSC derivatives are by far the 
largest group of TSC compounds studied as antitumour 
agents.
9
 Following reports by Domagk et al.
11
 and Hamre et 
al.
19
 on antitubercular and antiviral activities of TSCs in 
the mid 1950s, Brockman et al.
21
 reported the antitumour 
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antitumour activities, 3.9 (Fig. 3.3) was found to be the 
most effective compound. Consequently, several novel TSCs 
were investigated as potential antitumour agents. The 
hypothesis by French et al.
22
 about the mode of action of -
N-heterocyclic TSCs necessitated further investigations 





















Figure 3.5: Triapine (3.15), NQTS (3.16) and -lapachone (3.17). 
 
The most successful compound in this group however, is      
3-aminopyridine-2-carboxaldehyde TSC 3.15 (Triapine, Fig. 
3.5),
9,23
 which has reached Phase I and II clinical trials. 
It has been demonstrated that 3.15 is able to cure mice 
inoculated with L1210 leukemia. More importantly, compound 
3.15 has been shown to be potent against hydroxyurea 
(clinical established RR inhibitor) resistant cells, and 
inhibited a wide range of tumour xenografts in mice. 
 
Further investigations led to Afrasiabi et al.
24
 disclosing 
non-heterocyclic TSC derivative 1,2-napthaquinone TSC 
(3.16, NQTS, Fig. 3.5) containing a naphthaquinone scaffold 
from a natural product -lapachone (3.17). The in vitro 
evaluation of 3.16 against cancer cell lines revealed that 
appending of the thiosemicarbazide (TSCz) pharmacophore to 
the parent scaffold quinone enhanced its antiproliferative 
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similar observation was made by Adsule et al.
26
 when the 
TSCz scaffold was attached to the parent quinoline 
pharmacophore. 
 
3.2.5 Antiparasitic Activity 
 
Globally, the most important infectious diseases 
threatening humankind are caused by protozoan parasites.
27
 
The leading three diseases: malaria, leishmaniasis and 
trypanosomiasis (Chagas’ disease), which are associated 
with intense morbidity and extensive mortality mostly in 
resource poor countries, remain a huge public health 
challenge. The individuals with compromised immune systems 
are under severe threat from protozoan parasites.
27
 TSCs 
have been shown to be important scaffolds for designing 
potent antiparasitic agents against a wide range of 
protozoan parasites.
28
 In the context of TSCs, the most 




The first literature report on in vitro and in vivo 
antitrypanosomal activities of TSCs came to light in 1974.
1
 
From the reported series most effective compounds are best 













3.18: R = Cl
3.19: R = H
3.20: X = NHPh 
3.21: X = NH2
3.22: X = NR2
3.23: X = cyclic incoporating N
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In 1980, Casero et al.
29
 reported on in vitro biological 
evaluation of 2-acetylpyridine TSCs (3.20–3.23) against 
Trypanosoma rhodesience. In both studies, it was suggested 
that marked antitrypanosomal activities of TSCs may be due 
to the inhibition of protein synthesis as had been shown 
for the antiviral activity of 3.12 (Fig. 3.4). 
 
Following what could be described as an “abandoned study” 
of TSCs due to previous perceptions about their toxicity; 
Du et al.
30
 identified a library of TSCs, which displayed 
significant activities against cruzain, the cysteine 
protease of Trypanosoma cruzi.
31
 The compound A1 (Fig. 3.7) 
was found to be the most active TSC. Intrigued by these 
observations, Du and co-workers explored the SAR around 
this lead compound. This renewed interest into this class 








A: R1 = Br, R2 = H











Figure 3.7: TSCs as inhibitors of cruzain. 
 
A series of A analogues represented by 3.24 and 3.25 were 
synthesized and evaluated for their ability to inhibit 
cysteine proteases (Fig. 3.7). Compound 3.24 and 3.25 
effectively inhibited cruzain. More importantly, some of 
these compounds displayed no significant toxicity against 
                                                 
1
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the host cells. This study led to the synthesis of a second 
series of TSCs, which were evaluated against Trypanosoma 
brucei and cruzi, respectively.
32
 The deduced SAR study 
resulted in novel TSCs, which displayed greater 
trypanocidal activity.
33,34
 The recent report by Porcal et 
al.
35
 further illustrates the growing interest in TSCs as 
potential antitrypanosomal agents. 
 
3.2.5.2 Antimalarial Activity 
 
As mentioned in previous chapters, the antimalarial 
activity of TSCs was first demonstrated by Klayman et al.
36
 
three decades ago. Klayman and co-workers studied the 
antimalarial effects of these compounds on mice infected 
with P. berghei. Initially, it was observed that the 
4
N 
monosubstituted analogues 3.20 (Fig. 3.6) cured mice at 
doses below 200 mg/kg/day. However, further investigation 
revealed that the activity was enhanced when 
4
N is 
disubstituted (3.22, Fig. 3.6) or part of a ring system 
(3.23, Fig. 3.6).4 This led to extensive investigations into 
antimalarial properties of TSCs. 
 
In recent years a substantial amount of work has also been 
conducted in our laboratory to exploit the antimalarial and 
antitrypanosomial effects of TSCs including their ability 





3.3 THIOSEMICARBAZONES: POSSIBLE MODE OF ACTION 
 
A number of studies have suggested various modes of action 
of TSCs,
35,38
 but up to now the most common mechanisms on 
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 and the 
creation of lesions (through the inhibition of polymerase 
) in DNA strands.8 
 
3.3.1 Iron Chelation 
 
Iron is an essential element for the biological action of a 
number of proteins and other Fe dependent enzymes.
39
 Since 
TSCs (e.g. 3.15 in Fig. 3.5 and 3.20-3.23 in Fig. 3.6) are 
also members of a class of iron chelators, it has been 
suggested that these ligands may act by sequestering 
iron,
22,40
 thus interfering with supply of nutrients for 
protein proliferation. It has also been suggested that 
these compounds act by inhibiting RR through binding iron, 
which is involved in stabilising a tyrosol radical in the 
active site of the enzyme, ultimately, preventing the 





Although this mechanism could not be pursued in this work, 
the recent study of Richardson et al.
18
 clearly demonstrates 
that non--(N)-heterocyclic TSCs are poor iron chelators 
compared to -(N)-heterocyclic TSC counterparts, which 
possess the NNS tridentate ligating system. This suggests 
that non--(N)-heterocyclic TSCs act by mechanisms 
independent of iron chelation, and one of those is the 
inhibition of cysteine proteases (section 3.3.2).30 
 
Alternatively, TSCs can bind iron (from the iron pool) to 
form lethal complexes which intracellularly may be involved 
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free radical species, which could be important for their 
potential activity. 
 
3.3.2 Inhibition of Cysteine Proteases 
 
As previously mentioned, proteases are essential for living 
organisms to fulfil virtually all biological functions.   
Fig. 3.8 illustrates the proposed interaction with cysteine 





























Figure 3.8: Reversible inhibition of cysteine proteases by TSCs.30 
 
Due to inherent electrophilic centres (i.e. C=N, and C=S) 
in the chemical structures of TSCs, Du et al.
30
 demonstrated 
through experimental and computational approaches that TSCs 
are susceptible to nucleophilic attack by the thiolate 
anion (A) to produce a tetrahedral intermediate (B). Thus, 
this reversible process resulted in the inhibition of the 
cysteine protease cruzain. Moreover, the homology model 
suggested the C=S group as a favorable position of 
nucleophilic attack by thiolate anion compared to C=N. This 
was attributed to incompatible separation between 
1
N and 
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3.4 RATIONALE: SYNTHESIS OF THIOSEMICARBAZONES 
 
Fig. 3.9 indicates structural consequences on the potency 
of TSCs against cysteine proteases by varying each 
position.
32
 In summary, Du and co-workers showed that while 
modification of each position [i.e. (i), (ii) and (iv)] was 
important for cruzain and rhodesain, it was however, not 
tolerated by the malarial cysteine protease FP-2. The 
comparative data from this study unravelled the important 






























Figure 3.9: Rationale design of TSCs. 
 
As our main focus in this study is on malaria, it was of 
interest to exploit the effects of coordinating gold 
containing fragments with already studied TSCs as cysteine 
protease inhibitors against FP-2. An attendant hypothetical 
reasoning was that coordination of gold with TSCs may lead 
to gold complexes in which the ligands are “locked” in an 
orientation that is favourable for maximum interactions of 
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Herein, we opted to synthesise selected ligands which have 
been shown to exhibit inhibitory effects against cruzain 
and tryponosomal cultures,
28a,30
 but with no reports on their 
antimalarial activities with respect to their corresponding 
gold complexes. The rationale for the synthesis of these 
ligands was based on utilizing the existing coordinating 
sites (iii) in the ligands to access novel gold compounds 
(see Chapter 4) with potential antiplasmodial activities 
against P. falciparum strains (Chapter 5) presumably 
through the inhibition of the cysteine protease FP-2. 
 
3.5 RESULTS AND DISCUSSION 
 
3.5.1 Retrosynthetic Analysis 
 




















R' = Me, Et
R = Br, Cl, OH, OMe
 
 
Scheme 3.3: Retrosynthetic analysis of TSCs. 
 
The synthesis of TSCs (3.28) was envisaged as achievable 
from commercially available TSCz (3.27) and various ketones 
3.26. The starting materials employed for ferrocenyl-based 
ligands were ferrocene carboxaldehyde (3.29) and 
acetylferrocene (3.30), which are also accessible 
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from the condensation of 3.27 and the aldehyde, 3-methoxy-
4-hydroxybenzaldehyde (3.31). 
 
3.5.2 Synthesis of Mono-Thiosemicarbazone Ligands 
 
The desired ligands were synthesised as illustrated in the 


























Scheme 3.4: Reagents and conditions a) MeOH/EtOH, 1% AcOH, 
reflux, 24 h. 
 
A series of commercially accessible ketones (3.26) were 
each reacted with 3.27 in the presence of a catalytic (1%) 
amount of acetic acid in a 1:1 ratio in refluxing methanol 
to yield the corresponding TSCs 3.28a-e (Table 3.1).30 The 
reactions were allowed to reflux for 24 h. The reaction 
progress was monitored by thin layer chromatography (TLC). 
Despite leaving the reaction mixture to reflux for 24 h, 
TLC revealed the presence of unreacted starting material, 
which indicated that reaction did not fully converted into 
products. The desired TSCs and isolated yields are 
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Entry Code Product R R1 Yield/[%] 
1 DK-1R 3.28a 
 
CH3 49 

























7 DK-25D 3.28g CH3 70
43a
 






Similarly, compounds 3.28f, 3.28g and 3.28h were 
synthesised according to the reported method.
42,43,44
 As can 
be seen from Table 3.1, the compounds were isolated in poor 
to excellent yields. The low yield of compound 3.28d may be 
due to the fact that as most compounds crystallised on 
cooling, in some cases during refrigeration, to ambient 
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3.5.3 Characterisation of Compounds 3.28a-h 
 





and infrared (IR) spectroscopic techniques. Melting points 
were employed to assess the purity of targeted compounds 
relative to literature reported values (Table 3.2). 
 
Table 3.2: Melting points of isolated compounds. 
 
Compound 
Meting point (C) 
Observed Literature 
3.28a 193-194 190-19245 
3.28b 170-172 174-17530 
3.28c 193-194 196-19830 
3.28d 134-135 144-14530 
3.28e 180-182 185-18630 










C NMR (selected important regions) 
spectra for compound 3.28a are shown in Fig 3.10. The 1H NMR 
spectra of phenyl containing TSCs 3.28a-e revealed 
diagnostic 
3
NH proton signals as broad singlets in the range 
δ 10.15-10.35 ppm. These proton signals showed not only the 
formation of these ligands, but also unequivocally 
demonstrated the predominant thione form of all compounds 
in solution state. This is inconsistent with the reported 
mixture of tautomeric forms often observed in solution. The 
ferrocenyl analogues 3.28f and 3.28g showed chemical shifts 
of 
3
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similar pattern was also observed from the 
1
H NMR spectrum 























N protons (i.e. 
1
NHH) gave rise to two non-equivalent 
resonances in the 
1
H NMR spectra of all synthesised 
compounds. This phenomenon, which is a common feature in 
TSC structures,
48
 is attributed to the partial double bond 
character exhibited in the thioamide bond (C-N), ultimately 
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The 
1
H NMR results were supported by those of the 
13
C NMR 
spectra, which showed the chemical shifts of imine (C=N) 
carbons (C5) at δ 143.1-150.6 ppm, thus unambiguously 
confirming the formation of an imine functionality. The 
presence of thiocarbonyl (C=S) group in all of the proposed 
structures was also evident in the 
13
C NMR spectra at       
δ 176.4-179.4 ppm. 
 
The IR spectra of all compounds showed diagnostic bands in 
the regions 3138-3190, 1585-1599 and 805-850 cm
-1
, which 
were assigned to (NH), (C=N) and (C=S) stretches, 
respectively (Fig. 3.11). From the spectra of all 
compounds, the bands at approximately 2200-2500 cm
-1
, 
indicating the thiol form (SH) could not be observed, thus 
suggesting that these compounds existed predominantly in 
their thione form (A, in Scheme 3.2, p 69) in the solid 
state. This was also in agreement with observations made in 
the 
1
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3.5.4 Synthesis of Pyrazoline TSC Analogues 
 
A second series of TSCs, which was deemed suitable for the 
synthesis of novel gold complexes are pyrazoline analogues. 
This class of compounds are accessible in two reaction 
steps. The first step involves the Mannich reaction,
30
 while 
the second step involves Schiff-base chemistry to access 
the cyclised pyrazoline TSC analogues. The Mannich reaction 
is widely applied in organic chemistry to form carbon-
carbon and carbon-nitrogen bonds;
49
 and the components 
required for this reaction include: a) a compound with an 
acidic methylene moiety (I), b) formaldehyde (II) [a non-
enolizable aldehyde] and c) ammonia, a primary or secondary 


















Scheme 3.6: Essential component in Mannich reaction. 
 
Selected ketones (3.26) were each reacted under reflux 
(EtOH) with formaldehyde and a secondary amine salt in the 
















Scheme 3.7: Reagents and conditions a) (HCHO)n, (H3C)2N.HCl, 32% 
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The formation of Mannich base compounds 3.32 was evident 
from characteristic white precipitates upon cooling, and 
was isolated by means of filtration to give the desired 
products. It is noteworthy that compounds 3.32d and 3.32e 
were obtained as oil products. 
 
3.5.4.1 Reaction Mechanism of Mannich Base Formation 
 
The mechanism by which Mannich base products formed is 
















































Scheme 3.8: Mechanism of Mannich base formation. 
 
Nucleophilic attack of the secondary amine (III) onto the 
electrophilic carbonyl center of formaldehyde (II’) yields 
an alcohol intermediate (3.33). This intermediate under 
acid-dehydration conditions gives rise to the iminium salts 
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H NMR spectroscopy was used to confirm the Mannich base 
products. The new chemical shifts corresponding to the CH2 
appeared in the range δ 3.39-3.40 ppm and δ 3.62-3.65 ppm, 
respectively. The observed signals were consistent with 
those of the same compounds reported in the literature.
30
 
Having synthesized 3.32, the second step was to prepare the 
corresponding targeted cyclized TSCs. The Mannich products 
3.32a-f were each condensed with 3.27 in a 1:1 molar ratio 
in refluxing MeOH in a basic medium for 48 hours (Scheme 
3.9).
51
 In contrast to the adopted synthetic approach, Du et 
al.
30
 reported that these reactions were completed within   
1 h. However, in this case it was observed from TLC that 
the starting materials were still predominant within the 

















R = H, CH3
R1, R2 = Br, Cl
 
 
Scheme 3.9:2 Reagents and conditions a) 50% NaOH, MeOH, reflux, 
N2, 48 h. 
 
The resulting reaction products contained unreacted 
starting materials (TLC) and some unidentifiable side 
products. The product mixture was purified by means of 
silica gel column chromatography eluting with DCM-MeOH 
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(98:2) to afford crystalline solid compounds in low to 
moderate yields. Du et al.
30
 and Abid et al.
52
 obtained these 
ligands in yields ranging 20-62% and 35-51%, respectively. 
A summary of the corresponding TSCs 3.37a-f is provided in 
Table 3.3. 
 











Entry Code Product R R1 R2 Yield/[%] 
1 DK-20 3.37a H H Br 10
30
 
2 DK-38 3.37b H Cl Cl 2030 
3 DK-39 3.37c H Br H 41 
4 DK-45 3.37d CH3 Cl Cl 31
30
 
5 DK-47 3.37e CH3 H Br 69
30
 
6 DK-134 3.37f H Cl H 24 
 
3.5.5 Spectroscopic Characterisation of Pyrazolines 3.37a-f 
 
The pyrazoline derivatives were characterised using 
1
H NMR, 
IR and mass spectroscopic techniques. The purity of all 
compounds was determined via melting point (Table 3.4) and 
microanalyses. Abid et al.
52
 reported melting point for 
3.37a and 3.37e to be 141 C and 92 C, respectively. In the 
1
H NMR spectra, the pyrazoline protons (CH2) at C1’ and C2’ 
carbons in compounds 3.37a-c and 3.37f appeared as triplets 
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On the other hand, the chemical shifts of CH2 protons (C2’) 
of compounds 3.37d and 3.37e resonated as a doublet at δ 
4.37 ppm (J = 11.6 Hz) and doublet of doublets at δ 4.15 
ppm (J = 4.8 and 11.6 Hz). The CH proton at C1’ appeared as 
multiplet in the region 3.65-3.71 ppm. 
 












Melting point (C) 
Observed Literature 
1 3.37a 143-145 173-17530 
2 3.37b 195-197 199-20130 
3 3.37c 86-88 - 
4 3.37d 173-174 171-17230 
5 3.37e 120-122 107-10930 
6 3.37f 162-164 - 
 
The IR spectra of these compounds showed intense bands at 
807-914 cm
-1
, which were assigned to the (C=S) stretch of 
the thiocarboxamide moiety. The absorption bands due to the 
(C=N) stretch of the azomethine group appeared in the 
region 1571-1595 cm
-1
. The bands in the region 3364-3477 cm
-1
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The mass spectra of compounds 3.37a-f are summarised in 
Table 3.5. The ESI (high resolution) mass spectrometry 





Cl isotopic distribution. Whereas 
compounds 3.37e-f showed ion peaks consistent with m/z, 
(M+H). 
 














3.37a 285.9825 282.9779 
3.37b 276.0067 272.9894 
3.37c 285.9991 282.9779 
3.37d 288.010 287.0051 
3.37e 297.9979 296.9935 
3.37f 240.0340 239.0284 
 
3.6 BIOLOGICAL RESULTS AND DISCUSSION 
 
The biological activities of synthesized TSCs were 
evaluated in vitro against P. falciparum CQ-sensitive 
strains (D10 and 3D7) and CQ-resistant strains (W2 and K1). 
In all assays, CQ was used as control. The cytotoxicity 
tests of all compounds were conducted in human nasopharynx 
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a control drug. The compounds were also evaluated for their 
ability to inhibit the activity of the plasmodial cysteine 
protease FP-2. The biological tests were carried out in 
collaboration with various institutions: 1) Department of 
Medicine, San Francisco General Hospital, University of 
California in San Francisco (UCSF) - Professor P.J. 
Rosenthal (W2 and FP-2), 2) Department of Medicine, 
Division of Pharmacology, University of Cape Town - 
Professor P.J. Smith (D10) and 3) London School of Hygiene 
and Tropical Medicine (LSHTM) – Drs V. Yardley and Livia 
Vivas (3D7, K1 and KB). 
 
3.6.1 In vitro Antiplasmodial Activity of 3.28a-h 
 
The antiplasmodial activities of compounds 3.28a-h against 
D10, W2 and recombinant FP-2 were determined and the 
results are displayed in Table 3.6. From the data (Table 
3.6), it is clear that TSCs displayed no activities against 
D10 and W2 strains at the highest concentration tested. 
Generally, none of the compounds showed potency below 10 M 
against the D10 strain, except compound 3.28d which was 
moderately active against W2 was 3.28d with an IC50 value of 
4.94 M. The rest of compounds did not show any significant 
inhibitory effects against the whole parasites at the 
maximum concentration tested (IC50 > 20 M). 
 
To probe the ability of these compounds to inhibit a 
malarial cysteine protease, hence their antimalarial 
activities, the compounds were tested against recombinant 
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Entry Cmp. No. R R1 
IC50 / M 
D10 W2 rec FP-2 
1 3.28a 
 
CH3 31.1 >20 >100 
2 3.28b 
 
CH3 >10 4.94 >100 
3 3.28c 
 
CH3 95.8 >20 >100 
4 3.28d 
 
CH3CH2 18.2 >20 >100 
5 3.28e 
 
CH3CH2 26.9 >20 >100 
6 3.28f 
 
H 31.0 >20 36.8 
7 3.28g CH3 >10 >20 18.2 
8 3.28h 
 
H 382.2 >20 >100 
9 CQ - - 0.017 0.097 ND 
10 E64 - - ND ~3.0 0.049 
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The majority of the compounds were not effective against 
FP-2 at the highest concentration tested (IC50 > 100 M). 
These results suggest that the moderate inhibitory effect 
of compound 3.28b against W2 may be due to other mechanisms 
that exclude inhibition of FP-2. Despite the lack of 
inhibitory effects against the growth of cultured 
parasites, ferrocenyl TSCs 3.28f and 3.28g displayed modest 
activity against FP-2 with IC50 values of 36.2 and 18.2 M, 
respectively. Previously, the potencies of compounds 3.28f 
and 3.28g have been reported.37d 
 
In separate experiments, compounds 3.28a-h were evaluated 
for their activities against 3D7, K1 and KB assays and the 
results are summarised in Table 3.7. The antiplasmodial 
activities were generally in mid to higher micromolar range 
(16.8-68.8 M and 35.7-72.1 M) against both 3D7 and K1 
strains, respectively. In most cases, the IC50 values of 
these compounds against K1 were higher (except 3.28a) than 
those against 3D7. This suggested that P. falciparum 
parasites are likely to develop resistance against these 
compounds. 
 
In vitro cytotoxicity was evaluated against the KB cell 
line. From the data, these compounds exhibited no toxicity 
against KB cells; the IC50 values were generally well above 
100 M, with the exception of compound 3.28d with an IC50 
value of 87.5 M, independent of their antiplasmodial 
activities. Ferrocenyl TSCs 3.28f and 3.28g, whose 
antiplasmodial activities were moderate against 3D7, 
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suggesting that these compounds are selective towards 3D7, 
with selectivity indices of 14 and 11, respectively. 
Compounds 3.28f and 3.28g also showed selectivity towards 
K1 strain parasites. 
 






3.28a: R = Me, R1 = Br, R2 = H
3.28b: R = Me, R1 = H, R2 = Br
3.28c: R = Me, R1 = R2 = Cl
3.28d: R = Et, R1 = H, R2 = Br
3.28e: R = Et, R1 = R2 = Cl









3.28f: R = H





Entry Cmp. No. 
IC50 / M 
RIa SIb 
3D7 K1 KB 
1 3.28a 68.8 59.4 >100 0.9 >1.45 
2 3.28b 39.5 62.3 >100 1.6 >2.53 
3 3.28c 43.1 72.1 >100 1.7 >2.32 
4 3.28d 55.5 62.8 87.5 1.1 1.58 
5 3.28e 23.8 38.9 >100 1.6 >4.20 
6 3.28f 20.4 44.2 276.8 2.2 13.6 
7 3.28g 16.8 35.7 181.4 2.1 10.8 
8 3.28h 35.7 >20 >100 ND >2.80 
9 CQ 0.019 1.03 - 54.2 ND 
10 POD - - <0.003 - ND 
a
Resistance index calculated as [IC50 (K1)]/[IC50 (3D7)] 
b
Selectivity calculated as [IC50KB/IC503D7] 
 
3.6.2 In vitro Antiplasmodial Activity of Pyrazolines 
 
In the second series of synthesised TSCs, it was envisaged 
that the pyrazolines 3.37a-f (Table 3.3) may exhibit 
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antiplasmodial activities of pyrazolines 3.37a-f were also 
evaluated against 3D7 and K1 strains, along with their 
cytotoxicity against the KB cell line (Table 3.8). Although 
the activities remained in low to mid micromolar range, the 
results indicated that in moving from acyclic TSCs (3.28) 
to cyclic counterparts (3.37) there is a 1-5 fold 
improvement in the overall activity against 3D7 and K1, 
respectively. The pyrazoline TSCs were found to exhibit no 
toxicity against KB cell lines, with compound 3.37b 
displaying significant selectivity towards both strains. 
 









3.37a: R = H, R1 = H, R2 = Br
3.37b: R = H, R1 = R2 = Cl
3.37c: R = H, R1  = Br, R2 = H
3.37d: R = Me, R1 = R2 = Cl
3.37e: R = Me, R1 = H, R2 = Br
3.37f: R = H,   R1 = Cl, R2 = H
 
 
Entry Cmp. No. 
IC50 / M 
RI SI 
3D7 K1 KB 
1 3.37a 27.5 32.5 >100 1.2 >3.64 
2 3.37b 16.4 40.9 318.1 2.5 19.4 
3 3.37c 16.4 15.7 >100 0.9 >6.10 
4 3.37d 11.1 10.1 >100 0.9 >9.01 
5 3.37e 48.1 >20 72.0 ND 1.50 
6 3.37f 54.3 76.5 214.0 1.4 3.94 
7 CQ 0.019 1.03 - 54.2 ND 
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3.6.3 Discussion 
 
The observed antiplasmodial activity of compound 3.28b 
against cultured W2 parasites was independent of the 
inhibition of FP-2, suggesting that FP-2 is not the primary 
target. The same conclusion has been made by others on 
analogous TSCs that were modest against FP-2 but active 
against a drug resistant P. falciparum strain.
33
 Recently, 
de Oliveira et al.
47
 reported the antiplasmodial activities 
of TSCs illustrated in Fig. 3.12. As in our case, compound 
3.28h was not active against P. falciparum although it 
showed a lack of toxicity against human peripheral blood 
mononuclear cells (PBMC). The non-aromatic TSCs (Fig. 3.12) 
showed moderate antiplasmodial activities against the P. 
falciparum W2 strain. 
 
3.38: ClogP = 5.84
      IC50(W2) = 12.6 M



















3.39: ClogP = 3.60
      IC50(W2) = 9.2 M
      IC50(PBMC) = 31.3 M
3.40: ClogP = 3.22
      IC50(W2) = 7.2 M
      IC50(PBMC) = 73.5 M
3.28h: ClogP = 1.09
       % Inhibition(W2) = 23%
       % Proliferation (PBMC) = 95%
 
 





On close examination of active compounds 3.38-3.40,47 it was 
observed that these compounds exhibit similar 
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ineffectiveness of compounds 3.28a-h may be due to their 
poor solubility, an important physicochemical property of a 
compound, such that they hardly reach the target in 
sufficient concentration.
53
 Since compounds 3.38-3.40 
possess non-aromatic moieties it may tentatively be 
concluded that activities of 3.38-3.40 over 3.28a-e may be 
due to selective uptake of these compounds by the parasitic 
erythrocytes.
54
 More importantly, compounds 3.38-3.40 and 
3.28b (Table 3.6) lack the NNS tridentate ligating system, 
which preclude the assumption that their activities may be 




Unlike the W2 cultured parasites, mono-TSCs displayed 
modest activity against the K1 (resistant) strain. A 
similar trend was also noted in cyclic analogues, but more 
importantly the data suggests that the antiplasmodial 
activity against both 3D7 and K1 strains is enhanced when 
TSCs are converted to pyrazoline counterparts. Although 
these compounds were generally selective towards malaria 
parasites, further structural modifications are important 
to attain some physicochemical properties that may lead to 




In conclusion, a focused series of mono-TSCs and cyclic 
analogues was evaluated for antiplasmodial activity against 
P. falciparum strains and inhibitory effects against the 
FP-2 enzyme. Most of the compounds showed no cytotoxicity 
towards the KB cell line, but displayed modest activities 
against 3D7 and K1 strains of P. falciparum. Although the 
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TSCs to form the corresponding pyrazoline derivatives 
resulted in beneficial effects against both 3D7 and K1 
strains. Compound 3.28b was the only TSC which exhibited 
moderate activity (below 10 M) against W2 without any 
inhibition of the enzyme (IC50 > 10 M). From the data, 
there was no correlation observed between the 
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CHAPTER 4 
 
SYNTHESIS OF NOVEL GOLD COMPLEXES OF 
THIOSEMICARBAZONE AND PYRAZOLINE ANALOGUES 
 
ABSTRACT: A series of gold(I) and gold(III) TSC complexes 
have been prepared from the reaction of gold(I) precursors 
4.2, 4.3, 4.5, 4.27 and 4.37 as well as gold(III) 2.15 with 
various TSCs 3.28a-h including pyrazoline analogues 3.37a-c 
and 3.37f. Crystal structures of complexes 4.15 and 4.16 
were obtained as solvates with no evidence found of 
aurophilic Au(I)…Au(I) interactions contributing to the 
stability of their molecular structures. 
 
4.1 THE CHEMISTRY OF GOLD 
 
old as an element has been known to mankind since it 
was first discovered since earliest civilisation. 
Special interest in gold was connected with its value as a 
metal.
1
 Naturally, gold exists in its native metallic form 
(oxidation number 0).
1,2
 It is chemically unreactive and 
stable in the presence of oxygen and sulfur, but reacts 
readily with halogens or solutions containing and/or 
generating chlorine such as aqua regia. It dissolves in 
cyanide solutions in the presence of air or hydrogen 






To date, a number of oxidation states of gold (–I, +I, +II, 
+III, +IV and +V) are known.
4
 However, gold chemistry is 
dominated by the +I and +III oxidation states.
5
 Gold 
complexes in the +II oxidation state have been reported,
6
 












Chapter 4  Novel Gold Complexes of Thiosemicarbazones and Pyrazolines 
 
 
UCT 107 CHEMISTRY 
to be disclosed.
4b
 Gold compounds in the oxidation states –






Gold(I) has a closed-shell 5d
10
 electron configuration and 
exhibits linear, trigonal or tetrahedral geometry (Fig. 
4.1). Most gold(I) complexes have a linear two coordinate 
geometry, L-Au-X, where L is a 2-electron donor ligand, 
e.g. R3P, R2S, CO, and X is often a halogen or 
pseudohalogen.
7,8
 The phosphine complexes are generally 
stable, whereas R2S is more labile and renders some gold(I) 
















Figure 4.1: Possible geometries of gold(I) complexes. 
 
Gold(I) complexes in their three and four coordination 
numbers require the participation of the energetically high 
lying orbitals 6py and 6pz resulting in high promotion 
energy.
9
 Consequently, complexes of the general formula 
LnAuX, n > 1, are less common and often occur with S- and/or 
P-donor ligands known to form strong covalent bonds with 
gold(I). A few examples are also known with N-donor 
ligands. More importantly, stabilization of gold in higher 
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4.1.1.1 Aurophilicity and Aurophilic Interactions 
 
Aurophilicity and aurophilic interactions are terms widely 
used to describe Au(I)…Au(I) intra- and inter-molecular 
interactions in gold compounds.
10
 Aurophilicity is defined 
as the tendency of closed-shell gold(I) atoms to aggregate 
at distances shorter than the sum of van der Waals radii 
(2.884-3.60 Å).
11
 The energy involved in aurophilic 
interactions is comparable in strength to that of a 
hydrogen bond of 30 kJ.mol
-1.
11,12
 These interactions are 
commonly encountered in monovalent gold complexes occurring 
perpendicular to the axis of the linearly two coordinate 
gold(I) atoms. In compounds exhibiting coordination numbers 







Gold(III), isoelectronic with platinum(II), has a 5d
8
 
electronic configuration and can adopt a square planar 
(most common), square pyramidal or an octahedral 
coordination geometry, and it forms stable complexes with a 
variety of ligands. Gold(III) is considered as a “harder” 
acid than gold(I), hence it is more likely to form stable 
compounds with donor atoms such as nitrogen and oxygen. 
These types of ligands prevent reduction of gold(III) to 
gold(I). Gold(I) on the other hand exhibits a distinct 














Chapter 4  Novel Gold Complexes of Thiosemicarbazones and Pyrazolines 
 
 
UCT 109 CHEMISTRY 
4.1.3 Organogold Compounds 
 
Gold(I) and gold(III) ions also form -bonds with carbon.14 
The gold complexes derived from olefin, carbene and 
carbonyl compounds are some of the many well-known examples 
of organogold compounds.
7
 This class of compounds also 
includes alkyl complexes of the form R-Au-L, where L is a 





Another interesting class of organogold(I) complexes are 
binuclear ylid complexes [Au2{-(CH2)2PR2}2], which 
reversibly react with halogens to give Au-Au bonded 
gold(II) alkyls with further oxidation leading to gold(III) 
compounds.
7
 Organogold(III) compounds are also well-known 
and mainly form square-planar complexes of the types, R3AuL, 
[R2AuL2]
+
 and R2AuXL. As in gold(I), gold(III) organometallic 




4.1.4 Gold TSC Complexes 
 
TSCs have attracted increasing attention due to their 
bonding versatility. Since the early 1960s when the first 
report on their complexes was published, the number of 
reports on coordination chemistry of these ligands has 
expanded significantly.
15,16
 Currently, the chemistry of main 
group and transition metal TSC complexes with intriguing 
geometries is well established.
16,17
 In the context of gold 
chemistry, however, there are a few examples of gold(I) 
complexes which have been reported.
18
 A significant number 
of gold TSC complexes, which have received greater 
attention are gold(III) derivatives.
19











Chapter 4  Novel Gold Complexes of Thiosemicarbazones and Pyrazolines 
 
 
UCT 110 CHEMISTRY 
these complexes, which are also encountered in this work, 
is provided below. 
 
4.1.4.1 Gold(I)-Based TSC Complexes 
 
In the late 1990s, Ainscough et al.
20
 reported the reaction 
involving gold(I) [Au
I
ClS(CH2CH2OH)2] and 2-formylpyridine 
TSC (3.9, Fig. 3.3, p 72) to form gold(I) complex of the 
form 4.1 (Scheme 4.1). Although the resulting complex 4.1 
could not be fully characterised, microanalysis data 
suggested the molecular composition of atoms consistent 




















Scheme 4.1: Typical reaction of TSC with gold(I). 
 
In view of the wide interest in the pharmacological 
properties of TSCs and their complexes, Casas et al.
18a
 
recently explored the chemistry of gold(I) with TSC 
ligands. As a result the gold(I) complex 2.12 (Fig. 2.4,   
p 39) was synthesised by reacting Menadione sodium 
bisulfide (MSB) TSC with [Au
I
(PEt3)Cl] (4.2). This became 
the first gold(I) TSC complex to be reported and its 
molecular structure elucidated by single crystal X-ray 
diffraction. The molecular structure of the complex 
revealed that [Au
I
(PEt3)Cl] reacts with MSB TSC to form 2.12 
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Recently, Lobana and co-workers observed that in gold(I) 
chemistry the common starting materials of gold(I) are 
[Au
I
(THT)Cl] (4.3), [AuI(SMe2)Cl] (4.4) and [Au
I
(PPh3)Cl] 
(4.5), respectively.18b In light of this observation they 
investigated direct reaction of gold(I) chloride (AuCl) 
with N,S-donor ligands. Thus, direct (1:1 molar) reaction 
of AuCl with 3-nitrobenzaldehyde TSC (4.6) in CH3CN in the 
presence of one mole of PPh3 resulted in the formation of 

































Figure 4.2: Chemical structure of gold(I) TSC complexes. 
 
The molecular structure of 4.7 showed that the two 
monomeric molecules are linked to each other by Au(I)…Au(I) 
and S…S interactions to form the dimeric structure with a 
six membered cavity in the center. The S-Au-S bond angle 
deviates from linearity with an angle of 172.70 (16)°. 
 
More recently, Castiñeiras et al.
18c
 reported a binuclear 
gold(I) complex 4.9 (Fig. 4.3), which was isolated from a 
reaction employing the starting gold(III) complex 2.15 
(Fig. 2.6, p 42) and bis{3-hexamethylene-iminyl TSC} 
(H2Plhexim), 4.8, in methanol. Although studies have shown 
that the reaction of 2.15 with TSCs affords gold(III) TSC 
complexes,
18a
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the presence of thiols other than TSCs have been noted.
21
 
Castiñeiras and co-workers concluded that the formation of 
4.9 is due to the reduction of gold(III) in methanol.18c The 
same observation has been noted in our case (encountered in 
section 4.6.1) when 2.15 was reacted with TSCs to form 
gold(III) complexes also resulted in the formation of 



































Figure 4.3: Binuclear gold(I) bis-TSC complex. 
 
The molecular structure of 4.9 revealed a distorted linear 
coordination geometry with an S-Au-S bond angle of 
167.1(11)° around gold atoms. Due to the steric crowding 
produced by pyridyl and hexamethyleneiminyl rings, the 
structure exhibited a Au(I)…Au(I) distance of 6.0141(9) Å, 
which is an exceedingly large separation to suggest the 
possible Au(I)…Au(I) interactions within the structure. 
 
4.1.4.2 Gold(III)-Based TSC Complexes 
 
In the early 1990s, Zheng-Zhi and Yong-Xiang reported 
reactions involving 5-nitro-2-furful and 2-acetylpyridine 
TSCs and AuCl3 to form gold(III) complexes.
22
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were no suitable single X-ray crystals to ascertain the 
molecular structures of the complexes in order to support 
the data from microanalysis. In the late 1990s, Ortner et 
al.
19e
 reported the first crystal structures of square 
planar gold(III) TSC complexes represented by 4.10 and 4.11 
(Fig. 4.4). As a result, a significant number of gold(III) 
complexes with TSCs exhibiting NS, PNS and NNS ligating 
systems were reported.
17
 Castiñeiras et al.
18c
 also reported 
a gold(III) complex resulting from the reaction of 2.15 



















Figure 4.4: Chemical structures of gold(III) TSC complexes. 
 
4.2 RATIONALE: SYNTHESIS OF GOLD TSC COMPLEXES 
 
The structural features described previously (Chapter 3), 
showed that structural modifications on the TSC scaffold 
had no beneficial biological effects on the malaria 
parasite cysteine protease FP-2. However, a series of TSC 
derived metal complexes have been shown to be potent 




On the other hand, the cathepsin family of lysosomal 
cysteine dependent enzymes have been shown to be attractive 
targets of auranofin (2.7 in Fig. 2.3, p 37) and analogous 
complexes.
24
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effects of gold TSC complexes on the malaria parasite 
cysteine protease FP-2, and hence their antiplasmodial 
activities, would be a worthwhile effort. 
 
4.3 RESULTS AND DISCUSSION 
 
SECTION A: GOLD(I) TSC COMPLEXES 
 
Apart from the envisaged pharmacological effects which 
necessitated the search for new gold complexes, it was 
thought that the synthesis of these compounds would also 
contribute to the limited number of gold(I) TSC complexes 
previously reported in the literature. 
 
4.3.1 Synthesis of gold(I) TSC complexes: [Au(TSC)2]Cl 
 
Scheme 4.2 shows the synthetic route for the target gold(I) 
TSC complexes. Thus, treatment of starting gold(I) complex 
[Au
I
(THT)Cl] (4.3) with individual TSCs (3.28a-g) in MeOH in 
a ratio of 1:2 mol for 2 h readily led to the substitution 
of the labile THT ligand to produce S-coordinated 4.12-4.19 
complexes. Complex 4.19 was obtained by allowing the 
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The reaction mixtures were filtered through celite and 
evaporated to complete dryness. The resulting tan to red-
brown complexes are mainly soluble in DMSO, MeOH, CH3CN and 
insoluble in water. Although these complexes are generally 
stable, after prolonged periods in solution at ambient 
temperature, a fine dark-brown solid was often observed 
suggesting the possible decomposition. The desired gold(I) 
TSCs and isolated yields are summarised in Table 4.1. 
 






































Entry Code Comp. No R R1 R2 Yield/[%] 
1 DK-10 4.12 CH3 H Br 96 
2 DK-12 4.13 CH3CH2 H Br 83 
3 DK-13 4.14 H Ferrocene 89 
4 DK-15 4.15 CH3 Br H 96 
5 DK-16 4.16 CH3 Cl Cl 97 
6 DK-17 4.17 CH3CH2 Cl Cl 96 
7 DK-42 4.18 CH3 Ferrocene 95 
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4.3.1.1 Characterisation of Compounds 4.12-4.19 
 




C NMR; IR and MS. The molecular structures of 
these complexes were elucidated using single X-ray 
diffraction. The purity of all compounds was established 





C chemical shifts of the ligand 3.28b 
and those of the corresponding of gold(I) complex 4.12. 
 
Table 4.2: Chemical shifts of the ligand and gold complex. 
 
1H and 13C NMR (d6-DMSO) 
Comparison Comp. No N2H C=S 
Ligand 3.28b 10.15 179.0 
Complex 4.12 10.99 173.6 
 
As can be seen from the Table 4.2, the 
1
H-NMR data for 
gold(I) TSC complex 4.12 revealed the NH proton chemical 
shift downfield with respect to that of the free ligand 
3.28b. More importantly, the presence of NH signals 
suggested coordination of TSCs to gold(I) in their thione 
form.
17
 The appearance of different signals of NH2 at  9.12 
and 8.69 ppm indicated the non-equivalence of these protons 
due to the double bond character created around the C-N 




C spectrum of complex 4.12 showed an upfield shift of 
the thiocarbonyl (C=S) compared to 3.28b. Similar trends on 
coordination of TSCs have been observed by Lobana and co-
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TSC ligand,
25




The FT-IR spectra of the synthesised gold(I) complexes 
showed characteristic bands in ranges 3062-3251, 1587-1600 
and 796-845 cm
-1
, which can be assigned to (NH), (C=N) and 
(C=S) stretching frequencies, respectively. On gold 
coordination, the (C=S) stretch of all resulting complexes 
appeared at lower frequencies (shifted ca. 6–72 cm
-1
) 




 proposed a silver(I) complex with vanillin TSC 
(VTSC) as a ligand binding through the S-donor atom. The 
(C=N) band of the silver complex displayed no shift in 
comparison to that of the VTSC ligand, while the (C=S) 
stretching frequency shifted ca. 30 cm
-1
 to lower 
frequencies. This supported our deduction that TSCs 
coordinated with the softer gold(I) through S-donor atoms. 
 
The positive-ion FAB-MS spectra of all complexes contained 
molecular ion peaks at m/z 740.80 (4.12), 768.93 (4.13), 
770.95 (4.14), 740.93 (4.15), 720.87 (4.16), 748.97 (4.17) 
and 798.7 (4.18). Electron-spray ionization (ESI) mass 
spectrometry revealed a molecular ion peak for 4.19 at m/z 
647.0819. The fragmentation signals arising from the loss 
of a TSC moiety was also apparent in each spectrum of 
proposed structures. Microanalysis data showed atom 
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4.3.1.2 Crystal Structures of Compounds 4.15 and 4.16 
 
The single X-ray crystals of 4.15 (Fig. 4.5) and 4.16 (Fig. 
4.6) were grown from their CH3CN solutions by the slow 
evaporation method.
27
 The crystal structures of these 
complexes contain a solvent molecule in a 2:1 ratio and a 
Cl
-
 counter anion. The complexes 4.15 and 4.16 are 
isostructural
28 
and crystallize in centrosymmetric, 






Figure 4.5: Molecular structure of 4.15 with a hydrogen bonded 
solvent molecule. Thermal ellipsoids of the asymmetric unit are 
shown at 50% probability level. 
 
The Au1-S1 bond distances are similar in both structures: 
2.2825(13) Å (4.15) and 2.2818(13) Å (4.16).27 The Au-S 
distances in 4.15 and 4.16 are comparable to the bond 
distances of 2.278(4) and 2.279(5) Å in [Au2(3-
NO2Hbtsc)4]Cl2,
18b





 The Au-S distances of 
binuclear gold(I) complex 4.9 (see Fig. 4.9) are in 
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Figure 4.6: Molecular structure of 4.16 with a hydrogen bonded 
solvent molecule. Thermal ellipsoids of the asymmetric unit are 
shown at 50% probability level. 
 
The gold atoms exhibit distorted linear coordination 
geometries with an S-Au-S angle of 170.24º in 4.15 and 
169.66º in 4.16. The literature reported gold(I) complexes 
4.7 (Fig. 4.2) and 4.9 (Fig. 4.3) also showed distorted 
linear coordination geometries with an S-Au-S angle of 
172.70º and 167.07º, respectively.
18b,18c
 The relative angle 
of the two aromatic rings is 72.86º (4.15) and 73.47º 
(4.16). 
 
The chloride counter anion is on a two fold rotational 
axis and hydrogen bonded to four amide groups which are 
arranged in a distorted tetrahedral arrangement. The 
nitrogen atom of the acetonitrile molecule is hydrogen 
bonded to the amide group through N1-H1AN4 (Fig. 4.5 and 
4.6), while the methyl hydrogen of the solvent molecule is 
involved in C-Hπ interaction with the neighbouring 
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Figure 4.7: Molecular arrangement and significant intermolecular 
interactions in molecular structures 4.15 (a) and 4.16 (b). 
 
Unlike gold(I) complex 4.7 (Fig. 4.2), no aurophilic 
Au(I)Au(I) and SS interactions were observed in both 
molecular structures of 4.15 and 4.16. The crystal 
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interactions between the phenyl rings of the symmetry 
generated molecular pairs. The two rings (C4C9) are 
parallel with the neighbouring molecule and separation 
distances of 3.733 Å (4.15) and 3.489 Å (4.16). The 
brominated phenyl groups in 4.15 are in close to perfect 
overlap (Fig. 4.7a), while in 4.16 the dichlorinated 




To study weak interactions involved in both crystal 
structures, Hirshfeld surfaces were generated with the aid 
of CrystalExplorer,
30
 a tool commonly utilised to describe 
packing arrangements and intermolecular interactions in 
molecular crystals.
31
 By comparing the two fingerprint 
plots (Fig. 4.8) it can be seen that the intermolecular 
interactions are largely similar in the two structures, 




In both compounds two spikes are related to short contacts 
between H2 and H1B to the Cl anion () and the hydrogen 
bonded solvent molecule (H1AN4, ). The plot of 4.15 
revealed two symmetrical spikes, which are related to HBr 
and BrH weak interactions ( and , Fig. 4.8a) between 
the halogen negatively polarized region and the methyl 
hydrogen atoms of neighbouring molecules.
27
 A remarkable 
difference is observed on the plot of 4.16 indicated by 
the middle red region, which is related to the overlap of 
the ππ interaction between the aromatic rings () and 
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Figure 4.8: Fingerprint plots of the coordinated TSC gold(I) 
complex 4.15 (a) and 4.16 (b). The labels are referred to in the 
text. 
 
Having observed the ClCl contacts (), it was also worth 
determining the type of chlorine-chlorine interactions 
existing in complex 4.16. Although halogen-halogen contacts 
is a well known phenomenon, in the context of gold 
chemistry these interactions are rare. The interactions are 
dependent on the polarity of the C-X bond. Generally, in 
organic based compounds they are classified into two types, 
depending on the C-X…X' angle (Θ1 = C-X…X' and Θ2 = X…X'-C) 
within the C-X…X'-C' distance. Type I (Θ1 = Θ2 = 140-180°) 
interactions are driven by dispersion forces, while type II 
(Θ1 = 150-180°, Θ2 = 90-120°) are stabilized by Coulombic 
electrophile-nucleophile pairing. The observed geometric 
parameters for structure 4.16 suggest type I (Θ1 = 136.4°, 
Θ2 = 157.7°, Cl2…Cl3' = 3.43Å) (Fig. 4.9) driven by weak 
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Figure 4.9: The centrosymmetric pair of ClCl interaction 
analysed geometrically. 
 
4.3.2 Synthesis of gold(I) Pyrazoline Complexes 
 
The synthesis of pyrazoline gold(I) complexes 4.20-4.23 is 
illustrated in Scheme 4.3. Treatment of 4.3 with pyrazoline 
TSC analogues (3.37a-c and 3.37f) in MeOH in a ratio 0.5:1 
mol for 2 h readily produced the bis(PyTSC) gold(I) 
complexes as yellow to tan solids in moderate to good 
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Entry Code Compound No R1 R2 Yield/[%] 
1 DK-33 4.20 H Br 77 
2 DK-40C 4.21 Cl Cl 51 
3 DK-41 4.22 Br H 91 
4 DK-135 4.23 Cl H 55 
 
4.3.2.1 Characterisation of Compounds 4.20-4.23 
 




C NMR, IR, MS and microanalysis. The 
1
H NMR spectra of 
complexes 4.20-4.23 showed a slight shift in chemical 
shifts of methylene protons of C1’ and C2’ carbons relative 
to the free ligands. In the 
13
C NMR spectra there was no 
significant shifts observed except the signals of C=S 
carbons appearing upfield. The FT-IR spectra also confirmed 
the coordination of pyrazoline ligands with the gold(I) 
centre through the S-donor atom. 
 
ESI mass spectra of resulting complexes gave intense 
signals of molecular ion peaks at m/z 764.90(4.20), 
744.94(4.21), 764.92(4.22) and 975.02(4.23). The 
fragmentation peaks at m/z 750.93(4.20), 730.95(4.21), 
750.93(4.22) and 663.03(4.23) appeared consistent with the 
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4.4 SYNTHESIS OF TWO COORDINATE GOLD(I) COMPLEXES 
 
An overwhelming majority of phosphine ligands used in 
gold(I) coordination chemistry are monodentate tertiary 
phosphines of the type R3P.
14
 Synthetically, phosphine 
ligands are of great importance in coordination chemistry 
due to the fact that they are easily modified by varying 
organic substituents to introduce properties such as 
aqueous solubility.
32 This has received greater application 
in areas such as catalysis and medicine where water soluble 
compounds are generally a prerequisite.
32
 The ease of 
accessibility of these compounds, e.g. [Au
I
(Ph3P)Cl] (4.5), 
has rendered them attractive as starting materials for the 
synthesis of a wide range of novel gold(I) complexes. The 
following sections describe the synthesis of two coordinate 





(4.5) and [AuI(PTA)Cl] (4.24) as gold(I) sources. 
 
4.4.1 Gold(I) TSC Complexes Derived from [AuI(Ph3P)Cl] 
 

























Scheme 4.4: Reagents and conditions a) AgOSO2CF3, MeOH, r.t., 1 h, 
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Initially, treatment of the gold(I) precursor 4.5 with TSCs 
in MeOH at ambient temperature and under reflux yielded no 
desired products. Instead the starting material 4.5 was 
recovered and confirmed by 
31
P NMR spectroscopy. On the 
other hand, metathesis of 4.5 with silver triflate 
(AgOSO2CF3), presumably proceeding via the intermediate 
4.25, led to the formation of complexes 4.26a-f. The 
reaction products were all filtered (to remove AgCl 
precipitate) through celite and evaporated in vacuo to 
complete dryness. The resultant complexes were generally 
soluble in polar organic solvents. However, attempts to 
obtain suitable crystals for X-ray analysis were 
unsuccessful. Isolated compounds and respective yields are 
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Entry Code Product Ar/Fc R1 Yield/[%] 
1 DK-32G 4.26a 
 
CH3 72 
2 DK-52 4.26b 
 
CH3 66 
3 DK-53 4.26c 
 
CH3CH2 76 
4 DK-54 4.26d 
 
CH3 73 
5 DK-55 4.26e 
 
CH3CH2 76 




4.4.1.1 Characterization of Compounds 4.26a-f 
 




C NMR, IR and MS. The purity of these compounds was 
determined using microanalysis. The 
1
H NMR spectra of 











Chapter 4  Novel Gold Complexes of Thiosemicarbazones and Pyrazolines 
 
 
UCT 128 CHEMISTRY 
 11.20–12.12 ppm due to the NH protons, thus suggesting 
that TSCs bind with gold(I) predominantly in thione form.
18
 
The NH2 protons in the resulting complexes appeared as two 
separate broad peaks in the range  9.53–9.01 and  9.05–
8.26 ppm, due to restricted rotation about the C-N bond of 
the thioamide group (see Scheme 3.5).
18a
 These signals also 





C NMR spectra of all complexes revealed an upfield 
shift of C=S (ca. 168.5–171.6 ppm) on gold(I) complexation. 
The observed trends are consistent with gold(I) MSB TSC 
complex 2.12 (Fig. 2.4, p 39) reported by Casas et al.18a 
The 
31
P spectra of the complexes showed singlet resonances 
in the region  36.8–38.5 ppm. The peaks are also in 
agreement with those of 4.5 coordinated with sulfur-





In addition to the structural features described above, the 
FT-IR spectra of complexes 4.26a-f showed (C=S) bands in 
the range 791-831 cm
-1
, which shifted by 3-62 cm
-1
 towards 
lower frequencies relative to the ligands. 
 
The molecular ion peaks of complexes (positive-ion FAB) 
appeared as intense signals at m/z 731.9 (4.26a), 719.9 
(4.26b), 746.1 (4.26c), 732.1 (4.26d), 734.1 (4.26e) and 





 due to the loss of the TSC ligand 
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4.4.2 Gold(I) TSC Complexes Derived from [AuI(PTA)Cl] 
 
A second series of phosphine gold(I) TSC complexes involved 





 The ligand PTA 
(4.28) is well-known in terms of enhancing the aqueous 
solubility of metal complexes. It has accordingly attracted 
interest in biphasic catalysis.
32
 Recently, Grguric-Sipka et 
al.
35
 reported a novel PTA ruthenium(II)-TSC complex with 
noticeable aqueous solubility. 
 
Since complex 4.26a-f exhibited poor aqueous solubility, it 
was envisaged that replacement of the triphenylphosphine 
(TPP) ligand by 4.28 would lead to gold(I) TSC complexes 
with improved solubility. Scheme 4.5, below, outlines the 





















Scheme 4.5: Reagents and conditions a) THPC, aqu. NaOH, (HCHO)n, 
r.t., 17 h; b) 4.3, CHCl3, r.t., 2 h. 
 
The condensation of trishydroxymethylphosphine [P(CH2OH)3], 
generated in situ from tetrahydroxymethylphosphine chloride 
(THPC), with formaldehyde and hexamethylenetetraamine 
(4.27) afforded 4.28 in 37% yield. Recrystallisation of the 
solid residue from ethanol led to the isolation of 4.28 in 
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ambient temperature afforded linear two-coordinate gold(I) 
precursor 4.24. The formation of both 4.24 and 4.28 was 




P NMR spectroscopy in which the 
observed chemical shifts were consistent with the values 




Having synthesised 4.24, the subsequent step was to 
generate a series of PTA-based gold(I) complexes. Thus, 
treatment of equimolar amounts of the starting material 
gold(I) 4.24 with individual TSCs (3.28a-h) readily 
effected the displacement of the chloride ligand to produce 
























Scheme 4.6: Reagents and conditions a) 3.28a-h; MeOH, r.t, 1½ h. 
 
Reaction mixtures were filtered through celite to remove 
solid contaminants and dried in vacuo to give tan and/or 
yellow solids, which were soluble in polar organic 
solvents. The move to ascertain molecular structures of 
resulting complexes by X-ray was hampered by the poor 
quality of crystals. In some cases attempted methods for 
obtaining suitable X-ray crystals (e.g. cooling the 
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summary of isolated gold(I) complexes is displayed in Table 
4.5. 
 

















Entry Code Product Ar/Fc R Yield/[%] 
1 DK-109 4.29a 
 
CH3 87 
2 DK-112 4.29b 
 
CH3 84 
3 DK-113 4.29c 
 
CH3 81 
4 DK-114 4.29d 
 
CH3CH2 83 
5 DK-115 4.29e 
 
CH3CH2 80 
6 DK-116 4.29f 
 
H 98 
7 DK-117 4.29g 
 
H 96 
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4.4.2.1 Characterization of Compounds 4.29a-h 
 




C NMR, IR, MS and microanalysis. The 
1
H NMR spectra 
revealed that the gold(I) centre coordinates with TSC 
ligands through the   S-donor atom to form the desired 
complexes. The 
31
P NMR spectral data of all compounds showed 
one singlet phosphorus signals at ca  -50.9 ppm. A similar 
observation has been noted by Forward and co-workers when 
thiolate ligands are reacted with 4.24.37 
 
The infrared spectra of complexes showed a shift of (C=S) 
absorption bands to lower frequencies, thus lending support 
to the coordination of TSCs to the gold(I) center through 
S-donor atoms. The presence of NH (
1
H NMR) and absence of SH 
bands (IR) indicated TSCs coordination predominantly in 
their thione form. 
 
ESI mass spectral data of the complexes showed strong 
molecular ion peaks at m/z 625.0206 (4.29a), 625.0221 
(4.29b), 615.0338 (4.29c), 639.0355 (4.29d), 629.0517 
(4.29e), 579.1021 (4.29f), 641.0628 (4.29g) and 677.0770 
(4.29h), which were in agreement with calculated values. 
The elemental analysis data appeared consistent with the 
observed molecular ion peaks of anticipated compounds. 
 
4.4.3 Gold(I) Pyrazoline Complexes Derived from [AuI(PTA)Cl] 
 
Using a similar synthetic approach to that used for 
compounds 4.29a-h, pyrazoline TSC analogues 3.37b, 3.37c 
and 3.37f were employed as ligands to access complexes 
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1 DK-136 4.30a Br H 50 
2 DK-137 4.30b Cl H 67 
3 DK-138 4.30c Cl Cl 60 
 




H NMR spectra, the pyrazoline protons at C1’ and C2’ 
carbons in complexes 4.30a-c resonated as triplets at       
 3.27-3.29 and  4.15-4.18 ppm, respectively. The 
appearance of new PTA protons in each spectrum further 
confirmed the proposed structures. In the 
13
C NMR spectra, 
the C1’ and C2’ carbons, including those of characteristic 
signals (e.g. C=S, C=N, PTA, etc) were observed, further 
supporting the 
1
H NMR spectral data. As in compounds 4.29a-
h, the chemical shifts in the 31P NMR spectra also showed 
one singlet phosphorus signals at  -51.1 ppm. 
 
The mass spectra (ESI) of pyrazoline derivatives exhibited 
strong molecular ion peaks that confirmed the proposed 
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4.4.4 Gold(I) TSC Complexes Derived from [AuI(Et3P)Cl] 
 
The gold thioglucose derivative 2.7 (see also Fig. 2.3, p 
37), an orally active gold(I) drug, is considered the lead 
structure for the development of analogous 
antiproliferatively active gold(I) compounds.
38
 As mentioned 
previously, this complex has been shown to inhibit the in 
vitro growth of P. falciparum.
39
 Fig. 4.11 illustrates our 
rationale behind the synthesis of gold(I) complexes 4.31a-




































Figure 4.10: The effects of retaining Et3P-Au-S moiety. 
 
Early SAR studies derived from 2.7 and its analogues 
revealed that complexes lacking the R3P-Au-S moiety (Fig. 
4.11) display reduced antitumour activities.
40
 Currently, in 
order to design agents with biological properties beyond 
complexes with simple the central gold atom or gold ions, 
replacement of thioglucose by bioactive compounds as 
ligands and retention of the triethylphosphine (Et3P) moiety 
is considered an ideal approach to develop novel gold 
compounds.
38
 This prompted Otto et al.
41
 and Casas et al.
18a
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2.9 and 2.12 (Fig. 4.10) with pronounced antiproliferative 
effects in cultured tumour cells. In this regard, we 
envisaged that replacement of thioglucose ligands with TSCs 
and related pyrazoline analogues could be beneficial in 
addressing problems of antimalarial drug resistance. 
 
By employing a similar synthetic approach to that used for 
compounds 4.29a-h and reaction conditions reported by Casas 
et al.
18a
 the synthesis of Et3P gold(I) TSC complexes 4.31a-f 



















Scheme 4.7: Reagents and conditions a) 3.28a-f, MeOH, r.t, 4 h, 
N2. 
 
Treatment of equimolar amounts of gold(I) 4.2 with ligands 
3.28a-f readily afforded gold(I) complexes 4.31a-f after a 
simple work-up. The resultant compounds were soluble in 
polar organic solvents. A summary of these complexes and 
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Entry Code Product Ar/Fc R Yield/[%] 
1 DK-151 4.31a 
 
CH3 92 
2 DK-152 4.31b 
 
CH3 94 
3 DK-160 4.31c 
 
CH3 96 
4 DK-161 4.31d 
 
CH3CH2 98 
5 DK-162 4.31e 
 
CH3CH2 95 










P NMR spectra recorded in d6-DMSO provided good 
evidence of the formation of coordinated complexes 4.31a-f. 
In the 
1
H NMR spectra of 4.31a-f, the NH signals appeared 
downfield (relative to free ligands) as broad singlets at   
 10.33-11.19 ppm. The NH2 protons gave rise to two broad 
singlets, which also appeared downfield at  7.61-8.36 and 
8.01-8.68 ppm. The chemical shifts which appeared as 
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presence of the Et3P moiety. The 
31
P NMR spectra of each 
complex showed a singlet resonance at  35.1 ppm from the   
 38.5 ppm chemical shift of the starting gold(I) complex 
4.2. 
 
The ESI mass spectra of complexes 4.31a-f are summarised in 
Table 4.8. The spectral data showed molecular ion peaks of 
each complex and characteristic fragmentation signals due 
to the loss of TSC ligand from the complexes. The elemental 
analysis confirmed atomic composition in these compounds. 
 






1 4.31a 586.0344(8) 315.0520(58) 
2 4.31b 586.0396(27) 315.0531(33) 
3 4.31c 576.0489(53) 315.0546(23) 
4 4.31d 602.0474(70) 315.0550(35) 
5 4.31e 590.0621(55) 315.0584(29) 
6 4.31f 602.0744(100) 315.0255(20) 
 
4.4.5 Pyrazoline Gold(I) Complexes based on [AuI(Et3P)Cl] 
 
Using a similar synthetic approach to that used for 
compounds 4.31a-f, pyrazoline derivatives 4.32 and 4.33 
were synthesised by treating equivalent amounts of 4.2 with 
ligands 3.37c and 3.37f. The isolated compounds and 
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Entry Code Product R1 R2 Yield/[%] 
1 DK-165 4.32 Cl H 90 
2 DK-166 4.33 Br H 95 
 




H NMR spectra recorded in d6-DMSO, the pyrazoline 
protons at C1’ and C2’ carbons in complexes 4.32 and 4.33 
showed the expected two triplets with chemical shifts at  
3.27-3.29 and  4.13-4.15 ppm. The chemical shifts appearing 
as multiplets at 1.07-109 and 1.90-192 ppm are due to Et3P 
in the Et3PAu fragment. As found in 4.31a-f, the 
31
P NMR 
spectra showed the shifting of 
31
P resonances by ca 3.0 ppm 
to 35.1 ppm in 4.32 and 4.33. 
 
ESI mass spectra of Et3P gold(I) pyrazoline complexes 
exhibited molecular ion peaks that confirm the proposed 
structures at m/z 554.0851 (4.32) and 598.0349 (4.33). The 
diagnostic fragmentation signals at m/z 315.0549 {(Et3PAu)}
+
 
indicated the loss of TSCs in both 4.32 and 4.33, 
respectively. Microanalysis data revealed the molecular 
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4.5 SYNTHESIS OF ORGANOGOLD TSC COMPLEXES 
 
The chemistry of organogold compounds has been known for 
almost a century,
42
 and it has grown quite considerably over 
the past few decades. Several examples of organogold 
complexes are known, but the commonly used organogold 
precursor is pentafluorobenzene gold(I) complexes 
[Au(C6F5)THT], 4.34. Reactions involving 4.34 with S-donor 
ligands to form gold(I) complexes such as 4.3543 and 4.3644 
























Figure 4.11: Neutral methyl dithiocarbamate gold(I) complexes 
 
As part of our campaign to identify gold TSC complexes with 
potential antiplasmodial activities, we became interested 
in exploring the influence of other gold(I) compounds 
containing different moieties, e.g. pentafluorobenzyl, 
against plasmodial species. 
 
4.5.1 Pentafluorobenzene Gold(I) TSC Complexes 
 
Scheme 4.8 illustrates the synthesis of pentafluorophenyl 
gold(I) TSC complexes. Thus, the starting material gold(I) 
4.34 was prepared according to the published method from 
4.37.46 Simple substitution of the labile ligand (THT) from 
4.34 by ligands 3.28a-f readily afforded neutral gold(I) 
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Scheme 4.8: Reagents and conditions a) n-BuLi, Et2O, -78 °C, 1 h, 
N2; b) 4.3; c) 3.28a-f, DCM, r.t., 1 h. 
 
The resulting gold(I) compounds are mainly soluble in DCM, 
DMSO and slightly in MeOH and CH3CN. A summary of proposed 
structures (in the absence of X-ray crystallographic 
evidence) and their isolated yields is provided (Table 
4.10) 
 

















Entry Code Product R R1 R2 Yield/[%] 
1 DK-74 4.38a CH3 Br H 100 
2 DK-75 4.38b CH3 H Br 100 
3 DK-76 4.38c CH3 Cl Cl 100 
4 DK-77 4.38d CH3CH2 H Br 86 
5 DK-78 4.38e CH3CH2 Cl Cl 100 
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H NMR spectra of these complexes showed a downfield 
shift of the NH and NH2 signals of the ligands on gold(I) 
complexation. The non-equivalence of the NH2 proton chemical 
shifts was also clearly evident in 
1
H NMR spectra of all 
complexes. Infrared spectra of all the complexes revealed 
the (C=S) bands at lower frequencies compared to those of 
corresponding ligands. 
 
The molecular ion peaks of 4.38a, 4.38b and 4.38e were not 
observed in the mass spectra, only m/z values consistent 
with resulting fragments at 467.75 (4.38a), 469.94 (4.38b), 
471.97 (4.38e). The ESI mass spectral analysis of complex 
4.38d exhibited a weak molecular ion peak at m/z 650.97(4%) 
and a fragmentation signal m/z at 483.96. Microanalyses 
data confirmed atomic composition of these compounds. 
 
SECTION B: THE CHEMISTRY OF GOLD(III) TSC COMPLEXES 
 
4.6 SYNTHESIS OF ORGANOGOLD(III) TSC COMPLEXES 
 
Although a number of gold(III) TSC complexes have been 
reported,
17,19
 to our knowledge there are no reports dealing 
with their antimalarial evaluation. In view of antitumour 
activities of the gold(III) complex 2.15 (Fig. 2.6, p 42) 
and its analogues,
4c,47
 it seemed a worthwhile endeavour to 
investigate the influence of 2.15 on TSCs against P. 
falciparum strains. Thus, we pursued the synthesis and in 
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4.6.1 Synthesis of Gold(III) TSC Complexes 
 
The reaction of N,N-dimethylaminomethylbenzene (damp) 4.39 
with n-BuLi produced an organolithium intermediate in situ, 
which was subsequently treated with HgCl2 to give complex 
4.40 (Scheme 4.9).48 The formation of 4.40 was confirmed by 
both 
1














Scheme 4.9: Reagents and conditions a) n-BuLi, Et3O, 0 °Cr.t, 24 
h, N2. b) HgCl2, THF, -90 °C, 24 h, N2. c) Me4N[AuCl4]/Me4NCl, 
CH3CN, r.t., 24 h. 
 
Treatment of 4.40 with the gold(III) precursor Me4N[AuCl4] 
(4.41) in anhydrous acetonitrile afforded a yellow solid 
residue, which was extracted with DCM to produce complex 
2.15 as an analytically pure yellow solid.49 1H and 13C NMR 
spectroscopy, and microanalysis confirmed the formation of 
2.15. 
 
Having synthesised 2.15, the subsequent step was to prepare 
gold(III) TSC complexes 4.42a-f. By employing conditions 
reported by Ortner et al.
19e
, reaction of complex 2.15 with 
3.28a-f and 3.28h in methanol resulted in the formation of 
products as a mixture of 4.42a-f and gold(I) bis(TSC) 
complexes due to the in situ reduction of gold(III) to 
gold(I).
21
 This appeared unusual since 2.15 and analogous 
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due to the electron-rich phenyl group of the damp ligand 
stabilising the gold(III) center.
50
 It was later established 
that in order to circumvent the reduction of gold(III) to 
gold(I), the reactions should be conducted in polar aprotic 
solvents such as acetone.
18c
 The polar protic solvent, MeOH, 
is believed to be responsible in varying the redox 
behaviour of gold(III), thus favouring its reduction to 
























Scheme 4.10 Reagents and conditions: (a) 3.28a-f and 3.24h, 
Acetone, reflux 1 h, r.t., 5 h. 
 
Treatment of complex 2.15 with TSCs 3.28a-f and 3.28h in 
acetone led to the formation of complexes 4.42a-f (Scheme 
4.10) without any evidence (ESI mass spectroscopy) of the 
formation of competing gold(I) complexes being observed. 
These complexes were obtained as yellow, orange-yellow and 
dark-red solids after solvent evaporation and drying of the 
products in vacuo. In general complexes 4.42a-f are soluble 
in polar organic solvents and insoluble in non-polar 
solvents and water. Table 4.11 summarises isolated 
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Entry Code Product Ar/Fc R Yield/[%] 
1 DK-46M 4.42a 
 
CH3 98 
2 DK-51F 4.42b 
 
CH3 96 





4 DK-63F 4.42d 
 
CH3CH2 93 
5 DK-64F 4.42e 
 
CH3CH2 90 
6 DK-65F 4.42f 
 
CH3 91 






4.6.1.1 Characterisation of Gold(III) Compounds 4.42a-g 
 
The complexes were characterised by means of 
1
H NMR, FT-IR, 
MS, and elemental analysis. The 
1
H spectra of 4.42a-g in 
deuterated DMSO showed chemical shifts at δ 10.35-10.83 
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(NH
+
) group of damp ligand.
19
 Coordination of the damp 
ligand was also supported by the appearance of signals at δ 
4.30-5.40 ppm and δ 2.65-3.20 ppm, which were assigned to 
the –CH2 and –N(CH3)2 groups, respectively. The 
1
H NMR 
spectra showed no chemical shifts corresponding to NH. This 





The FT-IR spectra of complexes 4.42a, 4.42c19a, 4.42d, 4.42e 
and 4.42g19e displayed weak bands at 2664-2683 cm-1 due to 
NH
+
 stretches. These bands revealed that during the 
reaction, cleavage of the Au-N (2.15) bond is accompanied 
by protonation of the tertiary amine group in the damp 
ligand.
19
 Evidence of S-coordination of TSCs to the 
gold(III) was provided by a decrease in the (C=S) 
frequencies to lower streching frequencies. The absorption 
bands due to (C=N) appeared in the range 1580-1700 cm-1. 
 
The formation of cationic complexes 4.42a-f was supported 
by detection of molecular ion peaks in the ESI and FAB mass 
spectra at m/z 627.028 (4.42a), 637.0118 (4.42b), 653.1 
(4.42c), 651.025 (4.42d), 641.036 (4.42e), 637.011 (4.42f), 
591.0 (4.42g). The intense fragmentation peaks at m/z 
555.0-617.1 suggested the loss of a chloride anion (i.e. M
+
-
Cl) in each complex. Microanalytical data of all the 
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4.7 CONCLUSION 
 
In conclusion, we have demonstrated the synthesis of novel 
gold(I) and gold(III) TSC complexes from previously 
investigated bioactive ligands. The available experimental 
data showed that TSCs coordinate to gold(I) through the S-
donor atom. The data suggests that coordination of TSCs to 
gold(III) involve both sulfur and nitrogen donor atoms. 
 
The crystal structure of 4.15 revealed that the structure 
of this complex is partly held together by secondary 
interactions including H…Br and Br…H weak interactions. In 
both the crystal structures of 4.15 and 4.16, however, no 
inter- and intra-molecular aurophilic interactions were 
found, which is a common phenomenon in linear gold(I) 
compounds. In addition, complex 4.16 exhibited π…π 
interactions between the aromatic rings and the Cl…Cl 
contacts in the crystal. 
 
Although the formation of two coordinate gold(I) and 
gold(III) complexes has been supported by most analytical 
techniques, greater insight into their molecular structures 
could have been gained if crystals suitable for analysis 
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CHAPTER 5 
 
ANTIPLASMODIAL EVALUATION OF GOLD THIOSEMICARBAZONE 
COMPLEXES 
 
ABSTRACT: The main aim of this project was to identify 
antimalarial gold compounds based on the TSC scaffold. All 
the synthesised gold TSC complexes described in Chapter 4 
were evaluated for in vitro growth inhibitory activity 
against P. falciparum strains, and in selected cases for 
the inhibition of FP-2 activity. This chapter will discuss 




he target compounds were principally generated in order 
to assess their ability to inhibit plasmodial growth by 
determining the IC50 values. The IC50 is the drug 
concentration required to cause the measured parameter to 
fall to 50% of its original value. The term is used 
throughout this chapter to express the biological activity 
of each compound. The lower the IC50 value of a compound, 
the better is its efficacy. 
 
However, a good drug should exhibit good selectivity.
1
 The 
more selective a drug for its target, the less chance that 
it will interact with different targets, which may lead to 
undesirable side effects. Thus, a compound displaying good 
efficacy (low IC50) will not be a good drug if it has poor 
selectivity between host and the parasite. All experimental 
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5.2 BIOLOGICAL RESULTS AND DISCUSSION 
 
The synthesised gold compounds and corresponding precursors 
were evaluated in vitro against P. falciparum chloroquine-
sensitive (D10 and 3D7) and chloroquine-resistant (W2 and 
K1) strains. In all assays, chloroquine (CQ) and 
artemisinin (ART) were used as control drugs. The 
cytotoxicity tests of some of the compounds were conducted 
in human nasopharynx carcinoma cell line (KB). This was 
carried out in this study to gain an insight on toxicity of 
gold complexes towards human cell line (i.e. normal cells). 
Podophyllotoxin (POD) was used as a control drug. Some of 
the compounds were also evaluated for their ability to 
inhibit the malarial cysteine protease FP-2. 
 
The biological tests were carried out in collaboration with 
the following institutions: 1) Department of Medicine, San 
Francisco General Hospital, University of California in San 
Francisco (UCSF) - Professor P.J. Rosenthal, 2) Department 
of Medicine, Division of Pharmacology, University of Cape 
Town - Professor P.J. Smith and 3) London School of Hygiene 
and Tropical Medicine (LSHTM) – Drs V. Yardley and L. 
Vivias. 
 
5.2.1 In Vitro Antiplasmodial Activity of Gold Precursors 
 
Consistent with the objectives of this project, gold 
precursors (Table 5.1) were evaluated along with target 
compounds against D10, W2 and FP-2 to investigate the role 
of gold(I) and gold(III) starting materials as well as TSCs 
(Chapter 3) towards the overall activity of resulting gold 
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growth of chloroquine sensitive (D10, 3D7) and chloroquine-
resistant (W2, K1) strains as well as FP-2 inhibition were 
determined and results are shown in Table 5.1. 
 
Table 5.1: In vitro antiplasmodial, cytotoxicity and FP-2 











































 IC50 / M aSI 
3D7 D10 K1 W2 KB FP-2 
2.15 15.7 10.5 5.94 1.88 36.2 >100 2.3 
4.2 bND ND ND 8.04 ND ND ND 
4.3 16.4 193.7 34.6 >20 66.3 >100 4.0 
4.5 2.45 3.13 11.4 >20 2.51 25.0 1.0 
4.24 22.2 26.9 4.62 >20 20.9 >100 0.9 
4.34 11.3 31.0 12.4 >20 8.54 20.9 0.7 
4.41 ND >10 ND >20 ND >100 ND 
CQ 0.019 0.029 1.03 0.097 ND ND ND 
ART 0.003 ND 0.003 0.019 104.4 ND 34794 
E64 ND ND ND ~2.00 ND 0.049 ND 
POD ND ND ND ND <0.007 ND ND 
aSelectivity index calculated as [IC50KB/IC503D7]; 











Chapter 5       Antiplasmodial Evaluation of Gold Complexes 
 
 
UCT 156 CHEMISTRY 
These complexes displayed moderate to poor activities 
against D10. The most active complex against D10 was 4.5 
with an IC50 value of 3.13 M. Whereas gold(III) 2.15 and 
4.2 were the most active compounds against W2, with IC50 
values of 1.88 and 8.04 M, respectively. However, these 
complexes were less active than the control drugs (i.e. CQ 
and ART). The rest of complexes displayed no activities 
against W2 at highest concentration tested (IC50 > 20 M). 
 
Alternatively, the gold precursors were also evaluated 
against different strains (3D7, K1) of P. falciparum (Table 
5.1). It is noteworthy that some of the literature reported 
gold compounds have been tested for their antiplasmodial 
activities using these strains.
2,3
 All compounds showed 
antiplasmodial activities in the mid micromolar range. 
While most complexes showed better activity against 3D7 
than K1, compounds 2.15 (IC50 = 5.94 and 15.7 M) and 4.24 
(IC50 = 4.62 and 22.2 M) were generally active against K1 
compared to 3D7. 
 
Compounds 2.15, 4.3 and 4.24 showed low cytotoxicity 
towards human KB cell line. Although compounds 2.15 and 4.3 
showed some degree of selectivity (SI = 2.3 and 4.0), 
complexes 4.5 and 4.24 were not selective in favour of the 
parasite. 
 
Since thiol-containing molecules have been hypothesised as 
molecular targets of gold compounds, gold(I) (e.g. 4.2) and 
gold(III) (e.g. 2.15) complexes have been evaluated for 
their ability to inhibit cysteine proteases such as 
cathepsin B.
4,5
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compounds (Table 5.1) against the malaria cysteine protease 
FP-2. Although some of these compounds have been evaluated 
for growth inhibition of P. falciparum,
3
 no information is 
available on the inhibition of FP-2. 
 
From Table 5.1, it can be seen that gold complexes showed 
weak inhibition of FP-2. IC50 values of 4.5 and 4.34 were 
25.0 and 20.9 M, respectively. Although compound 2.15 
showed activity against W2 (IC50 = 1.88 M), it was not 
effective against the inhibition of FP-2. This suggests 
that the observed antiplasmodial activity was independent 
of enzyme inhibition. It is possible that the in vitro P. 
falciparum growth inhibition may be due to direct 
interaction of the gold center with specific parasitic 
molecular targets such as thioredoxin reductase,
3,6
 and/or 
other cysteine proteases. 
 
5.2.2 In Vitro Antiplasmodial Activity of Gold(I) Compounds 
 
The following sections discuss evaluation of various types 
of gold(I) TSC complexes for their ability to inhibit the 
growth of P. falciparum. These were tested on four 
different strains D10, 3D7, W2 and K1 as well as the 
inhibition of FP-2 activity. Cytotoxicities of compounds 
were determined against human KB cell line. 
 
5.2.2.1 Gold(I) TSC Complexes 4.12-4.17 and 4.19 
 
The in vitro antiplasmodial activity data of synthesised 
gold(I) TSC complexes 4.12-4.17 (also see Table 4.1, p 115) 
is shown in Fig. 5.1. The results revealed that gold(I) 
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to 4.19 which showed no activity at highest concentration 
tested) compared to the corresponding free ligands (see 
Chapter 3) against D10 and W2 strains. In this series the 
tested compounds 4.12-4.17 displayed antiplasmodial 
activity in the range 1.28-6.92 M. Whereas the gold(I) 
complex 4.19 (not shown in Fig. 5.1) showed poor activity 
against both D10 (IC50 > 10 M) and W2 (IC50 > 20 M) 
strains. These compounds were less effective compared to 
CQ, which displayed antiplasmodial activity against D10 and 






























































D10 6.26 3.84 2.02 6.92 4.76
W2 2.8 2.8 1.28 3.55 2.74 3.06
4.12 4.13 4.14 4.15 4.16 4.17
  
 
Figure 5.1: In vitro screen of gold(I) TSC complexes against P. 
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On the other hand, these compounds were also assessed 
against P. falciparum 3D7 and K1 strains. The in vitro data 
(Table 5.2) showed that the complexes have low to moderate 
activity against the malaria parasite strains 3D7 and K1. 
The IC50 values for growth inhibition of P. falciparum were 
in the low to mid micromolar (5.02-24.2 M) range. Some of 
the reported gold(I) complexes in the literature exhibited 
their antiplasmodial activities on the same strains within 
this range.
7
 Nevertheless, complexes 4.12, 4.14-4.18 and 
4.20-4.23 were 1-8 fold more active compared to their 
parent ligands in the 3D7 and K1 strains. 
 
By comparing complexes bearing similar substitution 
patterns (e.g. 4.16 against 4.21), pyrazoline-based gold(I) 
complexes 4.20-4.23 were approximately 3-fold better than 
their non-cyclic analogues (4.12 and 4.14-4.18) when tested 
against 3D7 and K1 strains (Table 5.2). Although gold 
precursors (Table 5.1) displayed comparable activities as 
4.12-4.23, their coordination to TSCs and pyrazoline 
analogues seemed to be beneficial to the antiplasmodial 
activities of these ligands. In the absence of complexes 
4.16 and 4.17, these compounds showed lower cytotoxicity 
against human KB cell line. In addition, these compounds 
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Table 5.2: Antiplasmodial activities and cytotoxicity of 





















































Substituent IC50 / M 
SI 
R R1 R2 3D7 K1 KB 
4.12 CH3 H Br 12.9 23.2 32.2 2.5 
4.14 H Ferrocene 8.48 14.3 22.0 2.6 
4.15 CH3 Br H 7.42 7.68 28.9 3.9 
4.16 CH3 Cl Cl 14.7 24.2 7.27 0.5 
4.17 CH3CH2 Cl Cl 19.2 12.2 7.23 0.4 
4.18 CH3 Ferrocene 10.4 16.0 18.3 1.8 
4.20 - H Br 10.1 10.2 73.5 7.4 
4.21 - Cl Cl 5.09 9.17 22.7 4.5 
4.22 - Br H 9.22 10.6 82.3 8.9 
4.23 - Cl H 9.83 18.1 19.1 1.9 
CQ - - - 0.019 1.03 ND ND 
ART - - - 0.003 0.003 104.4 34794 
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5.2.2.1.1 Assessment of Falcipain-2 Inhibition 
 
In order to establish the likely targets of 4.12-4.17 
against P. falciparum, the compounds were tested for their 
ability to inhibit the activity of the enzyme FP-2. The 





























































FP-2 93.9 46.5 8.19 59.4 0.87 63.6
4.12 4.13 4.14 4.15 4.16 4.17
 
 
Figure 5.2: In vitro screening of gold(I) complexes against FP-2 
 
As mentioned previously (Chapter 3, p 93), the free 
ligands, with the exception to ferrocenyl analogues 3.28f 
and 3.28g (see section 3.6.1, p 93), displayed no 
inhibitory effects against FP-2 at maximum concentration 
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showed enhanced potency against FP-2. The most effective 
compound was 4.16 with an IC50 value of 0.87 µM. The 
structural modification of these complexes, e.g. replacing 
the methyl groups in 4.12 and 4.16 with the ethyl as in 
4.13 and 4.17, lowered their efficacy against FP-2. 
However, substitution of Cl for Br atom, as in complexes 
4.12, 4.13 and 4.15, was tolerated by the enzyme. 
 
The enhanced activity of TSCs on complexation could be the 
ability of the gold(I) center to hold TSCs in a geometry 
that allows favourable interaction of TSCs with the target.
8
 
On the other hand, due to the ability of gold(I) to undergo 
facile ligand exchange and its affinity for S ligands,
9
 it 
could be possible that the inhibition of FP-2 involves 
direct interaction with the sulfhydryl groups in the active 
site. Urig et al.
10
 demonstrated direct interaction of 
gold(I) with sulfhydryl groups in the active site of human 
glutathione reductase (hGR) following a stepwise ligand 
displacement by these groups. These enzymes and other 
antioxidant enzymes have been shown to be potential targets 
for antimalarial chemotherapy.
11
 Overall, there was no 
correlation found between the antiplasmodial activity and 
FP-2 inhibition. This suggests that FP-2 is not the primary 
target for these compounds. 
 
5.2.2.2 Triphenylphosphine Gold(I) TSC Complexes 4.26a-f 
 
The in vitro antiplasmodial activity data of this series is 
shown in Table 5.3. The compounds displayed moderate 
antiplasmodial activities against both strains, with IC50 
values in the range 2.15-7.89 M. The least active compound 
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compounds 4.12-4.17, these complexes also displayed 
enhanced activity compared to their free ligands. It is 
worth noting that although the gold(I) starting material 
4.5 (Table 5.1) displayed poor activity (IC50 > 20 µM) 
against the W2 resistant strain, replacing the chloro 
ligand in [Au(PPh3)]Cl with TSCs led to compounds with 




Table 5.3: In vitro antiplasmodial, cytotoxicity and FP-2 















IC50 / M 
SI 
3D7 D10 K1 W2 KB FP-2 
4.26a 3.26 2.37 7.89 2.15 1.91 11.6 0.6 
4.26b 2.74 5.0 2.87 5.89 7.73 21.1 2.8 
4.26c ND 2.77 ND 7.89 ND 15.5 ND 
4.26d 1.44 3.12 2.01 6.38 5.49 14.3 3.8 
4.26f ND 3.44 ND 3.63 ND 10.7 ND 
CQ 0.019 0.029 1.03 0.097 ND ND ND 
ART 0.003 ND 0.003 0.019 104.4 ND 34794 
E64 ND ND ND ~2.00 ND 0.049 ND 
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The compounds were also tested for the inhibition of FP-2 
to gain insight into their possible antiplasmodial mode of 
actions. From the data (Table 5.3), it can be seen that 
complexes 4.26a-f exhibited significant activity against 
the enzyme compared to the parent ligands (see Table 3.6 in 
3.6.1, p 94). The gold(I) precursor 4.5 (Table 5.1) and 
complex 4.26a displayed similar activity against FP-2, 
while the rest of compounds were more active than 4.5. 
 
Apart from the presumed enhanced lipophilicity of resulting 
complexes, the improved activities of these compounds 
against FP-2 could be due to the presence of Ph3PAu, which 
has been suggested to bring complexes in close proximity to 
the active site.
7
 In this series, there was also no 
correlation found between the antiplasmodial activity and 
the inhibition of the enzyme. This suggests that the 
observed antiplasmodial activities may be due to the 
inhibition of other cysteine proteases or thioredoxin 
reductase.
12
 This is assuming compounds reach the site of 
action. Alternatively, the compounds may not possess the 
physicochemical properties to cross the various membranes 
to reach the presumed target in the acidic food vacuole 
(FV) of the parasite. 
 
On the other hand, complexes 4.26a-b and 4.26d displayed 
moderate antiplasmodial activities against both 3D7 and K1 
(Table 5.3). The IC50 values were in the range 1.44-7.89 M. 
The three compounds displayed cytotoxic activity towards 
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5.2.2.3 PTA Gold(I) TSC Complexes 4.29a-h and 4.30a-c 
 
Replacing the PPh3 with PTA led to a new series of gold(I) 
compounds 4.29a-h, which was also evaluated against W2 and 
the inhibition of FP-2 (Table 5.4). Although most compounds 
displayed no activity against W2 at highest concentration 
tested, IC50 > 20 µM, half of these complexes retained the 
antiplasmodial activity below 10 µM. Comparing the two 
series (i.e. 4.26 and 4.29), no marked difference in 
activity against the W2 strain was evident. This data 
suggests that replacing the PPh3 moiety with PTA was not 
beneficial against this particular strain of the drug 
resistant parasites. 
 
Similarly, the compounds were tested for their ability to 
inhibit the activity of FP-2. From the three selected 
compounds 4.29b and 4.29d-e, which exhibited moderate 
activity against W2 (IC50 = 3.98-7.85 µM), the most active 
compounds against FP-2 were 4.29d and 4.29e with the latter 
being the most potent compound against the enzyme with an 
IC50 value of 0.94 µM. Comparing the data of 4.29b with that 
of 4.29d and 4.29e, it can be seen that a single mode of 
action is unlikely to exist for these complexes. 
 
The PTA-derived complexes 4.29a-h and 4.30a-c were 
evaluated in vitro against 3D7 and K1 strains (Table 5.4). 
These complexes displayed in vitro antiplasmodial activity 
against 3D7 (IC50 = 4.40-18.4 M) and K1 (IC50 = 5.59-32.7 
M). However, these compounds were slightly less active 
compared to Ph3P-derived complexes 4.26a-b and 4.26d (Table 
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against the human KB cell line compared to compounds 4.26a-
b and 4.26d. 
 



































IC50 / M 
SI 
3D7 W2 K1 KB FP-2 
4.29a 9.09 >20 13.1 21.5 ND 2.4 
4.29b 10.3 3.98 8.97 21.8 >100 2.1 
4.29c ND >20 ND ND ND ND 
4.29d 4.40 6.69 16.5 23.6 27.9 5.4 
4.29e 20.9 7.85 10.8 25.1 0.94 1.2 
4.29f 17.1 >20 32.7 36.0 ND 2.1 
4.29g 9.53 >20 13.7 33.9 ND 3.6 
4.29h 13.8 >20 9.11 32.1 ND 2.3 
4.30a 4.51 ND 5.59 29.1 ND 6.5 
4.30b 18.4 ND 17.3 40.1 ND 2.2 
4.30c 5.30 ND 16.4 33.2 ND 6.3 
CQ 0.019 0.097 1.03 ND ND ND 
ART 0.003 0.019 0.003 104.4 ND 34794 
E64 ND ~2.00 ND ND 0.049 ND 
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5.2.2.4 Triethylphosphine Gold(I) TSC Complexes 4.31a-c, 
4.31e-f and 4.32-4.33 
 
The rationale behind the synthesis of these complexes has 
been provided in Chapter 4 (see section 4.4.4, p 134) and 
will not be repeated in this chapter. This series was 
evaluated for antiplasmodial activity against the W2 strain 
and data is shown in Fig. 5.3. The compounds displayed 
moderate antiplasmodial activities against W2 strain, with 






































W2 5.13 6.39 7.62 7.84 4.84 7.53 7.45
4.31a 4.31b 4.31c 4.31e 4.31f 4.32 4.33
  
 
Figure 5.3: In vitro antiplasmodial data of gold(I) complexes 
 
Comparing this series (Fig. 5.3) with other phosphine-based 
complexes [Au
I
(Ph3P)TSC]O3SCF3 (4.26a-d and 4.26f) and 
[Au
I
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4.31a-c, 4.31e-f, 4.32 and 4.33 had similar activity (Table 
5.5) against the W2 strain of the malaria parasite. The 
results suggest that introduction of different phosphine 
containing moieties had no effect on the antiplasmodial 
activity. 
 
Table 5.5: In vitro antiplasmodial activities range of 














































2.15-7.89 3.98-7.85 4.84-7.84 
 
 
5.2.2.5 Pentafluorobenzene Gold(I) TSC Complexes 4.38a-f 
 
All six pentaflourobenzyl gold(I) TSC complexes displayed 
enhanced in vitro antiplasmodial activities against D10 and 
W2 strains (Table 5.6). Excluding data on W2 for 4.38a, 
compounds 4.38b-d were modestly active against W2. The 
least active compounds were 4.38e and 4.38f with IC50 values 
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Table 5.6: Antiplasmodial and FP-2 activities of complexes 



















IC50 / M 
SI 
D10 W2 3D7 K1 KB FP-2 
4.38a 2.81 >20 5.15 9.37 5.18 ND 1.0 
4.38b 4.09 4.93 2.23 4.46 9.19 4.54 4.1 
4.38c 1.82 6.20 4.58 29.3 4.76 2.48 1.0 
4.38d 5.11 7.66 4.69 14.8 10.8 5.94 2.3 
4.38e 3.03 10.3 3.70 10.9 7.45 2.35 2.0 
4.38f 3.92 16.1 ND ND ND 3.31 ND 
CQ 0.029 0.097 0.019 1.03 ND ND ND 
ART ND 0.019 0.003 0.003 104.4 ND 34794 




POD ND ND ND ND <0.007 ND ND 
 
These complexes showed significant enzyme inhibition (Table 
5.6). In fact, the gold(I) TSC complexes derived from 4.34 
displayed better enzyme inhibition, IC50 = 2.35-4.54, than 
those derived from 4.5 (IC50 = 25.0 µM, Table 5.3) and 4.24 
(IC50 > 100 µM, Table 5.6), with the exception to complex 
4.29e whose activity against the enzyme was far superior 
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On the other hand, compounds 4.38a-e showed modest in vitro 
antiplasmodial activity against 3D7 (IC50 = 2.23-4.69 M) 
and K1 (IC50 = 4.46-29.3 M). The compounds generally showed 
low cytotoxicity against KB cell line. 
 
5.2.3 In Vitro Antiplasmodial Activities of Gold(III) TSC 
Complexes 
 
In view of the antitumour activities of square planar 
gold(III) TSC complexes of the type [Au(Hdamp-C
1
)Cl(TSC)]X 
and starting complex 2.15 (Fig. 2.6, p 42) against the 
human MCF-7 breast cancer cell line,
13
 analogous complexes 
reported in Chapter 4 (p 113) were evaluated for in vitro 
growth inhibition of P. falciparum and their ability to 
inhibit FP-2. Table 5.7 shows the results obtained against 
D10 and W2 strains as well as FP-2. From the data (Table 
5.7), it is apparent that complexes 4.42b [IC50 (W2) = 3.04 
M] and 4.42g [IC50 (D10) = 3.12 M] were the most active 
compounds. 
 
Complexes 4.42a, 4.42d and 4.42e were moderately active, 
with IC50 values in the range 7.17-7.22 M. The remaining 
compounds were inactive at the maximum concentration tested 
(IC50 > 20 M). The only complex evaluated against the 
inhibition of the enzyme was 4.42g, which showed no 
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Table 5.7: Antiplasmodial and FP-2 activities of gold(I) 
















Entry Compound No. 
IC50 / M 
D10 W2 FP-2 
1 4.42a ND 7.17 ND 
2 4.42b ND 3.04 ND 
3 4.42c 10.5 >20 ND 
4 4.42d ND 7.22 ND 
5 4.42e ND 7.22 ND 
6 4.42f 3.12 >20 ND 
7 4.42g >10 >20 >100 
8 CQ 0.0293 0.049 ND 
9 ART ND 0.0082 ND 




A series of gold TSC complexes have been demonstrated to 
exhibit antiplasmodial activity against the P. falciparum 
strains. From the data, it is evident that coordination of 
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effect. Although there was no noticeable difference in 
potencies of gold precursors and gold TSC complexes, 
regardless of the gold ion and nature of the complex, the 
resulting complexes generally displayed enhanced efficacy 
against P. falciparum compared to parent ligands. 
 
Whereas gold(I) TSC complexes inhibited FP-2, there could 
be no correlation found between their antiplasmodial 
activity and the ability to inhibit FP-2. The data suggest 
that these complexes exhibit their antiplasmodial 
activities against P. falciparum through the inhibition of 
more than one target. This implied that FP-2 is not the 
primary target for these compounds. On the other hand, it 
could be possible that the compounds do not possess 
suitable physicochemical properties to cross various 
membranes to reach the presumed target (FP-2) in the acidic 
FV. Most of these complexes showed low cytotoxicity towards 
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CHAPTER 6 
 
SYNTHESIS OF NOVEL POLYAMINE-THIOSEMICARBAZONE 
DENDRIMERS AND THEIR ANTIPLASMODIAL EVALUATION 
 
ABSTRACT: High proliferating and differentiating cells have 
been shown to exhibit elevated polyamine (PA) levels and an 
active polyamine transport system (PAT) to import exogenous 
polyamines (PAs). This and the tolerance of the PAT for 
non-native PAs have led to the design of PA conjugates, 
which mimic native PAs and enter cells through the PAT. 
This chapter describes an exploratory series of novel PA-
TSC dendrimers 6.24a-f and 6.25a-e. These were obtained 
from commercially available dendritic PAs 6.16 and 6.17 as 
well as thioesters 6.23a-g. All of the synthesised 
dendrimers were evaluated for in vitro antiplasmodial 




The majority of non--N-heterocyclic TSC derivatives have 
been found to exhibit low activity when evaluated in vitro 
against P. falciparum strains.
1
 This was also noted for the 
series 3.24a-g (see section 3.6.1, p 93) when profiled for 
in vitro antiplasmodial activity against D10 and W2 
strains. On the other hand, -N-heterocyclic TSCs have been 
shown to display potent antimalarial activities.
2
 In the 
current work, the important question and/or hypothesis we 
intended to probe is whether non--N-heterocyclic TSCs are 
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ineffectiveness can be attributed to insufficient cellular 
accumulation. 
 
Since natural PAs and unnatural analogues are recognised by 
PAT,
3
 it was hypothesized that conjugation of PAs with TSCs 
might lead to enhanced antiplasmodial activity of series 
3.24a-g presumably due to selective uptake by parasitic 
red-blood cells (RBCs). Anchoring of chemotherapeutic drugs 
to PAs has been shown to result in enhanced potency and 
selectivity against tumour cells.
4
 However, this approach is 







PAs such as putrescine (6.1), cadavarine (6.2) spermidine 
(6.3) and spermine (6.4) are widely distributed in nature, 
ranging from the plants to animals (Fig. 6.1).
6
 These are 
involved in diverse processes, including cell proliferation 
and differentiation, regulation of gene expression, 
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These aliphatic bases occur both in free polycationic form 












recent years, a vast array of synthetic PAs and conjugated 
analogues has been synthesised in an effort to find PA-
based compounds with potential pharmaceutical application.
14
 
Hence, a significant number of symmetrical and asymmetrical 
linear alkyl PAs as well as chemotherapeutic drug-PA 




More importantly, high proliferating and differentiating 
cells (e.g. tumour and parasitic) have been found to 
exhibit elevated PA levels and an activated PAT system for 
growth factors and importing of exogenous PAs.
16
 This 
prompted the design of PA-drug conjugates to selectively 
target tumour cells.
4a,17
 Several antitumour experiments 
showed that PAT tolerates large modification of PA 
structures.
18
 Consequently, a wide range of PA analogues has 
been demonstrated to target PAT to enter tumour cells. 
 
6.2 BIOSYNTHESIS OF POLYAMINES 
 
The biosynthetic pathways (Scheme 6.1) for the PAs are 
conserved from bacteria to animals including plants.
6a
 These 
involve the conversion of L-arginine (6.5) to L-ornithine 
(6.6) by enzyme arginase.6a,18 The decarboxylation of 6.6 
catalysed by ornithine decarboxylase (ODC) leads to the 
synthesis of the diamine 6.1. This is then converted to 
spermidine (6.3) by spermidine synthase (SpdS) and further 
to spermine (6.4) by spermine synthase (SpmS). The 
aminopropyl moieties in 6.3 and 6.4 are transferred from 
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derived from L-methione in two sequential reactions of 



































Enzymes: A, aginase; B, ornithine decarboxylase; 
         C, spermidine synthase; D, spermine synthase;
         dcSAM, decarboxylated S-adenosylmethionine
 
Scheme 6.1: Biosynthetic pathway of PAs. 
 
The biosynthetic pathway of PAs has been an important 
target for therapeutic intervention during the last 
decades.
19
 However, compensatory upregulation mechanisms in 
biosynthesis and induction of PAs uptake during the 
blockade of biosynthetic enzymes have shifted the focus to 




6.3 BIOLOGICAL SIGNIFICANCE OF SYNTHETIC PA CONJUGATES  
 
PA conjugates possessing biological properties have been 
isolated from natural resources (e.g. spiders, wasps, 
plants and marine organisms).
14
 On the other hand, synthetic 
analogues have been found to exhibit a multitude of 
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chelators
14
 and gene delivery agents.
14
 More importantly, the 
synthetic PA conjugates are designed to exhibit improved 
biological activity (in particular against cellular 
targets) compared to the parent molecules.
14
 To illustrate 
the importance of PA conjugates, a few examples of 
synthetic PA conjugates are discussed below. 
 
6.3.1 Conjugates with Nucleosides 
 
Polyamines conjugated to nucleosides have been synthesised 
and evaluated as inhibitors of PA biosynthesis. For 
example, adenosyl-SPD conjugate 6.7 (Fig. 6.2) was found to 
be a potent inhibitor of the anabolic enzyme SPD 
aminopropyl transferase, an enzyme that catalyses the 
















Figure 6.2: Example of PA conjugate with a nucleoside. 
 
6.3.2 Conjugates with Cytotoxic Agents 
 
In this group PAs are conjugated to known cytotoxic agents. 
A typical example includes the conjugation of branched PA 
with chlorambucil, a well-known cross-linker of DNA 
helices, to form conjugate 6.8 (Fig. 6.3).23 This conjugate 
showed enhanced activity compared to chlorambucil in 
forming interstrand cross-links with DNA.
24
 On the other 
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and its derivatives are well-known drugs for treatment of 
solid tumours,
25
 but their selectivity remains a great 
challenge. Battaglia et al.
26
 reported the synthesis of PA-
paclitaxel conjugate 6.9 with the primary objective of 
































Figure 6.3: PA conjugates with cytotoxic agents. 
 
6.3.3 Conjugates with Amino Acids 
 
Invertebrate venom toxins (e.g. 6.10 in Fig. 6.4) are 
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These act as potent antagonists of the mammalian 
neuroexcitatory glutamic acid receptors. Analogous 
conjugates have been synthesised to explore their 
biological activities. From the delineated SARs, it was 
found that longer PA chains often lead to increased 




6.3.4 Conjugates with Steroidal and Fatty Acids 
 
In this category conjugates of PAs with cholesterol and 
bile acids have been synthesised to introduce polynucleic 
acids into cells.
14
 These are best represented by PA 
















Figure 6.5: Example of PA conjugate with steroid. 
 
6.4 DENDRITIC POLYAMINES 
 
PAs (in particular branched PAs, see 6.6) are used in the 
synthesis of dendrimers, e.g. polypropylene imine (PPI) 
6.12 in Fig. 6.6.27 Dendrimers are highly branched 
macromolecules with „arms‟ emanating from the central 
core.
28
 This class of compounds are unique from traditional 
linear polymers due to several attractive properties: 1) 
regular and highly branched, 2) narrow polydispersity, 3) 
multivalency, 4) nano-sized scale, 5) globular architecture 
and well-defined molecular weights.
29
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constitute three features; namely multifunctional core, 
inner generations, which consist of repeating branched 
units and exterior surface groups where the outermost 








































Figure 6.6: Polyamine dendrimer. The complete dendrimer 6.12 is 
also represented by the structure A. Inner shells are depicted as 
a black „ball‟ and the number of functional groups on the surface 
are depicted by an italic number beneath the ball. 
 
The synthetic strategies for accessing these compounds are 
either convergent or divergent.
30
 In the convergent 
strategies, the synthesis starts from the exterior with the 
molecular structure that ultimately becomes the outer-most 
arm of the final dendrimer. Whilst in the divergent 
strategy the molecule is constructed radially outwards 
starting from the core by repeated addition of building 
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6.4.1 Dendrimer and Multivalency 
 
The most exploited property of dendrimers is multivalency.
31
 
Multivalency can be described as the interaction of a 
dendritic array of ligands and/or drug molecules with a 
cell or target bearing multiple receptors.
32
 Multivalent 
interaction is widely found in nature.
33
 Multivalency has 
been shown to lead to strongly increased activity compared 
to the monomeric interaction. 
 
Dendrimer multivalency is believed to enhance the affinity 
of substrates to complementary receptors mainly by co-
operative effect.
34
 This is referred to as a cluster or 
dendritic effects.
33
 One of the implications of multivalency 
is that by attaching multiple drugs on the periphery (i.e. 
exterior surface groups) of the dendritic structure this 
may in part address problems relating to drug dosing (e.g. 
frequent dosing and higher dosages), and ultimately patient 
compliance. 
 
6.5 ANTIMALARIAL ACTIVITY OF SYNTHETIC POLYAMINES AND 
CONJUGATES 
 
As in mammalian cells, infection with Plasmodial species 
has been shown to exhibit both increased PA content and an 
activated PAT system.
8
 The transport system has been 
suggested to meet the demand of PAs by the parasite.
7
 In the 
late 1990s, Singh et al.
35
 demonstrated that P. knowlesi 
infected erythrocytes acquire PAs through the putruscine 
transport (PuT) system. It has also been found that higher 
demand for PAs in intraerythrocytic malarial parasites is 
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synthesis. This suggested that in addition to biosynthesis 
of PAs, parasitic erythrocytes obtained PAs externally for 
growth and multiplication of the parasite.
7,36
 Greater 
understanding of PAT in tumour cells has led to the design 
of PA analogues and conjugates that selectively target 






 reported the design of putrescine conjugate 
(6.13, Fig. 6.7), which inhibited the influx of putrescine 
via the PuT (Ki = 43.2 M) in P. knowlesi infected 
erythrocytes. The conjugate displayed improved inhibitory 
effect in vitro against the growth of P. knowlesi (IC50 = 
7.64  0.97 ng/ml) compared to the chloroquine (IC50 = 10.8 
 0.45 ng/ml). Intraperitoneal administration of 6.13 (24 
mg/kg body weight twice a day for four days) cured the 

















Figure 6.7: Dendritic polyamine structures. 
 
However, an increasingly successful approach to interfere 
with PA biosynthesis in the context of malaria chemotherapy 
is the use PA analogues to manipulate and/or disrupt 
intracellular concentration of natural PAs.
16,37
 Increasing 
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with toxic synthetic PA analogues has been suggested to 
lead to the shortage of PAs for cell growth, hence parasite 
death. In addition to a decrease in PA synthesis, PA 
analogues lead to an increase in PA catabolism and export.
16
 
This approach has been considered an effective strategy for 
the development of chemotherapeutic molecules. 
 
A series of bis(benzyl)polyamine analogues such as 6.14 
(Fig. 6.8) with marked antimalarial activity against both 
CQ-sensitive and CQ-resistant P. falciparum in vitro has 
been reported.
7,38,39
 Bis(benzyl)diamine (6.15) displayed ten-





















Figure 6.8: Chemical structure of PA analogues. 
 
6.6 RATIONALE: POLYAMINE-TSC CONJUGATES 
 
The rationale for the design of PA-TSC dendrimers is based 
on combining the properties of PAs (cell recognition) and 
dendrimers (multivalency), Fig. 6.9. Branched PAs 6.16 and 
6.17 (Fig. 6.9) display natural PA backbones namely 
spermine and cadavarine. The latter the -CH2- is being 
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R' = Br, Cl












Figure 6.9: Dendritic polyamine structures. 
 
Herein, covalent linking of the branched PA framework with 
TSCs is envisioned to enhance accumulation of dendritic 
TSCs into the malaria parasite RBCs presumably due to the 
recognition of PA backbones by specific transporters. Wang 
et al.
40
 reported that conjugates closely resembling natural 
PAs are more likely to be recognised by the PAT system in 
tumour cells. Natural PAs putrescine (6.1) and spermidine 
(6.3) have been demonstrated to be transported by PA 
transporters into the malaria parasite infected RBCs.
35,36
 
Hence, it is hypothesised that motifs 6.16 and 6.17 could 
be recognised by these PA transporters. 
 
The multivalency of dendritic PA scaffolds 6.16 and 6.17 is 
hypothesised to enhance the antiplasmodial activities of 
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enhance the antiplasmodial activity of TSCs by increasing 
the number of TSC moieties is supported by the recent work 
of Yingyongnarongkul et al.
41
 on antibacterial activities of 
dihydrocaffeoyl-polyamine conjugates 6.18 and 6.19 (Figure 
6.10). This research group demonstrated that increasing the 
number of dihydrocaffeoyl moieties from mono analogue 6.18 
to tetra(dihydrocaffeoyl)polyamine 6.19 led to enhanced 
antibacterial activity against methicillin resistant 
Staphylococcus aureus (MRSA) and vancomycin-resistant S. 
aureus (VRSA) strains. 
 
H2N NH

























Figure 6.10: Structures of dihydrocaffeoyl-diamine (6.18) and 
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6.7 RESULTS AND DISCUSSION 
 
6.7.1 Retrosynthetic Analysis 
 
The synthesis of dendritic TSCs was envisaged according to 




































6.16: n = 4
6.17: n = 3
6.24: n = 4





Scheme 6.2: Retrosynthetic analysis of TSC thioesters. 
 
The C-N disconnection in 6.24 and 6.25 leads to dendritic 
PAs 6.16 and 6.17 as well as the key ferrocenyl and/or aryl 
TSC thioester motifs 6.23. Further analysis of 6.23 leads 
to commercially accessible carbonyl compounds (6.21 and 
6.22) and thiosermicarbazide thioester 6.20. Compound 6.20 
is easily obtained from carbon disulfide (CS2), hydrazine 
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6.7.2 Synthesis of TSC Thioesters 
 
The thioester 6.20 was synthesised according to the method 
described in the literature (Scheme 6.3).
2
 The reaction of 
CS2 with NH2NH2.H2O in an aqueous KOH-iPrOH solution and CH3I 
afforded 6.20 in 37% yield after recrystallisation of the 
resultant residue from chloroform. The 
1
H NMR spectroscopy 
in deuterated DMSO confirmed the formation of 6.20. 
 









Scheme 6.3: Reagents and condition a) KOH, <10 C, 6 h, iPrOH. 
 
The subsequent step was to synthesise a series of TSC 
thioester derivatives 6.23. Thus, condensation (Scheme 6.4) 
of 6.20 with a selected series of carbonyl compounds (6.21 
and 6.22) in iPrOH at ambient temperature resulted in 
thioesters 6.23a-g in low to good yields (Table 6.1). The 
compounds were isolated by gravity filtration of 































Chapter 6      Novel Polyamine_Thiosemicarbazone Dendrimers 
 
 
UCT 190 CHEMISTRY 










Entry Code Product R R1 Yield/[%] 
1 DK-87 6.23a 
 
CH3 68 
2 DK-88 6.23b 
 
CH3 56 
3 DK-89 6.23c 
 
CH3CH2 58 
4 DK-90 6.23d 
 
CH3 41 
5 DK-91 6.23e 
 
H 86 
6 DK-92 6.23f CH3 58 




6.7.2.1 Characterisations of Compounds 6.23a-b 
 
The prepared compounds were characterised using 
1
H NMR and 
FT-IR spectroscopic techniques. The structures were 
identified (
1
H NMR) by downfield chemical shifts of NH, 
which appeared within the range  12.45-12.99 ppm. The 
presence of SCH3 was confirmed (
1
H NMR) by singlet chemical 











Chapter 6      Novel Polyamine_Thiosemicarbazone Dendrimers 
 
 
UCT 191 CHEMISTRY 
The FT-IR confirmed characteristic features (i.e. C=N, C=S, 
C-S) of each compound. 
 
6.7.3 Chemical Synthesis of Tetrathiosemicarbazones 
 
Since thiosemicarbazide and carbonyl compounds are key 
starting materials in the synthesis of TSCs, Wiles et al.
42
 
reported the synthesis of di(TSCs) through the ethylene 
dithiosemicarbazide intermediate. This method has been 
widely used in the synthesis of a number of di(TSC) 
motifs.
43
 Initially, it was thought that the synthesis of 
tetrathiosemicarbazide (6.26, Scheme 6.5) intermediate 
would lead to the formation of tetra(TSC) dendrimers 6.24. 
This approach was considered ideal since it is shorter than 






















Scheme 6.5: Reagents and conditions a) CS2, aqu. NaOH, ambient 
temp., 4 h. b) ClCH2CO2Na, ambient temp. c) HCl, H2NNH2.H2O, 90 C, 
2h. d) Carbonyl precursors, EtOH/DMF, reflux, AcOH, 24 h. 
 
Sequential treatment (Scheme 6.5) of dendritic PA 6.16 
(“one pot” reaction) with a slight excess of CS2 in aqueous 
NaOH solution and four equivalents of sodium chloroacetate 
led to a brown reaction mixture. This mixture was acidified 
and on further treatment with excess hydrazine monohydrate 
generated 6.26 (Fig. 6.11) as a yellow solid in 65% yield. 
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Figure 6.11: Chemical structure of tetrathiosemicarbazide 6.26. 
 
Evidence for the formation of 6.26 was obtained from 1H and 
13
C NMR spectra analysis as well as ESI-MS. The 
1
H NMR 
spectrum revealed the presence of all aliphatic chain 
protons including thiourea and hydrazide NH2 protons. The 
presence of five aliphatic carbons (CH2) in 
13
C NMR spectrum 
at  24.0, 26.3, 41.9, 51.3 and 53.3 ppm as well as the 
carbonyl carbon at  181.0 ppm confirmed the carbon skeleton 
of 6.26. The ESI-MS showed a single peak at m/z 613.3143 
[(M  H)+, calc. mass 612.3069]. 
 
However, reaction of 6.26 with carbonyl compounds under 
refluxing EtOH for 24 h led to the isolation of starting 
materials only. Repeating the reaction by mixing EtOH with 
minimal DMF, since 6.26 dissolves in DMF and DMSO, as well 
as changing the reaction conditions also led to the same 
result. TLC plate analysis following the reaction in DMF 
revealed a new spot on the base line plus the spots 
corresponding to carbonyl starting materials. However, 
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Depict number of 
surface group,
i.e. TSCs
R1 = Me, Et
 
Scheme 6.6: Reagents and conditions a) MeOH, Reflux, 24 h. 
 
A three reaction sequence successfully used by Klayman et 
al.
2
 and other groups to synthesise N-terminal derivatised 
TSCs was employed despite being one step longer in 
comparison to the unsuccessful synthetic route (Scheme 
6.5). Having obtained key compounds 6.23a-g, the next step 
was to couple (Scheme 6.6) this series with dendritic PA 
motifs 6.16 and 6.17 (Fig. 6.10) to generate an exploratory 
series of dendritic TSCs.  
 
Thus, treatment of 6.16 with four equivalents of 6.23a-g in 
refluxing MeOH for 24 h generated novel compounds 6.24a-g 
in good yields (Table 6.2). These compounds were obtained 
as orange, yellow and red-brown solids and were soluble in 
DCM, DMSO and partially in alcohols. These compounds are 
insoluble in aqueous solution. A summary of isolated 
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Entry Code Cmp. No. R R1 R2 Yield/[%] 
1 DK-142E 6.24a CH3 Cl Cl 78 
2 DK-143C 6.24b CH3 Br H 94 
3 DK-144 6.24c CH3 H Br 63 
4 DK-145 6.24d CH3CH2 Br H 82 
5 DK-146 6.24e CH3CH2 Cl Cl 85 
6 DK-148 6.24f H - - 85 
7 DK-149 6.24g CH3 - - 66 
 






C NMR, FR-IR, MS, and elemental analysis were 
used to characterise compounds 6.24a-g. The 1H NMR spectra 
of all compounds revealed chemical shifts consistent with 
the presence of aliphatic chains (PA backbone) and thiourea 
NH protons. The chemical shifts indicating the presence of 
the SCH3 group was not observed. This suggested that PA 
motif 6.16 had displaced SCH3 to form compounds 6.24a-g. 
Evidence for the formation of 6.24a-f was also provided by 
the presence (
13
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 175.7-177.7 ppm as well as chemical shifts corresponding 
to iminic (C=N) and aliphatic carbons. 
 
ESI-MS showed molecular ion peaks in each spectrum at m/z 
1297.1724 (6.24a), 1337.1316 (6.24b), 1337.1259 (6.248c), 
1393.1880 (6.24d), 1353.2444 (6.24e), 1397.3008 (6.24f), 
1453.3694 (6.24g). Intense fragmentation peaks consistent 
with the sequential loss of TSC moiety provided further 
evidence of proposed structures. Microanalysis of all the 
compounds also appeared consistent with the atomic 
composition of 6.24a-g. 
 
6.7.4 Chemical Synthesis of Trithiosemicarbazones 
 
This set of compounds was synthesised in the same manner 
(Scheme 12) as that for tetra(TSC) dendrimers. In contrast 
to 6.24a-g, three equivalents of 6.23a-d and 6.23g as well 
as 6.17 were used in the reaction. Compounds 6.25a-e were 
obtained as yellow to orange solids in moderate to good 
yields, Table 6.3. Figure 6.12 illustrates the chemical 
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Entry Code Cmp. No. R R1 R2 Yield/[%] 
1 DK-153 6.25a CH3 Br H 72 
2 DK-154 6.25b CH3 H Br 74 
3 DK-155 6.25c CH3 Cl Cl 69 
4 DK-156 6.25d CH3CH2 Br H 86 
5 DK-157 6.25e CH3CH2 Cl Cl 85 
 





C NMR, FT-IR, MS, and elemental analysis were used 
to characterise compounds 6.25a-e. In the 1H NMR spectra, 
the chemical shifts of hydrazinic NH protons of 6.25a-e 
appeared upfield at  8.47-8.50 ppm compared to thioesters 
6.23a-d and 6.23g at  12.2-12.9 ppm. The 13C NMR spectral 
data revealed thiourea (C=S) carbons at  176.5-178.1. The 
rest of the signals indicating the presence of iminic (C=N) 






C NMR spectral data were complemented by ESI-MS 
data, which showed molecular ion peaks in the spectrum of 
each compound at m/z 911.0126 (6.25a), 912.2995 (6.25b), 
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fragmentation pattern of each structure appeared consistent 
with the sequential loss of TSC moiety in each structure. 
 
6.8 BIOLOGICAL EVALUATION OF DENDRITIC TSCs 
 
All the synthesised dendrimers were evaluated for in vitro 
growth inhibitory effects against the chloroquine-resistant 
(W2) strain of P. falciparum. The evaluation of non-
conjugated thioesters 6.23a-g as well as PA motifs 6.16 and 
6.17 was conducted to determine the contribution of each 
component. In all the assays, CQ and ART were used as 
control drugs. The biological tests were carried out in 
collaboration with Professor P.J. Rosenthal, Department of 
Medicine, San Francisco General Hospital, University of 




6.8.1.1 In Vitro Antiplasmodial Activity of Dendritic TSCs 
 
The antiplasmodial activities of compounds 6.23a-g against 
W2 (IC50 CQ = 49 nM, IC50 ART = 8.2 nM) were determined and 
the results are displayed in Table 6.4. It can be seen from 
the data that thioesters were not active against W2 strain 
at the maximum concentration tested (IC50 > 20 M). On the 
other hand, compounds 6.23a and 6.23d showed antiplasmodial 
activities against 3D7 and K1 strains with ED50 values of 
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Entry Compound No. R R1 






















Dendritic TSCs 6.24a-g were also tested in vitro against W2 
strain and the data is summarised in Table 6.5. In this 
series TSC moieties were anchored on a branched PA scaffold 
6.16 to establish the effects of this motif on the 
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Entry Compound No. R R1 R2 
IC50 / M 
W2 
1 6.24a CH3 Cl Cl 1.33 
2 6.24b CH3 Br H 2.25 
3 6.24c CH3 H Br 0.79 
4 6.24d CH3CH2 Br H 0.67 
5 6.24e CH3CH2 Cl Cl 4.14 
6 6.24f H Ferrocene 6.59 
7 6.24g CH3 Ferrocene 1.79 
8 CQ - - 0.049 
9 ART - - 0.0082 
 
From Table 6.5 it can be seen that dendrimers 6.24a-g were 
generally more active against the W2 strain in comparison 
to unconjugated thioesters (Table 6.4). However, dendritic 
PA 6.16 was ineffective against W2 at the highest 
concentration tested (IC50 > 20M). All tested dendritic 
TSCs 6.24a-g displayed IC50 values below 7 M. The most 
active compounds in this series were 6.24c and 6.24d with 
IC50 values below 1 M against W2. However, these compounds 
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The antiplasmodial activity of the second series 6.25 was 
also determined and the results are summarised in Table 
6.6. The data contained in this table also revealed that 
tris(TSCs) dendrimers generated from 6.17 were generally 
more active compared to unconjugated thioesters 6.23a-d and 
6.23g. Unlike the PA motif 6.16, compound 6.17 exhibited 
comparable activity (IC50 = 3.56 M) with conjugates 6.25a, 
6.25d and 6.25e against W2 strain (Table 6.6). 
 










Entry Compound No. R R1 R2 
IC50 / M 
W2 
1 6.25a CH3 Br H 4.31 
2 6.25b CH3 H Br 1.51 
3 6.25c CH3 Cl Cl 1.37 
4 6.25d CH3CH2 Br H 4.29 
5 6.25e CH3CH2 Cl Cl 5.08 
6 CQ - - - 0.049 
7 ART - - - 0.0082 
 
Although these compounds are more than 30-100 times less 
active compared to CQ and ART, they still retained activity 
in the low to mid micromolar range. The most active 
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6.25c (IC50 = 1.37 M). However, this series was found to be 




Previously, it was shown by Bitonti et al.
38
 and Klenke et 
al.
45
 that bis(benzyl)polamine and triazine-substituted PA 
conjugates displayed activity against malarial parasites 
within the range 0.2-14 M range. In this study, series 6.24 
and 6.25 are also active in the same range. Contrary to the 
reported PA-based compounds,
38,39
 the series 6.24 and 6.25 
displayed increased antimalarial potency against W2 with 
IC50 values below 7 M. The observed antimalarial activity 
of each series could be due to selective uptake of 6.24a-g 
and 6.25a-e through PA transporters by infected 
erythrocytes. These have been shown to exhibit enhanced PA 
uptake.
8
 The antimalarial activity of PA analogues, e.g. 
6.14 and 6.15 (Fig. 6.8), was found to correlate with 




It appears from this data that the poor activity of non--
N-heterocyclic TSC derivatives is due to the limited 
accumulation in RBCs as their corresponding PA-TSC 
dendrimers exhibited significant antiplasmodial potencies 
than the corresponding mono-TSC scaffolds. 
 
Although increasing the number of TSC moieties by using 
multivalent dendritic PA scaffolds 6.16 and 6.17 led to 
significant enhancement in the antiplasmodial activity, the 
difference in potencies between series 6.24 and 6.25 
appeared to be small when considering the similarity of 
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importantly, the formation of dendritic TSC structures led 
to enhanced antiplasmodial activities compared to mono 





In conclusion, we have demonstrated the synthesis of novel 
dendritic TSCs. Most of the target molecules showed 
antiplasmodial activities in the low micromolar range. The 
ferrocenyl containing tetra(TSC) showed similar activity as 
aryl-based analogues. In general, dendritic TSCs displayed 
better antiplasmodial activities compared to their non-
conjugated forms. From these results, dendritic PA 
scaffolds 6.16 and 6.17 appeared to have improved the 
antiplasmodial activity of TSCs possibly due to their 
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CHAPTER 7 
 
SUMMARY AND CONCLUSION 
 
Simple principles of organic chemistry have led to the 
synthesis of a focused series of TSCs and pyrazoline 
analogues. From these ligand systems, a significant number 
of novel gold(I) and gold(III) TSC complexes has been 
synthesised. Due to easy access of gold(I) precursors, 
gold(I) TSC complexes form the bulk of compounds identified 
for pharmacological evaluation against P. falciparum 
strains. The ligands were prepared without further 
modification of their chemical structure as it was deemed 
necessary to avoid additional coordination sites. 
 
Several gold precursors were used to synthesise the 
abovementioned gold complexes. All compounds reported in 





spectroscopy, infrared spectroscopy, mass spectrometry and 
elemental analysis (where possible). The X-ray crystal 
structures of two gold(I) complexes (4.15 and 4.16) were 
determined. In addition, interactions between molecules in 
crystal structures 4.15 and 4.16 were investigated using 
Hirshfeld surface analysis.
1
 This tool revealed rare Cl...Cl 
interactions in 4.16.2 
 
The resulting gold TSC complexes along with parent ligands 
and gold precursors were tested for in vitro growth 
inhibition of P. falciparum, the causative agent of 
malaria. The coordination of gold ions to TSCs appeared 
advantageous as most gold(I) and gold(III) derivatives 
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free ligands. It was also noted that the antiplasmodial 
activity of these compounds was independent of the nature 
of the complex. The introduction of different phosphine 
ligands (R3P) to form complexes of the type [Au
I
(R3P)TSC]X 
often led to compounds that showed similar activity against 
P. falciparum strains. The gold TSC complexes generally 
showed low cytotoxicity towards mammalian cells. These 
compounds presumably exert their antiplasmodial activities 
through multiple mechanism as no correlation was found 
between antiplasmodial activity and inhibition of FP-2. 
 
On the other hand, TSCs were also incorporated into 
branched polyamine scaffolds (6.16 and 6.17) to form first 
generation dendrimers. These compounds were characterised 
using common analytical techniques. The preliminary 
antiplasmodial results clearly showed that the presence of 
dendritic polyamine scaffolds was beneficial. Most of 
dendritic TSCs displayed enhanced antiplasmodial activities 
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Chapter 8          Experimental Section 
 
 





8.1 CHEMICALS AND PURIFICATION OF SOLVENTS 
 
All commercially available chemicals were purchased from 
either Sigma-Aldrich or Merck. All solvents were dried by 
appropriate techniques. Unless otherwise stated, all 
solvents used were anhydrous. 
 
8.2 CHROMATOGRAPHIC SEPARATION 
 
Merck Kieselgel 60: 70–230 mesh was used for all 
preparative and column chromatography. Reactions were 
monitored by thin layer chromatography (TLC) using Merck 
F254 aluminum-backed precoated silica gel plates and were 
visualized by the ultraviolet light. 
 
8.3 PHYSICAL AND SPECTROSCOPIC INFORMATION 
 



















spectra were referenced internally, while the 
31
P spectra 
were referenced externally to 85% H3PO4 using deuterated 
solvent (CDCl3 or DMSO-d6) at 298 K. Chemical shifts are 
reported on delta () scale in parts per million (ppm). 
Coupling constants, J, are measured in Hertz (Hz). 
Abbreviations used in the assignment are as follows: broad 
(br), singlet (s), doublet (d), doublet of doublets (dd), 
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Melting points were determined on a Reichert-Jung Thermovar 
hotstage microscope and are uncorrected. Infrared spectra 
were recorded on a Thermo Nicolete FT-IR instrument in the 
4000–300 cm
-1
 range using KBr discs. Microanalyses were 
determined using a Fisons EA 1108 CHNO-S instrument. Mass 
spectra were recorded on a Waters API Q-TOF Ultima (ESI, 70 
eV), University of Stellenbosch. At the University of 
Witwatersrand, SA, VG70-SEQ (FAB, 7 kV) instrument was 
used. 
 
Crystal intensity data were collected on a Nonius Kappa CCD 
Single Crystal X-ray Diffractometer, using a graphite 
monochromated MoK radiation ( = 0.7107 Å, T = 173K) 
generated by a Nonius FR590 generator at 50 kV and 30 mV. 
Accurate unit cell parameters were refined on all data. The 
structures were solved using SHELXS-97
1
 and refined using 
full-matrix least squares methods in SHELXL-97, with the 
aid of the program X-Seed.
2
 The analysis of short contacts 




8.4 EXPERIMENTAL DETAILS FOR CHAPTER 3 
 
A. General Procedure for the Synthesis of TSCs 3.28a-e 
 
A mixture of an appropriate aldehyde/ketone (1.52 mmol), 
thiosemicarbazide (1.52 mmol) and catalytic amount of 1% 
acetic acid in MeOH (15 cm
3
) was refluxed for 24 h. Cooling 
the solution to ambient temperature resulted in the 
formation of a precipitate, which was filtered, washed with 
cold MeOH and dried in vacuo to give the desired TSC. In 
some cases, the solvent was removed to give a crude 
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Off-white powder (1.41 g, 49%); 
Rf(EtOAc:Hex 3:7) 0.30; m.p. 193-194 ºC 
(lit.
5
 190-192 ºC); vmax (KBr)/cm
-1
 3412s, 
3226s, 3191s, 3132s (NH), 1585s (C=N), 
1501s (C=C), 1292s (C=S), 834s (CS, thioamide); δH
 
(300 
MHz, DMSO-d6) 10.18 (1H, s, NH), 8.25 (1H, br s, NHH), 7.95 
(1H, br s, NHH), 7.89 (2H, d, J 8.7 Hz, H2/H2’), 7.56 (2H, 
d, J 8.4 Hz, H3/H3’), 2.28 (3H, s, CH3); δC (75 MHz, DMSO-





White powder (2.03 g, 60%); Rf(EtOAc:Hex 
3:7) 0.30; m.p. 169-171 ºC (lit.
4
 174.2-
174.9 ºC); vmax (KBr)/cm
-1
 3383s, 3208s, 
3138 (NH), 1585s (C=N), 1512s (C=C), 
1289s (C=S), 850s (CS, thioamide); δH
 
(300 MHz, DMSO-d6) 
10.15 (1H, s, NH), 8.28 (1H, br s, NHH), 8.17 (1H, d, J 2.0 
Hz, H2), 8.08 (1H, br s, NHH), 7.88 (1H, dd, J 2.1 and 8.0 
Hz, H6), 7.56 (1H, dd, J 2.0 and 7.6 Hz, H4), 7.34 (1H, t, 
J 8.0 Hz, H5), 2.28 (3H, s, CH3); δC
 
(75 MHz, DMSO-d6) 179.1, 
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Off-white powder (2.62 g, 74%); 
Rf(EtOAc:DCM 3:7) 0.27; m.p. 193-194 ºC 
(lit.
4
 196.0-197.9 ºC); vmax (KBr)/cm
-1
 
3395s, 3190s, 3138s (NH), 1593s (C=N), 
1501s (C=C), 1291s (C=S), 805s (CS, thioamide); δH (300 
MHz, DMSO-d6) 10.21 (1H, s, NH), 8.28 (1H, br s, NHH), 8.24 
(1H, d, J 1.8 Hz, H2), 8.13 (1H, br s, NHH), 7.87 (1H, dd, 
J 2.1 and 8.4 Hz, H6), 7.60 (1H, d, J 8.4 Hz, H5), 2.28 
(3H, s, CH3); δC (75 MHz, DMSO-d6) 179.2, 145.2, 138.2, 





White crystalline needles (0.84 g, 30%); 
Rf(EtOAc:Hex 3:7) 0.45; m.p. 134-135 ºC 
(lit.
4
 144.3-144.1 ºC); vmax (KBr)/cm
-1
 
3418s, 3208br, 3144s (NH), 1597s (C=N), 
1507s (C=C), 1289s (C=S), 853s (CS, thioamide); δH (400 
MHz, DMSO-d6) 10.33 (1H, s, NH), 8.29 (1H, br s, NHH), 8.15 
(1H, s, H2), 8.06 (1H, br s, NHH), 7.87 (1H, d, J 7.8 Hz, 
H6), 7.57 (1H, d, J 7.8 Hz, H4), 7.35 (1H, t, J 8.2 Hz, 
H5), 2.86 (2H, q, J 7.8 Hz, H1’), 1.0 (3H, t, J 7.8 Hz, 
CH3); δC (101 MHz, DMSO-d6) 179.4, 150.6, 139.1, 132.1, 
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White solid (1.48 g, 54%); Rf (EtOAc:Hex 
3:7) 0.40; m.p. 179-180 ºC (lit.
4
 185.6-
186.4 ºC); vmax (KBr)/cm
-1
 3383s, 3249s, 
3167s (NH), 1594s (C=N), 1506s (C=C), 
1294m (C=S), 848s (CS, thioamide); δH (300 MHz, DMSO-d6) 
10.35 (1H, s, NH), 8.30 (1H, br s, NHH), 8.23 (1H, d, J 2.1 
Hz, H2), 8.12 (1H, br s, NHH), 7.86 (1H, dd, J 2.1 and 8.7 
Hz, H6), 7.61 (1H, d, J 8.4 Hz, H5), 2.87 (2H, q, J 7.8 Hz, 
H1’), 1.0 (3H, t, J 7.8Hz, CH3); δC (75 MHz, DMSO-d6) 178.6, 





A mixture of ferrocenecarbaxaldehyde 
(0.21 g, 0.98 mmol), thiosemicarbazide 
(0.090 g, 0.99 mmol) and 32% HCl (ca 10 
drops) in distilled water (20 cm
3
) was 
stirred at ambient temperature for 4 h. 
During this time, an orange precipitate formed, and was 
filtered, washed with water and dried to give 3.28f (0.23 
g, 81%) as an orange solid;
6
 m.p. 175-176 ºC (lit.
7
 175 ºC); 
vmax (KBr)/cm
-1
 3406s, 3348s, 3144s (NH), 1599s (C=N), 
1559s (C=C), 1291s (C=S), 824s (CS, thioamide); δH (400 
MHz, DMSO-d6) 11.13 (1H, s, NH), 7.97 (1H, br s, NHH), 7.89 
(1H, s, HC=N), 7.57 (1H, br s, NHH), 4.72 (2H, s, H2/H5), 
4.41 (2H, s, H3/H4), 4.20 (5H, s, Cp); δC (101 MHz, DMSO-d6) 
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1-(1-Ferrocenylethylidene)thiosemicarbazone, 3.28g 
 
A mixture of thiosemicarbazide (0.067 
g, 0.74 mmol) and 1-acetylferrocene 
(0.17 g, 0.73 mmol) in EtOH (15 cm
3
) 
was refluxed for 2 h. Upon cooling to 
ambient temperature, a reddish 
precipitate was formed. The precipitate was filtered, 
washed with EtOH and dried in vacuo to give 3.28g (0.16 g, 
73%) as a red-brown solid; m.p. 170-172 ºC (lit.
8
 169 ºC); 
vmax (KBr)/cm
-1
 3401s, 3219s, 3138s (NH), 1587s (C=N), 
1595s (C=C), 1286s (C=S), 833m (CS, thioamide); δH (400 
MHz, DMSO-d6) 9.91 (1H, s, NH), 8.06 (1H, s, NHH), 7.63 (1H, 
s, NHH), 4.79 (2H, t, J 2.0 Hz, H2/H5), 4.56 (2H, t, J 2.0 





A mixture of 
4-hydroxy-3-methoxybenzaldehyde (0.50 g, 
3.32 mmol), thiosemicarbazide (0.30 g, 
3.34 mmol) and catalytic amount of acetic 
acid (5 drops) in absolute EtOH (15 cm
3
) was refluxed for 2 
h. After consumption of starting materials (TLC), the 
reaction was cooled to ambient temperature, and solvent 
removed at reduced pressure to give a white solid residue. 
Drying the residue in vacuo afforded 3.28h (0.76 g, 100%) 
as a white solid;
9
 m.p. 194-196 ºC (lit.
9
 175.3–177.5 ºC); 
Rf(EtOAc:Hexane 3:7) 0.071; vmax (KBr)/cm
-1
 3438s (OH), 
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(C=S), 838sh (CS, thioamide); δH 400 MHz, DMSO-d6) 11.21 
(1H, s, NH), 8.06 (1H, br s, NHH), 7.93 (1H, s, HC=N), 7.91 
(1H, br s, NHH), 7.46 (1H, d, J 1.6 Hz, H2), 7.04 (1H, dd, 
J 1.6 and 8.0 Hz, H6), 6.77 (1H, d, J 7.6 Hz, H5), 3.83 
(3H, s, OCH3); δC (100 MHz, DMSO-d6) 176.7, 148.1, 147.4, 
142.2, 124.9, 121.6, 114.5, 108.7, 55.1. 
 
B. General Procedure for the Synthesis of Mannich Bases 
3.32a-f 
 
A mixture of an appropriate ketone (10.0 mmol), dimethyl 
hydrochloride (13.1 mmol) and paraformaldehyde (13.1 mmol) 
in 96.4% EtOH (5 cm
3
) was treated with 32% HCl (20 µl) at 
ambient temperature. The mixture was refluxed for 24 h 
under nitrogen. After cooling to ambient temperature, 
acetone (25 cm
3
) was added and the resulting solution cooled 
to -20 ºC to form a precipitate. The precipitate was 
filtered and dried to afford the desired hydrochloric 
salts.
4
 In some cases the solvent was concentrated to give 
solid residues. A few drops of HCl were added and the 
mixture worked-up with dichloromethane and water. The 
aqueous layer was adjusted to basic and extracted with 
dichloromethane. The organic layer was dried over MgSO4 and 








White solid (1.82 g, 62%), δH (300 MHz, 
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(1H, dd, J 1.8 and 7.4 Hz, H6), 7.89 (1H, d, J 8.4 Hz, H4), 
7.54 (1H, t, J 8.0 Hz, H5), 3.64 (2H, t, J 7.2 Hz, H2’), 





White crystalline needles (1.38 g, 47%), 
δH (300 MHz, DMSO-d6) 10.88 (1H, br, 
HCl.N(CH3)2), 7.94 (2H, d, J 8.4 Hz, 
H2/H2”), 7.78 (2H, d, J 8.7 Hz, H3/H3”), 
3.62 (2H, t, J 7.5 Hz, H2’), 3.39 (2H, t, J 7.5 Hz, H1’), 





White solid (2.24 g, 74%), δH (400 MHz, 
DMSO-d6) 11.08 (1H, br, HCl.N(CH3)2), 8.18 
(1H, s, H2), 7.95 (1H, d, J 8.4 Hz, H6), 
7.81 (1H, d, J 8.4 Hz, H5), 3.64 (2H, t, J 






Colourless oil (0.88 g, 33%), δH (400 MHz, 
CDCl3) 8.06 (1H, d, J 2.0 Hz, H2), 7.86 
(1H, dd, J 2.0 and 8.8 Hz, H6), 7.64 (1H, 
d, J 8.4 Hz, H4), 7.31 (1H, t, J 8.0 Hz, 
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Hz, HA2’), 2.29 (1H, dd, J 6.0 and 6.8 Hz, HB2’), 2.19 (6H, 





Yellowish oil (0.18 g, 15%), δH (400 MHz, 
CDCl3) 8.02 (1H, d, J 2.0 Hz, H2), 7.77 
(1H, dd, J 2.0 and 8.4 Hz, H6), 7.52 (1H, 
d, J 8.4 Hz, H5), 3.52-3.60 (1H, m, H1’), 
2.76 (1H, dd, J 4.8 and 7.6 Hz, HA2’), 2.29 (1H, dd, J 5.6 






White solid (1.61 g, 65%), δH (300 MHz, 
(DMSO-d6) 11.11 (1H, br, HCl.N(CH3)2), 
8.03 (2H, d, J 8.4 Hz, H-2/H2”), 7.63 
(2H, d, J 8.4 Hz, H3/H3”), 3.65 (2H, t, J 
7.5 Hz, H2’), 3.40 (2H, t, J 7.5 Hz, H1’), 2.80 (6H, s, 
N(CH3)2). 
 
C. General Procedure for the Synthesis of Pyrazoline TSCs 
3.37a-f 
 
Thiosemicarbazide (3.57 mmol) was dissolved in MeOH (10 cm
3
) 
upon refluxing under nitrogen. A 50% NaOH solution was 
added to the reaction mixture followed by an appropriate 
Mannich base (3.57 mmol). The mixture was allowed to reflux 
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resulting residue was dissolved in dichloromethane (25 cm
3
) 
and washed with water. The organic layer was dried over 
MgSO4, filtered and solvent evaporated to give a brown 
residue. The purification of the residue using silica gel 





Light brown solid (0.11 g, 10%); 
Rf(DCM:MeOH 98:2) 0.17; m.p. 143-145 ºC 
(Lit.
4
 172.9-174.5 ºC, Abid et al.
11
       
141 ºC); vmax (KBr)/cm
-1
 3477m, 3353m, 3152s 
(NH), 2924s (CH2), 1571s (C=N), 1502s (C=C), 914m 
(C=S); δH (300 MHz, CDCl3) 8.35 (2H,s, NH2), 7.88 (1H, s, 
H2), 7.61 (1H, d, J 7.8 Hz, H6), 7.58 (1H, d, J 8.7 Hz, H4), 
7.30 (1H, t, J 7.8 Hz, H5), 4.39 (2H, t, J 10.2 Hz, H2’), 




Yellow solid (0.29 g, 20%); Rf(DCM:MeOH 
98:2) 0.55; m.p. 190-192 ºC (Lit.
4
 
199.3-201.4 ºC); max (KBr pellets)/cm
-1
 
3434s, 3233s, 3135s (NH), 2930w (CH2), 
1589s (C=N), 1467s (C=C), 807s (C=S); δH (300 MHz, CDCl3) 
7.79 (2H, m, H2 and NHH), 7.54-7.48 (3H, m, H5/H6 and NHH), 
4.39 (1H, t, J 10.2 Hz, H2’), 3.26 (1H, t, J 10.5 Hz, H1’). 
Found: C, 45.1; H, 3.67; N, 13.9; S, 10.5%; Calc. for 
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3-(4-Bromophenyl)-2-pyrazoline-1-thiocarboxamide, 3.37c 
 
Yellow solid (0.49 g, 41%); Rf(DCM:MeOH 
98:2) 0.64; m.p. 86-88 ºC; max (KBr 
pellets)/cm
-1
 3431m, 3247s, 3144s (NH), 
2924m (CH2), 1583s (C=N), 1476s (C=C), 
814s (C=S); δH (300 MHz, CDCl3) 7.59-7.55 (6H, m, ArH and 
NHH), 4.37 (2H, t, J 10.2 Hz, H2’), 3.28 (2H, t, J 10.5 Hz, 
H1’). δC (400 MHz, CDCl3) 176.9, 156.5, 133.4, 132.8 (2C), 
128.2 (2C), 125.3, 48.6, 32.5; Found: C, 43.4; H, 3.90; N, 
13.1; S, 9.84%; Calc. for C10H10BrN3S: C, 42.3; H, 3.55; N, 





Yellow solid (0.49 g, 41%); Rf(DCM:MeOH 
98:2) 0.64; m.p. 173-174 ºC (Lit.
4
 171-
172 ºC; max (KBr pellets)/cm
-1
 3391m, 
3175s (NH), 2975m (CH2), 1595s (C=N), 
1470s (C=C), 821s (C=S); δH (300 MHz, 
CDCl3) 8.18 (2H, s, NHH), 7.75 (1H, s, H2), 7.43-7.49 (2H, 
m, H5/6), 4.39 (1H, t, J 11.6 Hz, HA2’), 4.15 (1H, dd, J 6.1 
and 12.0 Hz, HB2’), 3.62-3.65 (1H, m, H1’), 1.09 (3H, d, J 
7.2 Hz, CH3); Found: C, 44.5; H, 4.27; N, 14.1; S, 11.1%; 
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Yellow solid (0.81 g, 69%); Rf(DCM:MeOH 
98:2) 0.64; m.p. 120-122 ºC (Lit.
4
 107-
109 ºC, Abid et al.
11
 92 ºC; max (KBr 
pellets)/cm
-1
 3416s, 3146s (NH), 2967m 
(CH2), 1598s (C=N), 1468s (C=C), 856s 
(C=S); δH (300 MHz, CDCl3) 8.98 (2H, s, NHH), 7.83 (1H, s, 
H2), 7.59 (1H, d, J 8.0 Hz, H6), 7.51 (1H, d, J 8.1 Hz, 
H4), 7.27 (1H, t, J 8.0 Hz, H5), 4.37 (1H, t, J 11.6 Hz, 
HA2’), 4.15 (1H, dd, J 4.4 and 11.6 Hz, HB2’), 3.65-3.71 
(1H, m, H1’), 1.19 (3H, d, J 7.6 Hz, CH3); Found: C, 43.1; 
H, 4.32; N, 14.1; S, 10.7%; Calc. for C11H12BrN3S: C, 44.3; 




Yellow solid (0.33 g, 24%); Rf(DCM:MeOH 
98:2) 0.67; m.p. 165-167 ºC; max (KBr 
pellets)/cm
-1
 3364m, 3257s, 3154s (NH), 
2923w (CH), 1583s (C=N), 1478s (C=C), 
1378s (C=C), 793s (C=S); δH (300 MHz, CDCl3) 7.64 (2H, d, 
J 8.4 Hz, H2/H2”), 7.38 (2H, d, J 8.8 Hz, H3/H3”), 4.37 
(2H, d, J 9.6 Hz, H2’), 3.27 (2H, d, J 10.0 Hz, H1’); 
Found: C, 50.2; H, 4.45; N, 17.4; S, 13.3%; Calc. for 
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8.5 EXPERIMENTAL DETAILS FOR CHAPTER 4 
 
Synthesis of Hydrogen Tetrachloroauric Acid Tetrahydrate 
 
Au (4.85 g) was added to a freshly prepared aqua regia 
(HClconc: HNO3conc; 3:1) solution (40 cm
3
) and stirred for 24 h 
under mild heating until all the gold had dissolved. After 
evaporating the solution at 40-45 ºC for 48 h, the 
resulting yellow-orange residue was washed with 
concentrated HCl (2  10 cm3) and dried in vacuo to give 




Synthesis of Tetrahydrothiophene Gold(I)chloride 4.3 
 
Tetrahydrothiophene (THT) (20 cm
3
, 226.8 
mmol), while stirring the mixture rapidly, 
was added dropwise to the solution of 
H[AuCl4].4H2O (3.18 g, 7.72 mmol) in 96.4% 
EtOH (25 cm
3
). The reaction was accompanied by the formation 
a yellow precipitate (AuCl3THT), which transformed into a 
white precipitate as more THT solution is continuously 
added. After stirring at ambient temperature for 20 
minutes, the precipitate was filtered, washed with EtOH (3 
× 10 cm
3
) and dried in vacuo to give 4.3 (1.59 g, 64%) as a 
white solid;
13
 δH (400 MHz, CDCl3) 3.45 (4H, s, H1), 2.23 
(4H, s, H2). 
 
D. General Procedure for the Synthesis of Gold(I) Bis-TSC 
Complexes 4.12-4.18 and 4.20-4.23 
 
A mixture of TSC (0.19 mmol) and 4.3 (0.093 mmol) in 
anhydrous MeOH (10 cm
3
) was allowed to reflux for 2 h under 
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solution was filtered through celite and solvent 
concentrated to give a semi-solid residue, which was dried 
in vacuo to afford the desired gold complexes. 
 
Bis(3-bromoacetophenone thiosemicarbazone-S)- 
gold(I) chloride, 4.12 
 
Light brown powder (0.069 g, 96%); 
m.p. 118-120 ºC; vmax (KBr)/cm
-1
 
3395m, 3226m, 3251m (NH), 1594s 
(C=N), 1518s (C=C), 1265s (C=S), 
833m (CS, thioamide); δH (400 MHz, 
DMSO-d6) 10.99 (2H, br s, NH), 9.12 
(2H, br s, NHH), 8.69 (2H, br s, NHH), 7.93 (2H, d, J 7.2 
Hz, H6), 8.23 (2H, s, H2), 7.61 (2H, d, J 8.0 Hz, H4), 7.37 
(2H, t, J 7.6 Hz, H5), 2.37 (6H, s, CH3); δC (101 MHz, DMSO-
d6) 173.6, 151.7, 139.2, 132.4, 130.2, 129.2, 126.0, 121.9, 







 740.92), 467.82 (22%, M
+
-TSC); 
Found: C, 28.52; H, 2.81; N, 10.5; S, 8.56%; Calc. for 
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Bis(3-bromopropiophenone thiosemicarbazone-S)- 
gold(I) chloride, 4.13 
 
Greyish powder (0.023 g, 83%); m.p. 
103-104 ºC; vmax (KBr)/cm
-1
 3389m, 
3231m, 3132w (NH), 1599s (C=N), 
1518s (C=C), 1265s (C=S), 845m 
(CS, thioamide); δH (400 MHz, DMSO-
d6) 10.89 (2H, br s, NH), 8.88 (2H, 
br s, NHH), 8.55 (2H, br s, NHH), 8.19 (2H, s, H2), 7.91 
(2H, d, J 8.0 Hz, H6), 7.62 (2H, d, J 7.6 Hz, H4), 7.38 
(2H, t, J 7.6 Hz, H5), 2.91 (4H, q, J 7.6 Hz, H1’), 1.03 
(6H, t, J 7.6 Hz, CH3); δC (101 MHz, DMSO-d6) 173.6, 154.3, 
137.4, 131.7, 129.7, 128.7, 125.4, 121.4, 19.1, 10.1; m/z 




, 768.93. C20H24AuBr2N6S2 
requires M
+
, 768.95), 481.91 (44%, M
+
-TSC); Found: C, 31.9; 
H, 3.38; N, 9.24; S, 7.50%; Calc. for C20H24AuBr2N6S2: C, 
31.2; H, 3.14; N, 10.9; S 8.33%. 
 
Bis(ferrocenylcarboxaldehyde thiosemicarbazone-S) gold(I) 
chloride, 4.14 
 
Dark-red powder (0.037 g, 89%); 
m.p. 176-177 ºC; vmax (KBr)/cm
-1
 
3389w, 3231w (NH), 1590s (C=N), 
1544m (C=C), 1278m (C=S), 818s 
(CS, thioamide); δH (400 MHz, 
DMSO-d6) 11.79 (2H, br s, NH), 8.70 (2H, br s, NHH), 8.18 
(2H, br s, NHH), 8.10 (2H, s, HC=N), 4.78 (4H, s, H2/H5), 
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d6) 171.2, 147.4, 77.5, 70.1 (2C), 68.6 (5C), 67.6 (2C); m/z 




, 770.95. C24H22AuFe2N6S2 
requires, M
+
, 767.98), 483.82 (20%, M
+
-TSC); Found: C, 36.5; 
H, 3.43; N, 9.39; S, 8.80%; Calc. for C24H22AuFe2N6S2.H2O: C, 
36.34; H, 3.40; N, 10.90; S 8.31%. 
 
Bis(4-bromoacetophenone thiosemicarbazone-S)- 
gold(I) chloride, 4.15 
 
White powder (0.055 g, 96%); m.p. 
136-137 ºC; vmax (KBr)/cm
-1
 3389m, 
3226w (NH), 3068m,br (NH), 
1594s (C=N), 1521s (C=C), 1268s 
(C=S), 822s (CS, thioamide); δH 
(300 MHz, DMSO-d6) 10.91 (2H, br s, NH), 8.96 (2H, br s, 
NHH), 8.52 (2H, br s, NHH), 7.94 (4H, d, J 8.4 Hz, H2/2’), 
7.60 (4H, d, J 8.7 Hz, H3/3’), 2.35 (6H, s, CH3); δC (75 
MHz, DMSO-d6) 173.9, 151.5, 136.0, 130.9 (2C), 128.8 (2C), 







, 740.92), 469.91 (42%, M
+
-TSC); 
Found: C, 27.93; H, 2.96; N, 9.16; S, 8.12; Calc. for 
C18H20AuBr2ClN6S2: C, 27.83; H, 2.60; N, 10.82; S, 8.26. 
 
Bis(3,4-dichloroacetophenone thiosemicarbazone-S) gold(I) 
chloride, 4.16 
 
Light brownish powder (0.14 g, 
97%); m.p. 65-67 ºC; vmax 
(KBr)/cm
-1
 3395m, 3237w, 3062w 
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(C=C), 1272s (C=S), 796m (CS, thioamide); δH (300 MHz, 
DMSO-d6) 11.01 (2H, br s, NH), 9.10 (2H, br s, NHH), 8.77 
(2H, br s, NHH), 8.32 (2H, s, H2), 7.93 (2H, d, J 8.7 Hz, 
H6), 7.66 (2H, d, J 8.7 Hz, H5), 2.36 (6H, s, CH3); δC (75 
MHz, DMSO-d6) 173.1, 150.7, 137.0, 131.9, 130.9, 130.4, 





720.87. C18H18AuCl4N6S2 requires M
+
, 720.94), 457.89 (49%, M
+
-
TSC); Found: C, 27.5; H, 2.70; N, 10.1; S, 8.72%; Calc. for 
C18H18AuCl5N6S2.H2O: C, 28.9; H, 2.81; N, 10.7; S, 8.13%. 
 
Bis(3,4-dichloropropiophenone thiosemicarbazone-S) gold(I) 
chloride, 4.17 
 
Cream-white powder (0.047 g, 96 
%); m.p. 115-116 ºC; vmax (KBr)/cm
-1
 
3395w, 3226w (NH), 1600s (C=N), 
1521s (C=C), 1265s (C=S), 807w 
(CS, thioamide); δH (400 MHz, 
DMSO-d6) 11.0 (2H, br s, NH), 8.99 
(2H, br s, NHH), 8.68 (2H, br s, NHH), 8.28 (2H, s, H2), 
7.91 (2H, d, J 8.4 Hz, H6), 7.67 (2H, d, J 8.8 Hz, H5), 
2.91 (4H, q, J 7.6 Hz, H1’), 1.02 (6H, t, J 7.2 Hz, CH3); δC 
(101 MHz, DMSO-d6) 174.0, 153.9, 136.1, 132.0, 131.2, 130.1, 










-TSC); Found: C, 29.8; H, 3.15; N, 9.92; S, 
8.77%; Calc. for C20H22AuCl5N6S2.H2O: C, 29.9; H, 3.01; N, 
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Bis(acetylferrocene thiosemicarbazone-S) gold(I) chloride, 
4.18 
 
Dark-red powder (0.049 g, 95%); 
m.p. 125-127C; vmax (KBr)/cm
-1
 
3400m, 3212w, 3088m (NH), 1589s 
(C=N), 1469m (C=C), 1282s 
(C=S), 820s (CS, thioamide); δH 
(300 MHz, DMSO-d6) 10.60 (2H, br s, NH), 8.68 (2H, br s, 
NHH), 8.06 (2H, br s, NHH), 4.84 (4H, s, H2/H5), 4.41 (4H, 
s, H3/H4), 4.19 (10H, s, Cp), 2.26 (6H, s, CH3); δC (75 MHz, 
DMSO-d6) 172.8, 155.8, 81.6, 69.8 (2C), 68.8 (5C), 67.2 







, 795.3), 496.1 (41%, M
+
-FcTSC); 
Found: C, 38.3; H, 4.12; N, 6.62; S, 6.24; Calc. for 




gold(I) chloride, 4.19 
 
A solution of 3.28h (0.051 g, 
0.22 mmol) in anhydrous MeOH    
(10 cm
3
) was treated with 4.3    
(0.036 g, 0.11 mmol) at ambient 
temperature. The resulting cloudy 
solution was refluxed for 3 h. 
After cooling, the solution was filtered through celite and 
concentrated to give a brownish solid residue, which was 
dried in vacuo to afford 4.19 (0.074 g, 97%) as a light-
brown powder; m.p. 163-165 ºC; vmax (KBr)/cm
-1
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3251w (NH), 3127m (NH) 1587s (C=N), 1512s (C=C), 1281s 
(C=S), 823s (CS, thioamide); δH (400 MHz, DMSO-d6) 11.79 
(1H, br s, NH), 9.47 (1H, s, OH), 8.71 (1H, br s, NHH), 
8.42 (1H, br s, NHH), 8.12 (1H, s, HC=N), 7.51 (1H, d, J 
1.8 Hz, H2), 7.13 (1H, dd, J 2.1 and 8.1 Hz, H6), 6.82 (1H, 
d, J 8.1 Hz, H5), 3.84 (3H, s, OCH3); δC (101 MHz, DMSO-d6) 
170.9, 149.3, 147.8, 147.3, 124.4, 122.9, 114.9, 109.5, 







, 647.0804); Found: C, 31.34; H, 
3.11; N, 10.66; S, 9.22%; Calc. for C18H22AuClN6O4S2.CH3OH: C, 
31.92; H, 3.67; N, 11.19; S, 8.97%. 
 
Bis(3-(3-bromophenyl)-2-pyrazoline-1-thiocarboxamide-S) 
gold(I) chloride, 4.20 
 
Light brown solid (0.056 g, 77%); 
m.p. 160-163 C; vmax (KBr)/cm
-1
 
3408w, 3058m (NH), 1587s (C=N), 
1534s, 1469m (C=C), 788s (C=S); 
δH (300 MHz, DMSO-d6) 8.44 (4H, br, 
NHH), 8.18 (2H, s, H2), 7.81 (2H, 
d, J 7.8 Hz, H6), 7.70 (2H, d, J 8.1 Hz, H4), 7.45 (2H, t, 
J 8.1 Hz, H5), 4.23 (4H, t, J 9.6 Hz, H2’), 3.42 (4H, t, J 
9.9 Hz, H1’); δC (75 MHz, DMSO-d6) 173.2, 148.1, 133.2, 





, 764.90. C20H20AuBr2N6S2 
requires M
+
, 762.92); Found: C, 31.51; H, 3.82; N, 8.21; S, 
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Bis(3-(3,4-dichlorophenyl)-2-pyrazoline-1-thiocarboxamide-
S) gold(I) chloride, 4.21 
 
Tan solid (0.037 g, 51 %); m.p. 
136-138 C; vmax (KBr)/cm
-1
 3414w, 
3224w, 3065m (NH), 1592s 
(C=N), 1529s, 1469s (C=C), 
797m (C=S); δH (300 MHz, DMSO-
d6) 8.34 (4H, s, NHH), 8.19 (2H, s, H2), 7.82-7.73 (4H, m, 
H5/H6), 4.22 (4H, t, J 9.3 Hz, H2’), 3.39 (4H, t, J 9.9 Hz, 
H1’); δC (75 MHz, DMSO-d6) 173.9, 150.3, 137.5, 132.2, 





, 744.94. C20H21AuCl4N6S2 requires M
+
, 
742.95); Found: C, 32.41; H, 2.88; N, 7.87; S, 6.03; Calc. 
for : C, 32.23; H, 2.43; N, 11.28; S, 8.60%. 
 
Bis(3-(4-bromophenyl)-2-pyrazoline-1-thiocarboxamide-S) 
gold(I) chloride, 4.22 
 
Yellow solid (0.066 g, 91%); m.p. 
169-171 C; vmax (KBr)/cm
-1
 3218s, 
(NH), 1589s (C=N), 1532 (C=C), 
784s (C=S); δH (300 MHz, DMSO-d6) 
7.59-7.57 (8H, m, ArH), 4.33 (2H, 
t, J 9.6 Hz, H2’), 3.44 (2H, t, J 9.6 Hz, H1’); δC (1000.6 
MHz, DMSO-d6) 171.1, 150.3, 131.6 (2C), 131.1, 129.1 (2C), 





764.92. C20H20AuBr2N6S2 requires M
+
, 762.92); Found: C, 30.7; 
H, 2.85; N, 8.64; S, 6.63; Calc. for C20H20AuBr2N6S2.CH3OH: C, 
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Bis(3-(4-chlorophenyl)-2-pyrazoline-1-thiocarboxamide-S) 
gold(I) chloride, 4.23 
 
Tan solid (0.041 g, 55%); m.p. 
196-198 C; vmax (KBr)/cm
-1
 3401w, 
3075s (NH), 1594s (C=N), 1537s, 
1490s (C=C), 787 (C=S); δH (400 
MHz, CDCl3) 7.67-7.63 (4H, m, 
ArH), 7.43-7.38 (4H, m, ArH), 4.34 (4H, t, J 10.0 Hz, H2’), 
3.39 (4H, t, J 9.6 Hz, H1’); δC (100.6 MHz, DMSO-d6) 175.1, 





, 675.03. C20H21AuCl2N6S2 
requires M
+
, 675.02); Found: C, 31.8; H, 3.30; N, 11.1; S, 
8.55; Calc. for C20H20AuCl3N6S2.2H2O: C, 32.12; H, 3.23; N, 
11.2; S, 8.57%. 
 
Synthesis of Triphenylphosphine Gold(I) Chloride 4.5 
 
A solution of H[AuCl4].4H2O (1.01 g, 2.45 
mmol) in 96.4% EtOH (20 cm
3
) was treated 
with triphenylphosphine (1.30 g, 4.97 mmol) 
at ambient temperature under nitrogen. After 
stirring for 1 h, a white precipitate that formed was 
filtered, washed with EtOH and dried in vacuo to afford 4.5 
(1.19 g, 98%) as a white solid;
14
 δP (121 MHz, DMSO-d6) 34.02 
ppm. 
 
E. General Procedure for the Synthesis of Ph3P Gold(I) TSC 
Complexes 4.29a-f 
 
A mixture of AgOSO2CF3 (0.10 mmol) and 4.5 (0.10 mmol) in 
MeOH (5 cm
3
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under nitrogen.
15
 During this time, a ‘purple’ precipitate 
formed; and was filtered through celite to give a 
colourless solution. Nitrogen gas was bubbled through the 
filtrate followed by addition of individual TSC (0.10 
mmol). After stirring the reaction mixture for 4 h at 
ambient temperature, the colloidal solution was filtered 
and solvent concentrated to give a semi-solid residue, 




(triphenylphosphine)gold(I) triflate, 4.26a 
 
White solid (0.065 g, 73%); m.p. 
86-88 C; vmax (KBr)/cm
-1
 3402w 
br, 3286w, 3169m (NH), 1601s 
(C=N), 1531s (C=C), 1282s, 
1245s (C=S), 1026sh (P-C), 
831m (CS, thioamide); H (300 
MHz, DMSO-d6) 11.33 (1H, s, NH), 9.49 (1H, br, NHH), 9.01 
(1H, br, NHH), 8.23 (1H, s, H2), 7.94 (1H, d, J 7.8 Hz, 
H6), 7.67–7.63 (16H, m, 3 × Ph, H4), 7.38 (1H, t, J 8.4 Hz, 
H5), 2.36 (3H, s, CH3); C (75 MHz, DMSO-d6) 171.3, 155.3, 
138.9, 134.0, 132.4, 131.9, 130.5, 129.4, 128.6, 127.9, 
126.5, 122.2, 15.3; P (121 MHz, DMSO-d6) 38.1 ppm; m/z 




, 731.9. C27H25AuBrN3S 
requires M
+
, 731.4), 459.0 (100%, Ph3PAu
+
); Found: C, 36.4; 
H, 3.21; N, 4.23; S, 7.63; Calc. for C28H25AuBrF3N3O3PS2.2H2O: 
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White solid (0.060 g, 66%); m.p. 
205-207 C; vmax (KBr)/cm
-1
 3436m, 
3172m (NH), 1603s (C=N), 1527s 
(C=C), 1275s, 1244s (C=S), 
1028sh (P-C), 825w (CS, 
thioamide); H (300 MHz, DMSO-
d6) 11.36 (1H, s, NH), 9.53 (1H, br, NHH), 9.05 (1H, br, 
NHH), 8.29 (1H, s, H2), 7.92 (1H, d, J 8.4 Hz, H6), 7.72–
7.60 (16H, m, 3 × Ph, H5), 2.35 (3H, s, CH3); C (75 MHz, 
DMSO-d6) 171.4, 154.1, 137.0, 133.7, 132.8, 132.1, 131.5, 
130.2, 129.4, 128.7, 127.7, 127.2, 14.8; P (121 MHz, DMSO-







, 721.4), 458.9 (100%, Ph3PAu
+
); 
Found: C, 37.8; H, 3.20; N, 4.15; S, 7.51; Calc. for 





Orange solid (0.074 g, 76%); 
m.p. 172-173C; vmax (KBr)/cm
-1
 
3414m br, 3272w, 3176m (NH), 
1602s (C=N), 1528s (C=C), 
1282s, 1245s (C=S), 1028sh (P-
C), 791m (CS, thioamide); H 
(300 MHz, DMSO-d6) 11.23 (1H, s, 
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s, H2), 7.89 (1H, d, J 8.1 Hz, H6), 7.65–7.59 (16H, m, 3 × 
Ph, H4), 7.39 (1H, t, J 7.8 Hz, H5), 2.91 (2H, q, J 7.5 Hz, 
H1’), 1.0 (3H, t, J 7.5 Hz, CH3); C (75 MHz, DMSO-d6) 170.2, 
158.1, 137.6, 133.6, 132.6, 132.0, 130.2, 129.3, 128.4, 
127.6, 126.1, 121.9, 20.0, 10.7; P (121 MHz, DMSO-d6) 37.7 







, 745.4), 459.0 (100%, Ph3PAu
+
); 
Found: C, 37.3; H, 3.73; N, 4.59; S, 8.11; Calc. for 





White solid (0.065 g, 72%); m.p. 
215-217 C; vmax (KBr)/cm
-1
 3438m, 
3274w, 3172m (NH), 1602s, 
1587sh (C=N), 1528s (C=C), 
1275s, 1247s (C=S), 1029sh (P-
C), 829s (CS, thioamide); H 
(300 MHz, DMSO-d6) 11.25 (1H, s, NH), 9.41 (1H, br, NHH), 
8.84 (1H, br, NHH), 7.94 (2H, d, J 8.4 Hz, H2/H2’), 7.63–
7.59 (17H, m, 3 × Ph, H3/H3’), 2.36 (3H, s, CH3); C (75 
MHz, DMSO-d6) 171.6, 154.4, 135.3, 133.4, 131.7, 130.7 (2C), 
129.0 (2C), 128.7, 128.1, 127.3, 123.4, 14.4; P (121 MHz, 





732.1. C27H25AuBrN3S requires M
+
, 731.4), 459.1 (100%, 
Ph3PAu
+
); Found: C, 37.7; H, 3.18; N, 4.65; S, 7.50; Calc. 
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(3,4-Dichloroacetophinone-thiosemicarbazone-S) 
(triphenylphosphine)gold(I) triflate, 4.26e 
 
White solid (0.068 g, 76%); 
m.p. 175-176C; vmax (KBr)/cm
-1
 
3419m, 3275w, 3178m (NH), 
1602s (C=N), 1532s (C=C), 
1273s, 1247s (C=S), 1028sh 
(P-C), 828w (CS, thioamide); 
H (300 MHz, DMSO-d6) 11.41 (1H, s, NH), 9.49 (1H, br, NHH), 
9.01 (1H, br, NHH), 8.26 (1H, s, H2), 7.89 (1H, d, J 8.4 
Hz, H6), 7.71–7.54 (16H, m, 3 × Ph, H5), 2.90 (2H, q, J 7.5 
Hz, H1’), 1.0 (3H, t, J 7.5 Hz, CH3); C (75 MHz, DMSO-d6) 
171.6, 157.9, 135.7, 133.6, 132.7, 131.5, 130.2, 129.3, 
128.8, 128.4, 127.6, 127.3, 19.9, 10.6; P (121 MHz, DMSO-







, 735.4), 459.0 (100%, Ph3PAuP
+
); 
Found: C, 37.9; H, 3.28; N, 4.30; S, 7.72; Calc. for 





Dark-red solid (0.079 g, 85%); 
m.p. 129-130 C; vmax (KBr)/cm
-1
 
3414m, 3277w, 3169m (NH), 
1598s (C=N), 1282s, 1241s 
(C=S), 1027sh (P-C), 821s 
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DMSO-d6) 12.12 (1H, s, NH), 9.18 (1H, br, NHH), 8.56 (1H, 
br, NHH), 8.15 (1H, s, HC=N), 7.66–7.60 (15H, m, 3 × Ph), 
4.82 (2H, s, H2/H5), 4.52 (2H, s, H3/H4), 4.23 (5H, s, Cp); 
C (75 MHz, DMSO-d6) 168.5, 150.4, 133.5, 131.8, 129.2, 
128.3, 76.7, 70.5 (5C), 68.7 (2C), 67.9 (2C); P (121 MHz, 





746.2. C30H26AuFeN3PS requires M
+
, 744.4), 459.0 (100%, 
Ph3PAu
+
); Found: C, 38.8; H, 3.48; N, 3.93; S, 7.17; Calc. 
for C31H28AuF3FeN3O4PS2.3H2O: C, 38.6; H, 3.55; N, 4.35; S, 
6.64. 
 
Synthesis of  
1,3,5-Triaza-7-phosphatricyclo[3.3.1.13,7]decane 4.28 
 
A mixture of tetrakis(hydroxymethyl)phosphonium 
chloride (80% solution in water, 17 cm
3
, 95 mmol) 
and ice (12.4 g) was treated with a solution of 
NaOH (50% w/w, 6.39 g) solution, which was added 
slowly while manually stirring. After the resulting clear 
colourless solution reached ambient temperature, 
formaldehyde (37%, 40.0 g, 500 mmol) was added followed by 
hexamethylenetetramine (14.1 g, 100 mmol). The mixture was 
stirred at ambient temperature for 17 h followed by 
evaporation of water in the fume hood.
16
 The resulting solid 
was then filtered, washed with several aliquots of cold 
ethanol and allowed to dry. Subsequently, the solid was 
dissolved in chloroform (150 cm
3
) and the solution was 
gravity filtered and evaporated to complete dryness to give 
a white solid residue. Drying the residue in vacuo afforded 
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260 C; H (300 MHz, D2O) 4.39 (6H, s, NCH2N), 3.93 (6H, d, 





A solution of 4.3 (0.37 g, 2.35 mmol) in 
CHCl3 (10 cm
3
) was treated with 4.28 (0.75 
g, 2.34 mmol) dissolved in CHCl3 (20 cm
3
) at 
ambient temperature. After stirring the 
resulting mixture for 2 h, the precipitate was collected 
and washed with small portions of CHCl3.
17
 Drying the 
residue in vacuo afforded 4.24 (0.54 g, 59%) as a white 
powder; m.p. 255-256 ºC (with decomposition);
18
 H (300 MHz, 
DMSO-d6) 4.54 (1H, s, NCH2N), 4.49 (2H, s, NCH2N), 4.38 (3H, 
s, NCH2N), 4.33 (6H, s, NCH2P); P (121.5 MHz, DMSO) -51.04 
ppm. 
 
F. General Procedure for the Synthesis of PTA Gold(I) TSC 
Complexes 
 
A suspension of 4.24 (0.079 mmol) in MeOH (5 cm3) at ambient 
temperature was treated with TSCs (3.28a-h and 3.37a-d) 
(0.079 mmol) for 1½ h. The resulting cloudy or red solution 
was filtered through celite to give a colourless or red 
solution. The solvent was removed at reduced pressure to 
give a semi-solid residue, which was dried in vacuo to give 
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(4-Bromoacetophinone-thiosemicarbazone-S)(1,3,5-triaza-7-
phosphatricyclo[3.3.1.13,7]decane-P) gold(I), 4.29a 
 
Tan solid (0.047 g, 87%); m.p. 
124-126 C; vmax (KBr)/cm
-1
 3365w, 
3237w (NH), 1589s (C=N), 1522s 
(C=C), 1282s (C=S), 1245s (C-N), 
968s (P-C), 822s, 736s (CS, 
thioamide), 322w (Au-S); H (300 
MHz, DMSO-d6) 10.25 (1H, br, NH), 8.28 (1H, br, NHH), 7.99 
(1H, br, NHH), 7.88 (2H, d, J 8.7 Hz, H2/H2’), 7.57 (2H, d, 
J 8.7 Hz, H3/H3’), 4.55 (2H, s, NCH2N), 4.51 (2H, s, NCH2N), 
4.39 (2H, s, NCH2N), 4.34 (6H, s, NCH2P), 2.29 (3H, s, CH3); 
C (75 MHz, DMSO-d6) 177.8, 147.1, 136.4, 130.6 (2C), 128.2 
(2C), 122.2, 71.5 (3C), 50.7 (3C), 13.4; P (121 MHz, DMSO-
d6) -50.8 ppm; m/z (ESI) 625.0219 (100%, M
+
); (Found: 
625.0219. C15H22AuBrN6PS requires M
+
, 626.2847); Found: C, 
28.4; H, 3.34; N, 11.7; S, 5.65%; Calc. for C15H22AuBrN6PSCl: 





Light yellow solid (0.043 g, 84%); 
m.p. 117-119 C; vmax (KBr)/cm
-1
 
3378w, 3242w (NH), 1601s (C=N), 
1526s (C=C), 1282s (C=S), 1245s 
(C-N), 971s (P-C), 841m, 786s (CS, 
thioamide), 326m (Au-S); H (300 
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8.26 (2H, br, NHH), 8.15 (1H, s, H2), 7.88 (1H, d, J 7.8 
Hz, H6), 7.58 (1H, d, J 8.1 Hz, H4), 7.35 (1H, t, J 8.1 Hz, 
H5), 4.55 (2H, s, NCH2N), 4.51 (2H, s, NCH2N), 4.39 (2H, s, 
NCH2N), 4.34 (6H, s, NCH2P), 2.30 (3H, s, CH3); C (100.6 
MHz, DMSO-d6) 176.6, 148.2, 139.6, 132.0, 130.2, 128.9, 
125.8, 121.9, 71.8 (3C), 50.9 (3C), 14.2; P (121 MHz, DMSO-





, 626.2847); Found: C, 28.2; H, 
3.47; N, 12.4; S, 6.47%; Calc. for C15H22AuBrN6PS: C, 28.8; 





Light-yellow solid (0.041 g, 81%); 
m.p. 119-121 C; vmax (KBr)/cm
-1
 
3242w, 3133w (NH), 1601s (C=N), 
1525s (C=C), 1281s (C=S), 1241s 
(C-N), 972s (P-C), 785m (CS, 
thioamide), 324m (Au-S); H (300 
MHz, DMSO-d6) 10.33 (1H, s, NH), 8.24 (3H, s, H2, NHH), 7.88 
(1H, d, J 8.4 Hz, H6), 7.61 (1H, d, J 8.7 Hz, H5), 4.55 
(2H, s, NCH2N), 4.51 (2H, s, NCH2N), 4.39 (2H, s, NCH2N), 
4.34 (6H, s, NCH2P), 2.30 (3H, s, CH3); C (75 MHz, DMSO-d6) 
177.6, 146.8, 137.8, 131.7, 131.2, 130.1, 128.2, 126.7, 
71.8 (3C), 51.1 (3C), 13.8; P (121 MHz, DMSO-d6) -50.9 ppm; 







, 616.2788); Found: C, 28.6; H, 
3.31; N, 11.5; S, 6.21%; Calc. for C15H21AuCl2N6PS: C, 29.2; 
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Light yellow solid (0.044 g, 83%); 
m.p. 99-101 C; vmax (KBr)/cm
-1
 
3371w, 3242w (NH), 1598s (C=N), 
1525s (C=C), 1279s (C=S), 1241s (C-
N), 972s (P-C), 795s (CS, 
thioamide), 332m (Au-S); H (300 
MHz, DMSO-d6) 10.45 (1H, s, NH), 8.34 (2H, br, NHH), 8.13 
(1H, s, H2), 7.86 (1H, d, J 7.8 Hz, H6), 7.58 (1H, d, J 8.1 
Hz, H4), 7.36 (1H, t, J 7.8 Hz, H5), 4.55 (2H, s, NCH2N), 
4.51 (2H, s, NCH2N), 4.39 (2H, s, NCH2N), 4.34 (6H, s, 
NCH2P), 2.88 (2H, q, J 7.5 Hz, H1’), 1.02 (3H, t, J 7.2 Hz, 
CH3); C (75 MHz, DMSO-d6) 176.4, 152.3, 138.1, 131.6, 129.9, 
128.7, 125.4, 121.6, 71.5 (3C), 50.7 (3C), 19.0, 10.3; P 





, 639.0355. C16H24AuBrN6PS requires M
+
, 640.3113); 
Found: C, 29.7; H, 3.72; N, 11.9; S, 6.98; Calc. for 





Tan pellets (0.042 g, 80%); m.p. 
109-112 C; vmax (KBr)/cm
-1
 3371w, 
3242w, 3145w (NH), 1603s (C=N), 
1525s (C=C), 1279s (C=S), 1241s 
(C-N), 972s (P-C), 802w (CS, 
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MHz, DMSO-d6) 10.45 (1H, s, NH), 8.34 (2H, br, NHH), 8.21 
(1H, s, H2), 7.86 (1H, d, J 8.4 Hz, H6), 7.62 (1H, d, J 8.4 
Hz, H5), 4.55 (2H, s, NCH2N), 4.51 (2H, s, NCH2N), 4.39 (2H, 
s, NCH2N), 4.34 (6H, s, NCH2P), 2.88 (2H, q, J 7.2 Hz, H1’), 
1.01 (3H, t, J 7.5 Hz, CH3); C (75 MHz, DMSO-d6) 177.4, 
151.0, 136.8, 131.7, 131.4, 130.2, 128.3, 126.8, 71.8 (3C), 
51.1 (3C), 19.1, 10.5; P (121 MHz, DMSO-d6) -50.9 ppm; m/z 







, 630.3053); Found: C, 30.9; H, 
3.77; N, 11.9; S, 6.43%; Calc. for C16H23AuCl2N6PS: C, 30.5; 





Yellow solid (0.047 g, 98%); m.p. 
165-168 C; vmax (KBr)/cm
-1
 3120m 
(NH), 1596s (C=N), 1512s (C=C), 
1281s (C=S), 1236m (C-N), 970s (P-
C), 798s (CS, thioamide), 324s (Au-
S); H (300 MHz, DMSO-d6) 11.23 (1H, 
s, NH), 9.34 (1H, s, OH), 7.98 (1H, s, HC=N), 7.93 (2H, s, 
NHH), 7.45 (1H, d, J 1.5 Hz, H2), 7.06 (1H, dd, J 1.5 and 
8.1 Hz, H6), 6.79 (1H, d, J 8.1 Hz, H5); 4.55 (2H, s, 
NCH2N), 4.51 (2H, s, NCH2N), 4.39 (2H, s, NCH2N), 4.35 (6H, 
s, NCH2P), 3.83 (3H, s, OCH3); C (101 MHz, DMSO-d6) 175.9, 
148.7, 143.5, 125.1, 122.2, 114.9, 109.2, 107.6, 71.5 (3C), 





, 579.1021 C15H22AuBrN6PS 
requires M
+
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Red solid (0.051 g, 96%); m.p. 153-
155 C; vmax (KBr)/cm
-1
 3078m, (NH), 
1595s (C=N), 1560m (C=C), 1279s 
(C=S), 1239s (C-N), 968s (P-C), 
816s (CS, thioamide), 323m (Au-S); 
H (300 MHz, DMSO-d6) 11.17 (1H, s, 
NH), 7.94 (1H, s, HC=N), 7.59 (2H, 
br, NHH), 4.72 (2H, s, H2/H5), 4.55 (2H, s, NCH2N), 4.51 
(2H, s, NCH2N), 4.42 (2H, s, H3/H4), 4.39 (2H, s, NCH2N), 
4.35 (6H, s, NCH2P), 4.20 (5H, s, Cp); C (101 MHz, DMSO-d6) 
175.7, 144.6, 78.7, 71.9 (3C), 70.1 (2C), 68.9 (5C), 67.7 





, 641.0628. C18H25AuFeN6PS 
requires M
+
, 641.2816), Found: C, 32.6; H, 3.96; N, 11.3; S, 
4.68%; Calc. for C18H25AuClFeN6PS.CH3OH: C, 32.2; H, 4.12; N, 
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Red-brown solid (0.038 g, 70%); 
m.p. 96-98 C; vmax (KBr)/cm
-1
 
3365w, 3248w (NH), 1589s (C=N), 
1533s (C=S), 1280 (C=S), 1240s 
(C=S), 972s (P-C), 820s (CS, 
thioamide), 327m (Au-S); H (300 
MHz, DMSO-d6) 10.14 (1H, s, NH), 
8.24 (1H, s, NHH), 7.79 (1H, s, NHH), 4.79 (2H, d, J 9.6 
Hz, H2/H5), 4.56 (2H, s, NCH2N), 4.52 (2H, s, NCH2N), 4.39 
(2H, s, NCH2N), 4.35 (6H, s, NCH2P), 4.24 (2H, s, H3/H4), 
4.18 (5H, s, Cp), 2.22 (3H, s, CH3); C (75 MHz, DMSO-d6) 
177.1, 149.0, 71.7, 69.5, 69.3 (2C), 68.7 (5C), 67.0, 50.8, 













Tan solid (0.060 g, 50%); m.p. 
138-140 C; vmax (KBr)/cm
-1
 3246w, 
3053w (NH), 1589s (C=N), 1533s, 
1481s (C=C), 972s (P-C), 801s 
(C=S), 392m (Au-S); H (300 MHz, 
DMSO-d6) 7.99 (2H, br, NHH), 7.78 
(2H, d, J 8.0 Hz, H2/H2”), 7.66 (2H, d, J 8.4 Hz, H3/H3”), 
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NCH2N), 4.34 (6H, s, NCH2P), 4.15 (2H, t, J 10.0 Hz, H2’), 
3.27 (2H, m, H1’); C (100.6 MHz, DMSO-d6) 176.3, 156.6, 
132.1 (2C), 131.6, 130.9, 129.3 (2C), 72.3 (3C), 51.5 (3C), 





, 637.0228. C16H22AuBrN6PS 
requires M
+
, 637.0213); Found: C, 31.1; H, 3.55; N, 11.1; S, 
4.59%; Calc. for C16H22AuBrN6PS.2CH3OH: C, 30.5; H, 3.91; N, 






Tan solid (0.089 g, 67%); m.p. 112-
114 C; vmax (KBr)/cm
-1
 3247m, 3145w 
(NH), 1595s (C=N), 1538m, 1481s 
(C=C), 1364s (C-N), 973s (P-C), 
801s, 740s (C=S), 392m (Au-S); H 
(400 MHz, DMSO-d6) 8.09 (2H, br, 
NHH), 7.85 (2H, d, J 8.0 Hz, H2/H2”), 7.53 (2H, d, J 8.0 
Hz, H3/H3”), 4.53 (2H, s, NCH2N), 4.50 (2H, s, NCH2), 4.37 
(2H, s, NCH2N), 4.34 (6H, s, NCH2P), 4.16 (2H, t, J 10.0 Hz, 
H2’), 3.29 (2H, t, J 10.4 Hz, H1’); C (100.6 MHz, DMSO-d6) 
175.4, 156.0, 134.9, 129.9, 128.6 (2C), 128.5 (2C), 71.8 
(3C), 50.9 (3C), 48.4, 31.6; P (161.9 MHz, DMSO-d6) -51.1 







, 590.07); Found: C, 33.7; H, 3.99; 
N, 13.3; S, 5.95%; Calc. for C16H22AuClN6PS.CH3OH: C, 32; H, 
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Yellow solid (0.072 g, 60%); 
m.p.120-122 C; vmax (KBr)/cm
-1
 
3247m, 3140w (NH), 1591s (C=N), 
1547m, 1461s (C=C), 1365s (C-N), 
973s (P-C), 802s (C=S), 394w (Au-
S); H (300 MHz, DMSO-d6) 8.15 (2H, 
s, H2), 7.92 (2H, br, NHH), 7.78-7.30 (2H, m, H5/H6), 4.55 
(2H, s, NCH2N), 4.51 (2H, s, NCH2N), 4.38 (2H, s, NCH2N), 
4.34 (6H, s, NCH2P), 4.18 (2H, t, J 10.5 Hz, H2’), 3.29 (2H, 
t, J 10.2 Hz, H1’); C (75 MHz, DMSO-d6) 175.9, 154.7, 
132.5, 131.9, 131.5, 130.7, 128.2, 126.8, 71.8 (3C), 50.8 





, 627.03. C16H21AuCl2N6PS 
requires M
+
, 624.05); Found: C, 33.6; H, 3.51; N, 11.9; S, 
5.52%; Calc. for C16H21AuCl2N6PS: C, 30.6; H, 3.37; N, 13.4; 
S, 5.10%. 
 
G. General Procedure for the Synthesis of Et3P Gold(I) TSC 
Complexes 4.31a-f 
 
A solution of 3.28a (0.050 g, 0.18 mmol) in anhydrous MeOH 
(5 cm
3
) was reacted with Et3PAuCl (0.065 g, 0.19 mmol) at 
ambient temperature.
19
 After stirring the mixture for 4 h 
under nitrogen, the colourless solution was filtered 
through celite and solvent removed to give a semi solid 
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Off-white solid (0.11 g, 92%); 
m.p. 45-47 C; vmax (KBr)/cm
-1
 
3237w (NH), 1587s (C=N), 1523s 
(C=C), 1265br, 828s (C=S, 
thioamide), 349m (Au-S); H (300 
MHz, DMSO-d6) 10.21 (1H, s, NH), 
8.37 (1H, br, NHH), 8.05 (1H, br, NHH), 7.87 (2H, d, J 8.7 
Hz, H2/H2'), 7.55 (2H, d, J 8.7 Hz, H3/H3'), 2.29 (3H, s, 
CH3), 1.97 (6H, m, PCH2CH3), 1.09 (9H, m, PCH2CH3); P (121.5 





, 586.0344. C15H25AuBrN3PS requires M
+
, 587.2884), 315.0520 
(58%, Et3PAu
+
); Found: C, 27.2; H, 4.10; N, 5.38; S, 4.86; 






Off white solid (0.12 g, 100%); 
m.p. 35-37 C; vmax (KBr)/cm
-1
 
3389w, 3237w (NH), 1601s (C=N), 
1522s (C=C), 1264s (C=S), 839s 
(CS); H (300 MHz, DMSO-d6) 10.41 
(1H, s, NH), 8.54 (1H, br, NHH), 
8.28 (1H, br, NHH), 8.19 (1H, s, H2), 7.89 (1H, d, J 8.0 
Hz, H6), 7.58 (1H, d, J 8.8 Hz, H4), 7.34 (1H, t, J 8.0 Hz, 
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PCH2CH3); P (161.9 MHz, DMSO-d6) 35.2 ppm, m/z (ESI) 
586.0369 (27%, M
+
), 315.0531 (33%, Et3PAu
+
); Found: C, 27.7; 
H, 4.05; N, 5.28; S, 5.43; Calc. for C15H25BrClN3PS.2H2O: C, 





White solid (0.12 g, 100%); 
m.p.53-55 C; vmax (KBr)/cm
-1
 3236w 
(NH), 1603s (C=N), 1523s (C=C), 
1297s (C=S), 821m (CS); H (400 
MHz, DMSO-d6) 10.48 (1H, s, NH), 
8.54 (1H, br, NHH), 8.32 (1H, br, 
NHH), 8.28 (1H, s, H2), 7.89 (1H, d, J 7.6 Hz, H6), 7.63 
(1H, d, J 8.4 Hz, H5), 2.31 (3H, s, CH3), 1.92 (6H, m, 
PCH2CH3), 1.09 (9H, m, PCH2CH3); P (161.9 MHz, DMSO-d6) 35.1 







, 577.2825), 315.0546 (23%, 
Et3PAu
+
); Found: C, 28.8; H, 3.88; N, 5.64; S, 5.60; Calc. 





White solid (0.11 g, 98%); vmax 
(KBr)/cm
-1
 3230w (NH), 1603s, 
1568s (C=N), 1523s (C=C), 1266s 
(C=S), 774s (CS); H (400 MHz, 
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(2H, br, NHH), 8.14 (1H, s, H2), 7.86 (1H, d, J 8.0 Hz, 
H6), 7.56 (1H, d, J 8.8 Hz, H4), 7.35 (1H, t, J 8.0 Hz, 
H5), 2.86 (2H, q, J 7.6 Hz, H1’), 1.92 (6H, m, PCH2CH3), 
1.09 (12H, m, PCH2CH3) 1.0 (3H, t, J 7.2 Hz, CH3); P (161.9 










); Found: C, 29.8; H, 4.26; N, 5.99; 
S, 5.69; Calc. for C16H27AuBrN3PS.H2O: C, 29.4; H, 4.46; N, 





White solid (0.11 g, 99%); m.p. 47-
49 C; vmax (KBr)/cm
-1
 3218w, (NH), 
1603s (C=N), 1524s (C=C), 1272m 
(C=S), 825s (CS); H (400 MHz, 
DMSO-d6) 10.59 (1H, s, NH), 8.55 
(1H, br, NHH), 8.32 (1H, br, NHH), 
8.25 (1H, s, H2), 7.88 (1H, d, J 
8.4 Hz, H6), 7.63 (1H, d, J 8.4 Hz, H5), 2.88 (2H, q, J 7.2 
Hz, H1’), 1.92 (6H, m, PCH2CH3), 1.09 (9H, m, PCH2CH3), 1.00 
(3H, t, J 7.6 Hz, CH3); P (161.9 MHz, DMSO-d6) 35.1 ppm, m/z 







, 591.3091), 315.0584 (29%, 
Et3PAu
+
); Found: C, 29.6; H, 4.11; N, 5.10; S, 5.21; Calc. 
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Red solid (0.12 g, 100%); m.p. 
75-77 C; vmax (KBr)/cm
-1
 3399w, 
3237w (NH), 1594s (C=N), 1552s 
(C=C), 1276s (C=S), 821s (CS); 
H (400 MHz, DMSO-d6) 11.19 (1H, 
s, NH), 8.01 (1H, br, NHH), 7.91 
(1H, s, HC=N), 7.61 (1H, br, NHH), 4.72 (2H, s, H2/H5), 
4.41 (2H, s, H3/H4), 1.93 (6H, m, PCH2CH3), 1.10 (9H, m, 





, 602.0744. C18H28AuFeN3PS 
requires M
+
, 602.2853), 315.0255 (20%, Et3PAu
+
); Found: C, 
34.1; H, 4.46; N, 5.91; S, 4.50; Calc. for C18H28AuClFeN3PS: 





Yellow solid (0.12 g, 98%); m.p.  
46-48 C; vmax (KBr)/cm
-1
 3250w 
(NH), 1588s (C=N), 1538m (C=C), 
1379s (C-N), 1251s (C=S), 771s 
(CS); H (400 MHz, DMSO-d6) 7.93 
(2H, br, NHH), 7.78 (2H, d, J 8.4 
Hz, H2/H2”), 7.66 (2H, d, J 8.4 Hz, H3/H3”), 4.15 (2H, t, J 
9.6 Hz, H2’), 3.29 (2H, t, J 9.6 Hz, H1’), 1.92 (6H, m, 
PCH2CH3), 1.09 (9H, m, PCH2CH3); P (161.9 MHz, DMSO-d6) 35.1 
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C16H25AuCl2N3PS requires M
+
, 554.8481), 315.0560 (33%, 
Et3PAu
+
); Found: C, 32.9; H, 4.52; N, 6.49; S, 5.43; Calc. 





Yellow solid (0.12 g, 95%); m.p. 53-
55 C; vmax (KBr)/cm
-1
 3250w, 3116s 
(NH), 1593s (C=N), 1538s (C=C), 
1388s (C-N), 1257s (C=S), 773s 
(CS); H (400 MHz, DMSO-d6) 7.93 
(1H, s, NHH), 7.83 (2H, d, J 8.4 Hz, 
H2/H2”), 7.75 (1H, br, NHH), 7.50 
(2H, d, J 8.4 Hz, H3/H3”), 4.13 (2H, t, J 9.6 Hz, H2’), 
3.27 (2H, t, J 9.6 Hz, H1’), 1.90 (6H, m, PCH2CH3), 1.07 





, 598.0349. C18H28AuBrN3PS 
requires M
+
, 599.2991), 315.0538 (42%, Et3PAu
+
); Found: C, 
32.0; H, 4.66; N, 6.34; S, 5.18; Calc. for C16H25AuBrN3PS: C, 
32.1; H, 4.20; N, 7.01; S, 5.35. 
 
Synthesis of Tetrahydrothiophene Gold(I) Pentafluorophenyl 
4.34 
 
A solution of bromopentafluorobenzene 
(0.50 g, 2.04 mmol) in freshly distilled 
diethyl ether (20 cm
3
) was treated with n-
butyllithium in hexane (2.5 M, 2.04 mmol) 
at -78 ºC. The resulting mixture was 
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added and the mixture stirred for further 15 minutes at -78 
ºC.
13
 The mixture was allowed to warm to -30 ºC over 30 
minutes interval. After 15 minutes at -30 ºC the cooler was 
removed and the white suspension stirred for additional 20 
minutes. The solution was filtered through MgSO4 and solvent 
evaporated in vacuo to yield 4.34 (934.3 mg, 90%) as a 
white solid.
13
 Found: C, 26.2; H 1.89; Calc. for C10H8AuF5S: 
C, 26.6; H, 1.78%. 
 
H. General Procedure for the Synthesis of Pentaflourobenzyl 
gold(I) TSC Complexes 4.38a-f 
 
A solution of 4.34 (0.51 g, 0.11 mmol) in DCM (15 cm3) was 
treated with 3.28a (0.30 g, 0.11 mmol) at ambient 
temperature.
20
 The resulting clear solution was stirred for   
1 h followed and then filtered through celite. The solvent 
was concentrated to give a white residue. Drying the 






Yellow solid (0.077 g, 100%); m.p. 
155-156 C; vmax (KBr)/cm
-1
 3492m, 
3373s (NH2), 3262m (NH), 1593s (C=N), 
1525s (C=C), 1486s δ(NSC), 1271m 
(C=S), 797m (CS, thioamide); H (300 
MHz, DMSO-d6) 10.85 (1H, br s, NH), 
9.15 (1H, br, NHH), 8.88 (1H, br, 
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Hz, H3/H3’), 2.36 (3H, s, CH3); m/z (ESI) 467.95 (8%, 
TSCAu
+
) ; Found: C, 29.0; H, 1.99; N, 5.54; S, 5.05; Calc. 





Yellow solid (0.073 g, 100%); m.p. 
145-146 C; vmax (KBr)/cm
-1
 3429s, 
3380m, (NH), 3269m (NH), 1591s (C=N), 
1519s (C=C), 1270s (C=S), 839m (CS, 
thioamide), 321w (Au-S); H (300 MHz, 
DMSO-d6) 10.80 (1H, br s, NH), 8.95 
(2H, br, NHH), 8.23 (1H, s, H2), 7.93 (1H, d, J 7.8 Hz, 
H6), 7.62 (1H, d, J 7.5 Hz, H4), 7.37 (1H, d, J 7.8 Hz, 
H5), 2.36 (3H, s, CH3); m/z (ESI) 467.94 (10%, TSCAu
+
); 
Found: C, 28.5; H, 1.74; N, 5.83; S, 5.59; Calc. for 





Yellow-organge solid (0.073 g, 
100%); m.p. 160-161 C; vmax (KBr)/cm
-
1
 3429w, 3381s (NH), 3257m (NH), 
1593s (C=N), 1517s (C=C), 1256s 
(C=S), 795sh (CS, thioamide), 319m 
(Au-S); H (300 MHz, DMSO-d6) 10.87 
(1H, br, NH), 9.14 (2H, br, NH), 8.31 (1H, s, H2), 7.93 
(1H, d, J 8.7 Hz, H6), 7.65 (1H, d, J 8.7 Hz, H5), 2.36 
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Orange solid (0.062 g, 86%); m.p. 
124-125 C; vmax (KBr)/cm
-1
 3479m, 
3360s (NH), 3284m (NH), 1587s (C=N), 
1520s (C=C), 1268s (C=S), 797s (CS, 
thioamide), 371m (Au-S); H (300 MHz, 
DMSO-d6) 10.81 (1H, br s, NH), 8.85 
(1H, br, NHH), 8.19 (1H, s, H2), 7.90 (1H, d, J 8.1 Hz, 
H6), 7.62 (1H, d, J 8.1 Hz, H4), 7.38 (1H, t, J 8.1 Hz, 
H5), 2.90 (2H, q, J 7.8 Hz, H1’), 1.04 (3H, t, J 7.8 Hz, 







 650.21), 483.96 (12%, TSCAu
+
); 
Found: C, 30.1; H, 1.80; N, 5.85; S, 6.61; Calc. for 





White solid (0.073 g, 100%); m.p. 
138-140 C; vmax (KBr)/cm
-1
 3492m, 
3373s (NH), 3262m (NH), 1593s (C=N), 
1525s (C=C), 1271m (C=S), 797m (CS, 
thioamide); H (400 MHz, DMSO-d6) 
10.88 (1H, br, NH), 8.92 (2H, br, 
NHH), 8.28 (1H, s, H2), 7.90 (1H, d, J 2.1 and 8.4 Hz, H6), 
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1.03 (3H, t, J 7.5 Hz, CH3); m/z (ESI) 471.97 (5%, TSCAu
+
); 
Found: C, 31.1; H, 1.78; N, 5.82; S, 5.43; Calc. for 





Yellow solid (0.077 g, 69%); vmax 
(KBr)/cm
-1
 ; H (300 MHz, DMSO-d6) 12.02 
(1H, br s, OH), 9.52 (1H, s, NH), 8.92 
(1H, br s, NHH), 8.72 (1H, br s, NHH), 
8.15 (1H, s, HC=N), 7.54 (1H, s, H2), 
7.17 (1H, d, J 8.1 Hz, H6), 6.82 (1H, 
d, J 8.1 Hz, H5), 3.85 (3H, s, OCH3); Found: C, 31.95; H, 
1.82; N, 5.18; S, 5.50; Calc. for C15H10AuBrF5N3S: C, 30.57; 





A solution of N,N-dimethylaminomethylbenzene 
(2.25 cm
3
, 15.0 mmol) in dried Et2O (20 cm
3
) 
was treated with t-butylithium (2.5 M in 
hexane, 15.0 mmol), which was slowly added 
at 0 ºC. The reaction mixture was allowed to 
warm to ambient temperature and stirred for 24 h under 
nitrogen. The mixture was cooled to -90 ºC and HgCl2 (4.05 
g, 15.0 mmol) dissolved in THF (10 cm
3
) was slowly added 
accompanied by the formation of a grey precipitate. After 
warming to ambient temperature, the resulting mixture was 
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celite, solvent removed at reduced pressure to give a 
yellow semi-solid residue. Recrystallisation from pentane 
gave 4.40 (4.28 g, 77%) as a white-yellow crystals;21,22 m.p. 
67-68 ºC (lit.
21
 76-77 ºC); δH
 
(400 MHz, CDCl3) 7.39–7.31 
(4H, m, ArH), 3.79 (2H, s, CH2), 2.49 (6H, s, CH3); Found: 
C, 28.51; H 3.57; N 3.11%; Calc for C9H12ClHgN: C, 29.20; H, 
3.27; N, 3.78%. 
 
Synthesis of methylammonium tetrachloroaurate 4.41 
 
A mixture of H[AuCl4].4H2O (0.44 g, 1.08 mmol) and 32% HCl 
(6 cm
3
) in water (10 cm
3
) was cooled to 0 ºC. A solution of 
Me4NCl (0.12 g, 1.11 mmol) in water (2 cm
3
) was slowly added 
with concomitant of a yellow precipitate. After 5 minutes, 
the yellow precipitate that formed was filtered, washed 
successively with water (5 cm
3
) and Et2O (5 cm
3
). Drying the 
precipitate in vacuo afforded 4.41 (0.30 g, 68%) as a 
yellow powder;
23
 Found: C, 11.9; H 3.98; N 3.14%; Calc. for 
C4H14AuCl4N.H2O: C, 11.3; H, 3.27; N, 3.25%. 
 
Synthesis of  
[2-(Dimethylaminomethyl)phenyl]gold(III)dichloride 2.15 
 
A mixture of 4.41 (0.20 g, 0.55 mmol), 4.40 
(0.23 g, 0.56 mmol) and Me4NCl (0.064 g, 
0.58 mmol) in anhydrous acetonitrile (15 
cm
3
) was stirred at ambient temperature for 
24 h. During this time a white precipitate, 
Me4N(Hg2Cl6), that formed was filtered and solvent 
evaporated to give a yellow solid residue. The residue was 
extracted with DCM (3 × 40 cm
3
) and solvent evaporated to 
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95%) as a yellow solid;
24
 m.p. 182-183 ºC (lit. 185 ºC); δH
 
(300 MHz, CDCl3) 7.63–7.54 (2H, m, ArH), 7.39–7.33 (2H, m, 
ArH), 4.43 (2H, s, CH2), 3.34 (6H, s, NMe2);
25
 Found: C, 
27.3; H, 3.17; N, 2.66; Calc. for C9H12AuCl2N.CH2Cl2: C, 
27.9; H, 3.52; N, 2.72. 
 
I. General Procedure for the Synthesis of Mono-Gold(III) 
Chelates 4.42a-f 
 
A solution of 3.28c (0.021 g, 0.077 mmol) in dry acetone 
(20 cm
3
) was treated with 2.15 (0.031 g, 0.077 mmol) at 
ambient temperature.
26
 The mixture was allowed to reflux for 
1 h; then stirred for further 5 h at ambient temperature. 
After the reaction, a yellow solution was filtered through 
celite and solvent concentrated to give yellow residue. 





Yellow solid (0.050 g, 98%); m.p. 92-
94 C; vmax (KBr)/cm
-1
 3378w, 3060m 
(NH), 2667w (NH+), 1624s, (C=N), 
1547s (C=C), 798w (CS), 428w (Au-
N), 357m (Au-S), 313s (Au-Cl); H 
(300 MHz, DMSO-d6) 10.35 (1H, br, 
(CH3)2NH
+
), 8.27 (1H, s, H2), 7.90 
(1H, d, J 8.1 Hz, H6), 7.64 (1H, d, J 8.4 Hz, H5), 7.51 
(1H, m, ArH'), 7.27 (2H, m, ArH'), 7.15 (1H, m, ArH'), 4.62 





, 627.0275. C18H21AuCl3N4S requires M
+
, 
627.0213), 591.0453 (100%, M
+
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N, 7.40; S, 4.72; Calc. for C18H21AuCl3N4S.(CH3)2CO: C, 36.7; 




Yellow solid (0.081 g, 96%); m.p. 94-
96C; vmax (KBr)/cm
-1
 3277w, (NH), 
1698s, 1625s (C=N), 1552s (C=C), 
788s (CS), 426w (Au-N), 355w (Au-
S), 329m (Au-Cl); H (300 MHz, DMSO-
d6) 10.40 (1H, br s, NH
+
), 8.19 (1H, 
s, H2), 7.90 (1H, d, J 7.5 Hz, H6), 
7.61 (1H, d, J 7.2 Hz, H4), 7.48 (1H, m, ArH'), 7.36 (1H, 
t, J, 7.8 Hz, H5), 7.28 (2H, m, ArH'), 7.17-7.11 (1H, m, 
ArH'), 4.63 (2H, s, CH2), 3.19 (6H, s, N(CH3)2), 2.34 (3H, 







, 637.0097), 601.0171 (100%, M
+
-
Cl); Found: C, 37.4; H, 4.49; N, 7.02; S, 4.38; Calc. for 





Dark-red solid (0.13 g, 98%); m.p. 
142–143 C (lit.27 179 ºC); vmax 
(KBr)/cm
-1
 3264m, 3130m (NH), 2664–
2466m (NH+), 1599s, 1539s (C=N), 
750sh (CS), 490s (Au-N), 356m,br 
(Au-S), 318m (Au-Cl); H (400 MHz, 
DMSO-d6) 10.44 (1H, br, NH
+
), 8.17 























































Chapter 8          Experimental Section 
 
 
UCT 259 CHEMISTRY 
ArH’), 5.40 (1H, s, CHH), 5.10 (1H, s, CHH), 4.69 (2H, s, 
H2/4), 4.46 (2H, s, H3/H5), 4.29 (5H, s, Cp), 2.74 (6H, s, 







, 653.05), 617.1 (10%, M
+
-Cl); 
Found: C, 38.0; H, 4.26; N, 5.90; S, 4.09; Calc. for 




Orange-yellow solid (0.79 g, 93%); 
m.p. 80-82 C; vmax (KBr)/cm
-1
 3237w 
(NH), 2683 (NH+), 1698m, 1625s 
(C=N), 1537s (C=C), 791m (CS), 426w 
(Au-N), 352m (Au-S), 325m (Au-Cl); 
H (300 MHz, DMSO-d6) 10.83 (1H, br, 
NH
+
), 8.16 (1H, s, H2), 7.88 (1H, d, 
J 7.2 Hz, H6), 7.62 (1H, d, J 7.5 Hz, H4), 7.48 (1H, m, 
ArH'), 7.38 (1H, t, J 7.8 Hz, H5), 7.27 (2H, m, ArH'), 
7.17-7.11 (1H, m, ArH'), 4.62 (2H, s, CH2), 3.18 (6H, s, 
N(CH3)2), 2.94 (2H, q, 7.5 Hz, CH2), 1.0 (3H, t, J 7.5 Hz, 







, 651.0254), 617.0136 (100%, M
+
-
Cl); Found: C, 34.6; H, 4.44; N, 5.69; S, 5.33; Calc. for 
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Compound 4.42e 
 
Yellow solid (0.088 g, 90%); m.p. 
102-104 C; vmax (Kbr)/cm
-1
 3237w 
(NH), 2683m (NH+), 1698s, 1625s 
(C=N), 1543s (C=C), 785w (CS), 
427w (Au-N), 361m (Au-S), 328s 
(Au-Cl); H (300 MHz, DMSO-d6) 10.77 
(1H, br, NH
+
), 8.25 (1H, s, H2), 7.88 
(1H, d, J 7.5 Hz, H6), 7.64 (1H, d, J 8.4 Hz, H5), 7.48 
(1H, ArH'), 7.27 (2H, m, ArH'), 7.16-7.14 (1H, m, ArH), 
4.63 (2H, s, CH2), 3.19 (6H, s, N(CH3)2), 2.94 (2H, q, J 7.5 





, 641.0357. C19H23AuCl3N4S requires M
+
, 
641.0369), 605.0240 (100%, M
+
-Cl); Found: C, 37.7; H, 4.38; 
N, 6.85; S, 4.53; Calc. for C19H23AuCl3N4S.2(CH3)2CO.2H2O: C, 




Orange-yellow powder (0.068 g, 
91%); m.p. 97-99 C; vmax (Kbr)/cm
-1
 
3255w (NH), 1698s (C=N), 1585s 
(C=C), 829s (CS), 428w (Au-N), 
360w (Au-S), 325m (Au-Cl);       
H (300 MHz, DMSO-d6) 10.45 (1H, br, 
NH
+
), 7.91 (2H, d, J 7.8 Hz, H2/2”), 
7.58 (2H, d, J 8.4 Hz, H3/3”), 7.51-7.47 (1H, m, ArH'), 
7.27 (2H, m, ArH'), 7.16-7.13 (1H, m, ArH'), 4.62 (2H, s, 
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UCT 261 CHEMISTRY 
requires M
+
, 637.0097), 602.9982 (100%, M
+
-Cl); Found: C, 
36.1; H, 4.12; N, 7.52; S, 4.14; Calc. for 





A suspension of 3.24h (0.079 mmol) 
in anhydrous MeOH (15 cm
3
) was 
treated with 2.15 (0.23 mmol) at 
ambient temperature. The mixture was 
allowed to reflux for 2 h. The 
solution was filtered through celite 
and solvent concentrated to give an 
orange solid residue. Drying the 
residue in vacuo afforded 4.42g (0.51 g, 96%) as an yellow 
solid;
28
 m.p. 158-160 C; vmax (KBr)/cm
-1
 3267m (NH), 3130br 
(OH), 2673br (NH+), 1578s (C=N), 1533m (C=C), 784 (CS, 
thioamide), 366w (Au-S), 317w (Au-Cl); H (300 MHz, DMSO-
d6) 10.45 (1H, br s, NH
+
), 10.22 (1H, s, OH), 8.16 (1H, s, 
HC=N), 8.14 (2H, s, NHH), 7.81–7.76 (3H, m, H2/ArH’), 7.38 
(1H, d, J 7.2 Hz, H6), 7.24–7.20 (2H, m, ArH’), 6.95 (1H, 
d, J 8.4 Hz, H5), 4.30 (2H, s, CH2), 3.87 (3H, s, OCH3), 





591.0. C18H23AuClN4O2S requires M
+
, 591.09), 555.0 (30%, M
+
-
Cl); Found: C, 35.4; H, 4.36; N, 7.75; S, 4.05; Calc. for 
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8.6 EXPERIMENTAL DETAILS FOR CHAPTER 6 
 
Synthesis of Methyl Hydrazinecarbothioate 6.20 
 
A cooled solution of KOH (19.8 g, 300 mmol) 
in water (25 cm
3
) and iPrOH (20 cm
3
) was 
treated with hydrazine monohydrate (17 cm
3
). 
Cold CS2 was added dropwise to the stirred 
solution while maintaining the temperature below 10 C. 
After 2.5 h, cold CH3I (18.7 cm
3
, 0.3 mol) was added over 2 
h. After a further 90 min the white precipitate that formed 
was filtered, washed with cold water and recrystallised 
from DCM to give the 6.20 (16.0 g, 37%) as white needles,29 
m.p. 82-84 C; vmax (KBr)/cm
-1
 3136 m (NH), 1599s (NH), 1283s 
(C=S), 709 (CS); H (300 MHz, DMSO-d6) 9.01 (br s, 1H, NH), 
4.80 (br s, 1H, NH), 4.20 (br s, 1H, NH), 2.65 (s, 3H, 
SCH3). 
 
J. General Procedure for the Synthesis of TSC Thioesters 
6.23a-g 
 
A suspension of methyl hydrazinecarbodithioate 6.20 (4.11 
mmol) in iPrOH (15 cm
3
) was treated with an appropriate 
aldehyde and/or ketone (4.11 mmol) at ambient temperature. 
The mixture was stirred for 4 h accompanied by the 
formation of a precipitate. In some cases the precipitate 
formed by allowing the reaction to stir for 24 h.
29
 The 
precipitate was filtered, washed with iPrOH and evaporated 
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Yellowish powder (0.84 g, 68%);
30
 m.p. 
125-126 ºC; vmax (KBr)/cm
-1
 3208s (NH), 
1585m (NH), 1557s (C=N), 1473s (C=C), 
1281s (C=S), 802s (C=S), 685s (C-S); δH
 
(400 MHz, DMSO-d6) 12.49 (1H, s, NH), 8.01 (1H, s, H2), 7.85 
(1H, d, J 7.6 Hz, H6), 7.65 (1H, d, J 7.6 Hz, H4), 7.41 






Tan powder (0.70 g, 56%);
31
 m.p. 164-165 
ºC; vmax (KBr)/cm
-1
 3174s (NH), 1601w 
(NH), 1582m (C=N), 1474s (C=C), 1282s 
(C=S), 829s (C=S), 688sh (C-S); δH
 
(400 MHz, DMSO-d6) 12.45 (1H, s, NH), 7.80 (2H, d, J 8.4 Hz, 
H2/H2’), 7.65 (2H, d, J 8.4 Hz, H3/H3’), 2.52 (3H, s, SCH3), 





Light yellow powder (0.75 g, 58%); m.p. 
100-102 ºC; vmax (KBr)/cm
-1
 3168s (NH), 
1585m (NH), 1557s (C=N), 1496s (C=C), 
1288s (C=S), 816s (C=S), 692s (C-S); δH 
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(1H, d, J 8.0 Hz, H6), 7.65 (1H, d, J 8.0 Hz, H4), 7.42 
(1H, t, J 8.0 Hz, H5), 2.94 (2H, q, J 7.6 Hz, H1’), 2.52 
(3H, s, SCH3), 1.03 (3H, t, J 7.2 Hz, CH3). 
 
Methyl 3-[1-(3’,4’-dichlorophenyl)ethylidene]- 
hydrazine carbodithioate, 6.23d 
 
Tan powder (0.50 g, 41%); m.p. 148-149 
ºC; vmax (KBr)/cm
-1
 3158s (NH), 1611m 
(NH), 1552m (C=N), 1460s (C=C), 1269s 
(C=S), 811sh (C=S), 715sh (C-S); δH (400 
MHz, DMSO-d6) 12.51 (1H, s, NH), 8.02 (1H, d, J 2.0 Hz, H2), 
7.81 (1H, dd, J 2.0 and 8.4 Hz, H6), 7.70 (1H, d, J 8.4 Hz, 
H5), 2.51 (3H, s, SCH3), 2.37 (3H, s, CH3). 
 
Ferrocenemethylidene Hydrazinecarbothioate, 6.23e 
 
Red powder (1.12 g, 86%); m.p. 162-164 
ºC; vmax (KBr)/cm
-1
 3120s (NH), 1682m 
(NH), 1597s (C=N), 1522s (C=C), 1312s 
(C=S), 813s (C=S), 614sh (C-S); δH (400 
MHz, DMSO-d6) 12.99 (1H, s, NH), 8.12 
(1H, s, HC=N), 4.67 (2H, s, H2/H5), 4.51 (2H, s, H3/H4), 




Brown powder (0.81 g, 58%);
32
 m.p. 112-
113 ºC; vmax (KBr)/cm
-1
 3152s (NH), 
1596s (NH), 1498s (C=N), 1460m (C=C), 
1284s (C=S), 816s (C=S), 738s (C-S); δH 
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4.71 (2H, s, H2/H5), 4.44 (2H, s, H3/H4), 4.20 (5H, s, Cp), 





Tan powder (0.63 g, 50%); m.p. 143-145 
ºC; vmax (KBr)/cm
-1
 3152s (NH), 1552w 
(NH), 1497s (C=N), 1448s (C=C), 1286s 
(C=S), 810s (C=S), 705s (C-S); δH (400 
MHz, DMSO-d6) 12.65 (1H, s, NH), 8.03 (1H, d, J 2.0 Hz, H2), 
7.81 (1H, dd, J 2.0 and 8.4 Hz, H6), 7.71 (1H, d, J 8.4 Hz, 
H5), 2.94 (2H, q, J 7.6 Hz, H1’), 2.52 (3H, s, SCH3), 1.02 
(3H, t, J 7.6 Hz, CH3). 
 
K. General Procedure for the Synthesis of Dendritic TSCs 
6.24a-g 
 
A suspension of hydrazinecarbodithioate, 6.23 (0.23 g, 0.80 
mmol) in MeOH (10 ml) was treated with polypropylenimine 
tetraamine dendrimer (62.1 µl, 0.20 mmol) at room 
temperature. The mixture was allowed to reflux for 24 h. 
After cooling, the solution was concentrated to give a 
sticky yellow residue, which was dissolved in DCM (20 cm
3
) 
and water (20 cm
3
). The DCM layer was washed with water 
until the solution became clear and dried over Na2SO4. The 
solvent was concentrate to give from the filtrate to give a 
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Yellow solid (0.20 g, 
78%); m.p. 119-121 ºC; vmax 
(KBr)/cm
-1
 3396m (NH), 
1670s (NH), 1528s (C=N), 
1468s (C=C), 820s (CS, 
thiourea); H (400 MHz, 
DMSO-d6) 8.64 (4H, s, 
HNN), 8.09-8.06 (8H, m, 
H2”/CH2NH), 7.84-7.78 (4H, 
m, H6”), 7.59-7.56 (4H, m, H4”), 3.58 (8H, m t, H4), 2.42-
2.38 (12H, m, H2/H2’), 1.70-1.68 (8H, m, H3), 1.42-1.39 
(4H, m, H1); C (100 MHz, DMSO-d6) 177.3, 144.8, 137.8, 
131.0, 130.7, 129.6, 127.5, 126.1, 53.1, 50.9, 42.5, 25.5, 





1297.1724. C52H64Cl8N14S4 requires M, 1297.0424), 1051.213 
(100%), 807.259 (39), 561.304 (5); Found: C, 48.1; H, 5.80; 
N, 14.8; S, 8.52; Calc. for C52H64Cl8N14S4: C, 47.5; H, 5.06; 
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Yellow solid (0.18 g, 94%); 




3177m (NH), 1527s (C=N), 
1466s (C=C), 834s (CS, 
thiourea); H (400 MHz, 
DMSO-d6) 8.62 (4H, s, HNN), 
8.03 (8H, s, H2”/CH2NH), 
7.82 (4H, d, J 6.0 Hz, 
H6”), 7.54 (4H, d, J 8.0 Hz, H4”), 7.34 (4H, t, J 7.6 Hz, 
H5”), 3.61 (8H, t, J 4.4 Hz, H4), 2.35-2.32 (12H, m, 
H2/H2’), 2.28 (12H, s, CH3), 1.71-1.68 (8H, m, H3), 1.42-
1.40 (4H, m, H1); C (101 MHz, DMSO-d6) 177.7, 146.2, 140.1, 
131.6, 130.1, 128.7, 125.4, 121.8, 53.5, 51.3, 43.0, 25.8, 





1337.1316. C52H68Br4N14S4 requires M, 1337.0661), 1083.175 
(100%), 827.228 (92), 571.663 (28); Found: C, 49.9; H, 
6.14; N, 14.9; S, 9.10; Calc. for C52H68Br4N14S4.H2O: C, 46.1; 
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Yellow solid (0.21 g, 




(NH), 1586w (NH), 
1531s (C=N), 1482s 
(C=C), 826s (CS, 
thiourea); H (300 MHz, 
DMSO-d6) 8.49 (4H, s, 
HNN), 7.80 (4H, s, 
CH2NH), 7.78 (8H, d, J 
8.0 Hz, H2”/H2”’), 7.53 (8H, d, J 8.1 Hz, H3”/H3”’), 3.62 
(8H, m, H4), 2.41 (12H, t, J 6.9 Hz, H2/H2”), 2.27 (12H, s, 
CH3), 1.71 (8H, unresolved t, H3), 1.43 (4H, t, J 6.9 Hz, 
H1); C (75.5 MHz, DMSO-d6) 176.9, 145.6, 136.0, 130.1 (2C), 





, 1337.1259. C52H68Br4N14S4 
requires 1337.0661), 1081.1851 (76%), 827.2379 (11), 
573.2930 (8); Found: C, 47.9; H, 5.79; N, 14.6; S, 8.19; 
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Yellow solid (0.27 g, 




3177m (NH), 1527s 
(C=N), 1471s (C=C), 
883w (CS, thiourea); H 
(300 MHz, DMSO-d6) 8.54 
(4H, s, HNN), 7.96 (8H, 
s, H2”/CH2NH), 7.79 (4H, 
d, J 7.2 Hz, H6”), 7.54 
(4H, d, J 8.1 Hz, H4”), 7.34 (4H, m, H5”), 3.61 (8H, 
unresolved t, H4), 2.83 (8H, q, J 7.2 Hz, H5), 2.38 (12H, 
m, H2/H2’), 1.69 (8H, m, H3), 1.24-1.29 (4H, m, H1), 1.00 
(12H, unresolved t, CH3); C (75.5 MHz, DMSO-d6) 176.9, 
149.4, 138.1, 130.7, 129.4, 127.9, 124.7, 121.0, 52.7, 





, 1393.1880. C52H76Br4N14S4 requires M
+
, 
1393.1994), 1125.2191 (100%), 855.2638 (45); Found: C, 
48.3; H, 5.97; N, 13.6; S, 9.70; Calc. for C52H64Cl8N14S4: C, 
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Yellow solid (0.21 g, 




3167w (NH), 1527s 
(C=N), 1468s (C=C), 
823w (CS, thiourea); H 
(400 MHz, DMSO-d6) 8.69 
(4H, s, HNN), 8.09 
(8H, s, CH2NH/H2”), 
7.83 (4H, m, H6”), 
7.64 (4H, m, H5”), 
3.63 (8H, m, H4), 2.88 (8H, m, H5), 2.37-2.35 (12H, m, 
H2/H2’), 1.72 (8H, m, H3), 1.44-1.30 (4H, m, H1), 1.0 (12H, 
m, CH3); C (101 MHz, DMSO-d6) 177.7, 149.1, 137.2, 131.4, 
131.3, 130.2, 128.1, 126.6, 53.5, 51.3, 42.9, 25.9, 24.2, 





1353.1487. C56H72Cl8N14S4 requires M
+
, 1353.1487), 1093.2708 
(100%), 835.2927 (55), 575.6839 (13); Found: C, 51.3; H, 
6.06; N, 15.1; S, 8.99; Calc. for C56H72Cl8N14S4: C, 49.7; H, 
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Red powder (0.28 g, 




3348w, 3093w (NH), 
1603m (NH), 1531s 
(C=N), 1466m (C=C), 
820s (CS, thiurea); 
H (300 MHz, DMSO-
d6) 8.14 (4H, s, 
HNN), 7.92 (8H, s, 
CH2NH/HC=N), 4.68 
(8H, s, H2”/H5”), 4.41 (8H, s, H3”/H4”), 4.20 (20H, s, Cp), 
3.58 (8H, t, J 4.8 Hz, H4), 2.46-2.40 (12H, m, H2/H2’), 
1.71-1.69 (8H, m, H3), 1.51-1.49 (4H, m, H1); C (75.5 MHz, 
DMSO-d6) 175.7, 142.7, 78.5, 69.5 (2C), 68.4 (5C), 66.9 





, 1397.3008. C64H80Fe4N14S4 requires M
+
, 
1397.0538), 1127.3112 (75%), 857.3220 (53), 584.1761 (75); 
Found: C, 54.9; H, 5.86; N, 11.8; S, 9.15; Calc. for 
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(0.22 g, 66%); 




3079w (NH), 1626m 
(HN), 1528s 
(C=N), 819s (C=S); 
H (300 MHz, DMSO-
d6) 8.21 (4H, s, 
HNN), 4.75 (8H, s, 
H2”/H5”), 4.37 
(8H, s, H3”/H5”), 4.17 (20H, s, Cp), 3.84 (8H, m, H4), 2.61 
(4H, s, CH2NH), 2.42-2.34 (12H, m, H2/H2’), 2.20 (12H, s, 
CH3), 1.70 (8H, m, H3), 1.48 (4H, unresolved t, H1); C 
(75.5 MHz, DMSO-d6) 177.3, 150.5, 83.0, 69.7 (2C), 69.0 
(5C), 67.2 (2C), 53.7, 51.5, 42.7, 26.4, 24.6, 15.2; m/z 




, 1453.3694. C68H88Fe4N14S4 
requires M
+
, 1453.3597), 1169.0023 (80%), 885.3535 (73); 
Found: C, 58.4; H, 6.82; N, 12.1; S, 6.50; Calc. for 
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The compound was synthesised 
following the general procedure 
from 6.23a (0.32 g, 1.04 mmol) 
and tris(2-aminoethyl)amine 
(0.05 g, 0.34 mmol), and was 
obtained (0.23 g, 72%) as a 
yellow-orange solid; m.p. 96-97 
ºC; vmax (KBr)/cm
-1
 3342w, (NH), 
1528s (C=N), 1469m (C=C), 1286m 
(C=S), 784s (CS); H (400 MHz, 
DMSO-d6) 8.48 (3H, s, HNN), 8.02 (3H, s, H2), 7.84 (3H, d, J 
8.0 Hz, H6), 7.57 (3H, d, J 7.2H, H4), 7.35 (3H, t, J 7.6 
Hz, H5), 3.70 (6H, t, J 6.8 Hz, H-1’), 2.87 (6H, t, J 7.2, 
H2’), 2.27 (9H, s, CH3); C (101 MHz, DMSO-d6) 177.8, 146.1, 
139.9, 131.7, 130.2, 128.6, 125.3, 121.8, 52.4, 41.6, 13.9; 







, 911.6368), 657.0591 (100%); Found: 
C, 43.6; H, 5.03; N, 15.6; S, 8.89; Calc. for C33H39Br3N10S3: 
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The compound was synthesised 
following the general procedure 
from 6.23b (0.32 g, 1.04 mmol) 
and tris(2-aminoethyl)amine (0.05 
g, 0.34 mmol), and was obtained 
(0.23 g, 74%) as an organge 
solid; m.p. 107-109 ºC; vmax 
(KBr)/cm
-1
 3343m, 3173w (NH), 
1530s (C=N), 1482s (C=C), 1288s 
(C=S), 824s (CS); H (400 MHz, 
DMSO-d6) 8.47 (3H, s, HNN), 7.81 (6H, d, J 8.4 Hz, H2/2’), 
7.58 (6H, d, J 8.8 Hz, H3/3’), 3.68 (6H, t, J 6.8 Hz, H1”), 
2.75 (6H, t, J 6.8 Hz, H2”), 2.25 (9H, s, CH3); C (101 MHz, 
DMSO-d6) 177.8, 146.3, 136.7, 130.9 (2C), 128.3 (2), 122.4, 





912.2995. C33H39Br3N10S3 requires M
+
, 911.6360), 656.5025 
(68); Found: C, 43.2; H, 5.18; N, 16.9; S, 9.96; Calc. for 
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The compound was synthesised 
following the general procedure 
from 6.23d (0.29 g, 1.04 mmol) 
and tris(2-aminoethyl)amine 
(0.05 g, 0.34 mmol), and was 
obtained (0.21 g, 69%) as an 
orange solid; m.p. 118-120 C; 
vmax (KBr)/cm
-1
 3341w, 3155w 
(NH), 1528 (C=N), 1467s (C=C), 
1291m (C=S), 817m (CS); H (400 
MHz, DMSO-d6) 8.54 (3H, s, HNN), 8.06 (3H, d, J 1.6 Hz, H2), 
7.82 (3H, dd, J 1.6 Hz, 8.4 Hz, H6), 7.62 (3H, d, J 8.8 Hz, 
H5), 3.69 (6H, t, J 6.8 Hz, H1’), 2.75 (6H, t, J 6.4 Hz, 
H2’), 2.26 (9H, s, CH3); c (100.6 MHz, DMSO-d6) 177.9, 
145.0, 138.1, 131.4, 130.1, 127.8, 126.2, 124.8, 52.3, 





881.0412. C33H36Cl6N10S3 requires M
+
, 881.6189), 637.0580 
(100%), 391.1178 (48); Found: C, 45.6; H, 4.60; N, 15.6; S, 
10.9; Calc. for C33H36Cl6N10S3.CH3OH: C, 44.7; H, 4.41; N, 
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The compound was synthesised 
following the general procedure 
from 6.23c (0.33 g, 1.04 mmol) 
and tris(2-aminoethyl)amine 
(0.05 g, 0.34 mmol), and was 
obtained (0.28 g, 86%) as a 
yellow solid, m.p. 85-87 C; vmax 
(KBr)/cm
-1
 3349m, 3136m (NH), 
1530s (C=N), 1284m (C=S), 784s 
(CS); H (400 MHz, DMSO-d6) 8.49 
(3H, s, HNN), 7.98 (3H, m, H2), 7.84 (3H, m, H6), 7.55 (3H, 
m, H5), 7.36 (3H, m, H4), 3.75-3.70 (6H, m, H1’), 2.86-2.81 
(8H, m, H2’ and H3’), 1.09-0.95 (9H, m, CH3); C (100.6 MHz, 
DMSO-d6) 176.5, 148.5, 137.3, 130.1, 128.9, 127.2, 126.3, 





, 953.0519. C36H45Br3N10S3 requires 953.7165), 
685.0781 (100%); Found: C, 45.4; H, 4.86; N, 14.7; S, 11.2; 
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The compound was synthesised 
following the general procedure 
from 6.23g (0.32 g, 1.04 mmol) 
and tris(2-aminoethyl)amine 
(0.05 g, 0.34 mmol), and was 
obtained (0.27 g, 85%) as a 
brownish solid; m.p. 83-85 C; 
vmax (KBr)/cm
-1
 3351w, 3132w (NH), 
1528s (C=N), 1471s (C=C), 1288m 
(C=S), 820m (CS); H (400 MHz, 
DMSO-d6) 8.50 (3H, s, HNN), 8.02 (3H, s, H2), 7.81 (3H, m, 
H6), 7.64-7.56 (3H, m, H5), 3.74-3.68 (6H, m, H1’), 2.87-
2.79 (8H, m, H2’ and H3’); C (100.6 MHz, DMSO-d6) 178.1, 
149.1, 137.2, 131.6, 130.4, 128.1, 126.6, 125.2, 52.4, 





923.0916. c36H42Cl6N10S3 requires M
+
, 923.6987), 665.1063 
(100%), 405.1408 (13); Found: C, 46.9; H, 4.71; N, 16.0; S, 
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Synthesis of Compound 6.26 
 
NaOH (0.77 g, 19.2 mmol) 
dissolved in water (40 
cm
3





, 4.79 mmol) at 
room temperature. CS2 
(1.44 cm
3
, 23.9 mmol) 
was added to the 
reaction mixture and allowed to stir for 4 h. The orange 
solution was reacted with chloroacetate (2.24 g, 19.3 mmol) 
and left stirring for 24 h at room temperature. The 
resulting brown solution was acidified (2 M HCl, 10 cm
3
) 
followed by addition of H2NNH2.H2O (13 cm
3
, 268.0 mmol). The 
mixture was heated at 90 C for 2 h. After cooling, a 
‘gummy’ yellow residue separated from the solution. The 
solution was decanted and the residue washed several times 
with aliquitos of water. Drying the residue in vacuo gave 
6.26 (6.40 g, 65%) as a yellow solid; vmax (KBr)/cm
-1
 ; H 
(400 MHz, DMSO-d6) 8.46 (4H, s, NH), 7.93 (4H, s, NH), 4.38 
(8H, br, NHH), 3.45 (8H, t, J 6.0 Hz, H4), 2.37 (12H, t, J 
6.0 Hz, H2/2’), 1.62 (8H, m, H3), 1.38 (2H, unresolved t, 
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8.7 PROCEDURES FOR BIOLOGICAL ASSAYS 
 
In Vitro Antiplasmodial Assays: D10 and W2 strains of P. 
falciparum 
 
The test compounds were tested in duplicate against the 
chloroquine sensitive (CQS) strain of P. falciparum (D10). 
Continous in vitro cultures of asexual erythrocyte stages 
of P. falciparum were maintained using a modified method of 
Trager and Jensen.
33
 Quantitative assessment of 
antiplasmodial activity in vitro was determined via the 
parasite lactate dehydrogenase assay using a modified 




The samples were prepared to a 2 mg/ml stock solution in 
10% methanol and sonicated to enhance solubility. Samples 
were tested as a suspension if not completely dissolved. 
Stock solutions were stored at -20 ºC. Further dilutions 
were prepared on the day of the experiment. Chloroquine 
(CQ) was used as the reference drug in all experiments. A 
full dose-response was performed for all compounds to 
determine the concentration inhibiting 50% of parasite 
growth (IC50 – value). Test samples were tested at a 
starting concentration of 10 μg/ml, which was then serially 
diluted 2-fold in complete medium to give 10 
concentrations; with the lowest concentration being 0.02 
μg/ml. The same dilution technique was used for all 
samples. CQ was tested at a starting concentration of 100 
ng/ml. The highest concentration of solvent to which the 
parasites were exposed to had no measurable effect on the 
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obtained using a non-linear dose-response curve fitting 
analysis via Graph Pad Prism v.4.0 software. 
 
W2-strain P. falciparum parasites (1% parasitaemia, 2% 
hematocrit) were cultured in 0.5 ml of medium in 48-well 
culture dishes. Appropriate inhibitors from 10 mM stocks in 
DMSO were added to cultured parasites to a final 
concentration of 20 μM. From 48-well plates, 125 μM of 
culture was transferred to two 96 well plates (duplicates). 
Serial dilutions (1%) of inhibitors were made to final 
concentrations of 10 μM, 2 μM, 0.4 μM, 80 nM, 16 nM and 3.2 
nM. Cultures were maintained at 37 °C for 2 days after 
which the parasites were washed and fixed with 1% 
formaldehyde in PBS. After two days, parasitaemia was 
measured by flow cytometry using the DNA stain YOYO-1 as a 




In Vitro Assay: Falcipain-2 
 
IC50 values against the recombinant enzyme (falcipain-2) 
were determined as described by Du and coworkers.
30,35
 Thus, 
equal amount of recombinant protein (ca 1 nM) was incubated 
with different concentrations of inhibitors (added from 
100x stock solutions in DMSO) in 100 mM sodium acetate (pH 
5.5)-10 mM dithiothreitol for 30 min at room temperature 
before addition of the substrate benzoxycarbonyl-Leu-Arg-7-
amino-4-methyl-coumarin (final concentration = 25 μM). 
Fluorescence was continuously monitored for 30 min at room 
temperature in a Labsystems Fluoroskan® II 
spectrofluorometer. IC50 values were determined from plots 
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Prism® software. IC50s for rhodesain were determined 
similarly at 3 nM. 
 
In Vitro Antiplasmodial Assays: 3D7 and K1 strains of P. 
falciparum 
 
Two clones of P. falciparum are used: (a) the 3D7 clone of 
NF54 which is known to be sensitive to all antimalarials, 
(b) the K1 strain originating from Thailand that is 
resistant to chloroquine and pyrimethamine, but sensitive 
to mefloquine. The cultures are naturally asynchronous (65 
– 75% ring stage) and are maintained in continuous log 
phase growth in RPMI1640 medium supplemented with 5% washed 
human A+ erythrocytes, 25 mM Hepes, 32 nM NaHCO3, and 
AlbuMAXII (lipid-rich bovine serum albumin) (GIBCO, Grand 
Island, NY) (CM). All cultures and assays are conducted at 
37 °C under an atmosphere of 5% CO2 and 5% O2, with a 
balance of N2. 
 
Drug sensitivity assays 
 
Stock drug solutions are prepared in 100% DMSO at 20 mg/ml 
unless otherwise suggested by the supplier. The compound is 
further diluted to the appropriate concentration using 
complete medium RPMI1640 supplemented with 15 nM cold 
hypoxanthine and AlbuMAXII. Assays are performed in sterile 
96-well microtitre plates; each plate contains 100 μl of 
parasite culture (0.5% parasitaemia, 2.5% hematocrit). Each 
drug is tested in triplicate and parasite growth compared 
to control and blank (uninfected erythrocytes) wells. After 
24 h of incubation at 37 °C, 3.7 Bq of [
3
H]hypoxanthine is 
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h before they are harvested onto glass-fiber filter mats. 
The radioactivity is counted using a Wallac Microbeta 1450 
scintillation counter. The results are recorded as counts 
per minute (CPM) per well at each drug concentration, 
control and blank wells. Percentage inhibition is 
calculated from comparison to blank and control wells, and 
IC50 values calculated using Microsoft XLFit line fitting 




The preliminary screen uses the 3D7 strain. The compounds 
are tested at 4 concentrations (30, 10, 3, 1, 0.3, and 0.1 
μg/ml). If the compound does not affect parasite growth at 
10 μg/ml it is classified as inactive, between 10 and 1 
μg/ml, the compound is designated as partially active, and 
if <1 μg/ml, the compound is classified as active and is 





Both the 3D7 clone and the K1 line are used. The compound 
is diluted three-fold over at 12 different concentrations 
with an appropriate starting concentration based on the 
preliminary screen. The IC50 is determined by a sigmoidal 
dose response analysis using Microsoft XLFit™ (IDBS, UK). 
For each assay, the IC50 and IC90 values for each parasite 
line are determined against the known anti-malarial 
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Cell cultures 
 
KB cells – a cell line derived from a human carcinoma of 
the nasopharynx, typically used as an assay for 
antineoplastic agents. KB cells are maintained as 
monolayers in RPMI 1640 + 10% HIFCS. All cultures and 
assays are conducted at 37 °C under an atmosphere of 5% 
CO2/95% air mixture. 
 
Drug toxicity assays 
 
Stock drug solutions are prepared in 100% DMSO unless 
otherwise suggested by the supplier at 20 mg/ml, and ball 
milled or sonicated if necessary. The stocks are kept at    
4 °C. For the assays, the compound is further diluted to 
the appropriate concentration using complete medium. 
 
Day 1: KB cells are harvested, counted and washed in serum-
free medium (2000 rpm, 10 mins., 4 ºC) and resuspended in 
fresh medium (RPMI 1640 + 10% HIFC) at a concentration of 4 
× 104/ml. 100 μl is added to wells on a 96-well plate (4 × 
103/well). The plate is incubated overnight at 37 ºC, 
5%CO2/air mix to allow the cells to adhere. 
 
Day 2: Test compounds are prepared in 100% DMSO 20 mg/ml 
and diluted down to a starting concentration of 600 μg/ml 
(2 × top concentration) with RPMI + 10% HIFCS. Control 
wells had no drug. A 10-fold serial dilution is performed 
across the plate – 300, 30, 3 etc. Podophyllotoxin is the 
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Day5: Each well is assessed by microscope observation. 20 
μl Alamar Blue™ is then added to each well. Plates are 
incubated for a further 2-4 hours before reading (Gemini), 
EX/EM 530/580, cut-off 550 nm IC50 (IC90) values are 
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APPENDICES 
 
Appendix A: Crystallographic data for compound 4.15 
 
Table A1: Crystal data of structure 4.15. 
 
                       Crystal Data 
Formula                         [C18H20N6Au1Br2S2].2(C2H3N).Cl
-
 
Formula Weight                                       858.86 
Crystal System                                   Monoclinic 
Space group                           C2/c         (No. 15) 
a, b, c [Angstrom]      11.846(2)    10.358(2)    24.577(5) 
alpha, beta, gamma [deg]      90    101.89(3)            90 
V [Ang**3]                                       2950.9(10) 
Z                                                         4 
D(calc) [g/cm**3]                                     1.933 
Mu(MoKa) [ /mm ]                                      7.952 
F(000)                                                 1648 
Crystal Size [mm]                      0.01 x  0.01 x  0.01 
                     Data Collection 
Temperature (K)                                         173 
Radiation [Angstrom]                      MoKa      0.71073 
Theta Min-Max [Deg]                              2.6,  25.3 
Dataset                         -14: 14 ; -12: 12 ; -29: 29 
Tot., Uniq. Data, R(int)              12752,   2705,  0.055 
Observed data [I > 2.0 sigma(I)]                       2313 
                      Refinement 
Nref, Npar                                       2705,  167 
R, wR2, S                              0.0321, 0.0688, 1.05 
w = 1/[\s^2^(Fo^2^)+(0.0282P)^2^+4.8300P] where P = 
(Fo^2^+2Fc^2^)/3 
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Min. and Max. Resd. Dens. [e/Ang^3]             -0.83, 1.12 
 
Table A2: Bond Distances (Angstrom) of 4.15. 
 
Au1    -S1       2.2825(13)     C5     -C6         1.387(7) 
Au1    -S1_a     2.2825(13)     C6     -C7         1.378(7) 
Br1    -C7         1.905(5)     C7     -C8         1.356(9) 
S1     -C1         1.719(5)     C8     -C9         1.390(9) 
N1     -C1         1.318(6)     C3     -H3B          0.9800 
N2     -N3         1.399(5)     C3     -H3C          0.9800 
N2     -C1         1.340(6)     C3     -H3A          0.9800 
N3     -C2         1.287(6)     C5     -H5           0.9500 
N1     -H1A          0.8800     C6     -H6           0.9500 
N1     -H1B          0.8800     C8     -H8           0.9500 
N2     -H2           0.8800     C9     -H9           0.9500 
N4     -C10        1.127(8)     C10    -C11        1.444(8) 
C2     -C3         1.496(7)     C11    -H11A         0.9800 
C2     -C4         1.481(7)     C11    -H11B         0.9800 
C4     -C5         1.397(7)     C11    -H11C         0.9800 
C4     -C9         1.386(7) 
 
Table A3: Bond angles (degrees) of 4.15. 
 
S1   -Au1   -S1_a   170.24(6)   C7   -C8    -C9    119.8(5) 
Au1   -S1   -C1   109.59(17)    C4   -C9    -C8    120.8(6) 
N3   -N2    -C1   116.4(4)      C2   -C3   -H3A      109.00 
N2   -N3    -C2   117.6(4)      C2   -C3   -H3B      109.00 
H1A  -N1    -H1B   120.00       C2   -C3   -H3C      109.00 
C1   -N1    -H1A   120.00      H3A   -C3   -H3B      109.00 
C1   -N1    -H1B   120.00      H3A   -C3   -H3C      109.00 
N3   -N2    -H2    122.00      H3B   -C3   -H3C      110.00 
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S1   -C1   -N1    118.2(3)      C6   -C5   -H5       120.00 
S1   -C1   -N2    122.5(4)      C5   -C6   -H6       121.00 
N1   -C1   -N2    119.2(4)      C7   -C6   -H6       120.00 
N3   -C2   -C3    125.7(4)      C7   -C8   -H8       120.00 
C3   -C2   -C4    119.2(4)      C9   -C8   -H8       120.00 
N3   -C2   -C4    115.1(4)      C4   -C9   -H9       120.00 
C2   -C4   -C9    121.6(5)      C8   -C9   -H9       120.00 
C5   -C4   -C9    118.2(5)      N4   -C10  -C11    178.6(6) 
C2   -C4   -C5    120.2(4)      C10  -C11  -H11A     109.00 
C4   -C5   -C6    120.8(5)      C10  -C11  -H11B     109.00 
C5   -C6   -C7    119.1(5)      C10  -C11  -H11C     109.00 
Br1  -C7   -C6    120.0(4)     H11A  -C11  -H11B     109.00 
C6   -C7   -C8    121.3(5)     H11A  -C11  -H11C     109.00 
Br1  -C7   -C8    118.7(4)     H11B  -C11  -H11C     110.00 
 
Table A4: Selected torsion angles (deg.) of 4.15. 
 
         Au1    -S1     -C1     -N1         166.5(3) 
         Au1    -S1     -C1     -N2         -11.6(4) 
         C1     -N2     -N3     -C2        -170.6(4) 
         N3     -N2     -C1     -S1        -178.2(3) 
         N3     -N2     -C1     -N1           3.7(6) 
         N2     -N3     -C2     -C3           1.0(7) 
         N2     -N3     -C2     -C4        -178.6(4) 
         N3     -C2     -C4     -C5          22.5(7) 
         N3     -C2     -C4     -C9        -157.0(5) 
         C3     -C2     -C4     -C5        -157.2(5) 
         C3     -C2     -C4     -C9          23.4(7) 
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Table A5: Hydrogen Bonds (angstrom, deg.) of 4.15. 
 
N1    -- H1A    N3    0.8800   2.2500   2.609(6)     104.00 
N1    -- H1A    N4    0.8800   2.2800   3.030(7)     144.00 
N1   -- H1B  Cl1  0.8800   2.3700   3.237(4)  168.00  5_545 
N2    -- H2    Cl1    0.8800   2.5600   3.242(4)     135.00 
C3    -- H3C    N2    0.9800   2.3900   2.809(6)     105.00 
 
Appendix B: Crystallographic data for compound 4.16 
 
Table B1: Crystal data for structure 4.16. 
 
                     Crystal Data 
 
Formula                         [C18H18N6S2AuCl4].2(C2H3N1).Cl
-
 
Formula Weight                                       838.83 
Crystal System                                   Monoclinic 
Space group                           C2/c         (No. 15) 
a, b, c [Angstrom]      11.776(2)    10.658(2)    24.515(5) 
alpha, beta, gamma [deg]       90     96.79(3)           90 
V [Ang**3]                                       3055.3(10) 
Z                                                         4 
D(calc) [g/cm**3]                                     1.824 
Mu(MoKa) [ /mm ]                                      5.417 
F(000)                                                 1632 
Crystal Size [mm]                      0.05 x  0.05 x  0.05 
                     Data Collection 
Temperature (K)                                         173 
Radiation [Angstrom]                      MoKa      0.71073 
Theta Min-Max [Deg]                              2.6,  25.7 
Dataset                         -14: 13 ; -11: 12 ; -28: 29 
Tot., Uniq. Data, R(int)               9300,   2889,  0.040 
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                     Refinement 
Nref, Npar                                       2889,  176 
R, wR2, S                              0.0330, 0.0702, 1.07 
w = 1/[\s^2^(Fo^2^)+(0.0275P)^2^+5.3451P] where P = 
(Fo^2^+2Fc^2^)/3 
Max. and Av. Shift/Error                         0.00, 0.00 
Min. and Max. Resd. Dens. [e/Ang^3]             -1.18, 1.74 
 
Table B2: Bond distances (Angstrom) of 4.16. 
 
Au1    -S1       2.2818(13)     C4     -C5         1.391(7) 
Au1    -S1_a     2.2818(13)     C5     -C6         1.373(7) 
Cl2    -C6         1.730(5)     C6     -C7         1.382(7) 
Cl3    -C7         1.737(5)     C7     -C8         1.380(7) 
S1     -C1         1.729(5)     C8     -C9         1.393(7) 
N1     -C1         1.314(6)     C3     -H3B          0.9800 
N2     -N3         1.389(5)     C3     -H3C          0.9800 
N2     -C1         1.329(6)     C3     -H3A          0.9800 
N3     -C2         1.286(6)     C5     -H5           0.9500 
N1     -H1A          0.8800     C8     -H8           0.9500 
N1     -H1B          0.8800     C9     -H9           0.9500 
N2     -H2           0.8800     C10    -C11        1.451(8) 
N4     -C10        1.137(8)     C11    -H11A         0.9800 
C2     -C4         1.479(6)     C11    -H11B         0.9800 
C2     -C3         1.501(7)     C11    -H11C         0.9800 
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Table B3: Bond angles (deg.) of 4.16. 
 
S1  -Au1    -S1_a    169.66(6)   C6   -C7   -C8    119.8(5) 
Au1  -S1    -C1     109.52(17)   Cl3  -C7   -C8    118.9(4) 
N3   -N2    -C1     116.5(4)      C7  -C8   -C9    120.2(5) 
N2   -N3    -C2     118.7(4)      C4  -C9   -C8    120.4(4) 
C1   -N1    -H1A    120.00        C2  -C3   -H3A     109.00 
C1   -N1    -H1B    120.00        C2  -C3   -H3B     109.00 
H1A  -N1    -H1B    120.00        C2  -C3   -H3C     109.00 
C1   -N2    -H2     122.00       H3A  -C3   -H3B     110.00 
N3   -N2    -H2     122.00       H3A  -C3   -H3C     109.00 
S1   -C1    -N2     122.3(4)     H3B  -C3   -H3C     110.00 
N1   -C1    -N2     120.2(4)      C4  -C5   -H5      119.00 
S1   -C1    -N1     117.5(3)      C6  -C5   -H5      119.00 
N3   -C2    -C3     126.1(4)      C7  -C8   -H8      120.00 
N3   -C2    -C4     114.7(4)      C9  -C8   -H8      120.00 
C3   -C2    -C4     119.2(4)      C4  -C9   -H9      120.00 
C5   -C4    -C9     118.1(4)      C8  -C9   -H9      120.00 
C2   -C4    -C9     121.3(4)      N4  -C10  -C11   178.5(6) 
C2   -C4    -C5     120.6(4)     C10  -C11  -H11A    109.00 
C4   -C5    -C6     121.6(4)     C10  -C11  -H11B    109.00 
Cl2  -C6    -C5     119.4(4)     C10   -C11 -H11C    109.00 
C5   -C6    -C7     119.9(4)     H11A  -C11 -H11B    109.00 
Cl2  -C6    -C7     120.8(4)     H11A  -C11 -H11C    109.00 
Cl3  -C7    -C6     121.3(4)     H11B  -C11 -H11C    109.00 
 
Table B4: Selected torsion angles (deg.) in 4.16. 
 
         Au1    -S1     -C1     -N1         162.4(3) 
         Au1    -S1     -C1     -N2         -16.3(4) 
         C1     -N2     -N3     -C2        -166.0(4) 
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         N3     -N2     -C1     -N1           1.5(6) 
         N2     -N3     -C2     -C3           3.1(6) 
         N2     -N3     -C2     -C4        -177.4(4) 
         N3     -C2     -C4     -C5          17.1(6) 
         N3     -C2     -C4     -C9        -162.9(4) 
         C3     -C2     -C4     -C5        -163.3(4) 
         C5     -C6     -C7     -Cl3       -178.7(4) 
         C5     -C6     -C7     -C8           1.4(7) 
         Cl3    -C7     -C8     -C9         178.3(4) 
         C6     -C7     -C8     -C9          -1.8(8) 
         C7     -C8     -C9     -C4           1.0(8) 
 
Table B5: Hydrogen Bonds (Angstrom, deg.) in 4.16. 
 
N1   -- H1A   N3   0.8800   2.2700   2.612(5)   103.00 
N1   -- H1A   N4   0.8800   2.2800   3.040(6)   144.00 
N1  -- H1B  Cl1  0.8800  2.3800  3.254(4)  173.00  5_545 
N2   -- H2   Cl1   0.8800   2.4700   3.221(4)   144.00 
C3   -- H3C   N2   0.9800   2.4200   2.837(6)   105.00 
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